coronavirus vaccine

RNA-based vaccines encoding optimized SARS-CoV-2 S protein variants in lipid nanoparticles address the challenge of emerging variants by inducing strong immune responses, providing effective protection against SARS-CoV-2.

JP2024540949AInactive Publication Date: 2024-11-06BIONTECH SE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024523699
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-10-21
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Effective vaccine strategies are needed to combat the ongoing pandemic of SARS-CoV-2, particularly against emerging variants that pose challenges to existing vaccines.

Method used

Development of RNA-based vaccines encoding immunogenic variants of the SARS-CoV-2 S protein, optimized for stability and translation efficiency, administered in lipid nanoparticles to induce robust antibody and T cell responses.

Benefits of technology

The RNA-based vaccines induce potent immune responses, including high antibody titers and T cell responses, effectively protecting against SARS-CoV-2 and its variants, with minimal side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540949000038
    Figure 2024540949000038
  • Figure 2024540949000039
    Figure 2024540949000039
  • Figure 2024540949000040
    Figure 2024540949000040
Patent Text Reader

Abstract

The present invention relates to the field of RNA for the prevention or treatment of coronavirus infection. In particular, the present invention relates to methods and agents for vaccination against coronavirus infection and induction of effective coronavirus antigen-specific immune responses, such as antibody and / or T cell responses. In particular, in one embodiment, the present invention relates to a method comprising administering to a subject an RNA encoding a peptide or protein comprising an epitope of the SARS-CoV-2 S protein, i.e., a vaccine RNA encoding a vaccine antigen, to induce an immune response against the coronavirus spike protein (S protein), in particular the S protein of SARS-CoV-2, in the subject.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to the field of RNA for preventing or treating coronavirus infection. In particular, the present invention relates to methods and agents for vaccinating against coronavirus infection and inducing an effective coronavirus antigen-specific immune response, such as an antibody and / or T cell response. These methods and agents are particularly useful for preventing or treating coronavirus infection. Administration of the RNA disclosed herein to a subject can protect the subject against coronavirus infection. In particular, in certain embodiments, the present invention relates to a method for inducing an immune response in a subject against coronavirus spike protein (S protein), particularly the S protein of SARS-CoV-2, comprising administering to the subject RNA encoding a peptide or protein comprising an epitope of the SARS-CoV-2 S protein, i.e., vaccine RNA encoding a vaccine antigen. Administration of the RNA encoding the vaccine antigen to a subject can provide the vaccine antigen (after expression of the RNA by appropriate target cells) for inducing an immune response against the vaccine antigen (and disease-associated antigens) in the subject. [Background technology]

[0002] Coronaviruses are positive-sense, single-stranded RNA ((+)ssRNA) enveloped viruses that encode four structural proteins: spike protein, envelope protein (E), membrane protein (M), and nucleocapsid protein (N). The spike protein (S protein) is responsible for receptor recognition, cell attachment, infection via the endosomal pathway, and genome release driven by fusion of the viral and endosomal membranes. Although the sequence varies among different family members, conserved regions and motifs within the S protein allow it to be divided into two subdomains, S1 and S2. The S2 domain, together with its transmembrane domain, is responsible for membrane fusion, while the S1 domain recognizes virus-specific receptors and binds to target host cells. A receptor-binding domain (RBD) has been identified in several coronavirus isolates, and the general structure of the S protein has been defined (Figure 1).

[0003] In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China, and a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was identified as the underlying cause. The genetic sequence of SARS-CoV-2 was made available to the WHO and published (MN908947.3), and the virus was classified as a member of the Betacoronavirus subfamily. Sequence analysis revealed a phylogenetic tree that showed a closer relationship to severe acute respiratory syndrome (SARS) virus isolates, namely the Middle East respiratory syndrome (MERS) virus, than to other coronaviruses that infect humans.

[0004] SARS-CoV-2 infection and the resulting disease, COVID-19, are spreading worldwide, affecting a growing number of countries. On March 11, 2020, the WHO characterized the COVID-19 outbreak as a pandemic. As of December 1, 2020, there have been more than 63 million confirmed COVID-19 cases worldwide, with over 1.4 million deaths, affecting 191 countries / territories. The ongoing pandemic remains a significant challenge to global public health and economic stability.

[0005] All individuals are at risk of infection because there is no pre-existing immunity to SARS-CoV-2. After infection, some individuals develop protective immunity in terms of neutralizing antibody responses and cell-mediated immunity, but not all. However, the extent and duration of this protection are currently unknown. According to the WHO, 80% of infected individuals recover without needing hospital treatment, while 15% develop more severe disease and 5% require intensive care. Increasing age and underlying health conditions are considered risk factors for developing severe disease.

[0006] Symptoms of COVID-19 generally include cough and fever, with ground-glass opacities or patchy opacities on chest radiographs. However, many patients present without fever or radiographic changes, and infection may be asymptomatic, which is relevant for controlling transmission. In symptomatic subjects, disease progression can lead to acute respiratory distress syndrome requiring mechanical ventilation, followed by multiorgan failure and death. Common symptoms in hospitalized patients include (in descending order of frequency) fever, dry cough, shortness of breath, fatigue, myalgia, nausea / vomiting or diarrhea, headache, weakness, and rhinorrhea. In approximately 3% of patients with COVID-19, anosmia (loss of smell) or dysgeusia (loss of taste) may be the only symptom.

[0007] Although people of all ages can suffer from the disease, the case fatality rate (CFR) is particularly high in people over 60 years of age. Comorbidities such as cardiovascular disease, diabetes, hypertension, and chronic respiratory diseases are also associated with an increased CFR. Healthcare workers account for the majority of COVID-19 patients due to occupational exposure to infected patients.

[0008] In most situations, molecular testing is used to detect SARS-CoV-2 and confirm infection. Reverse transcription-polymerase chain reaction (RT-PCR) testing, which targets SARS-CoV-2 viral RNA, is the gold standard in vitro method for diagnosing suspected cases of COVID-19. Samples to be tested are collected from the nose and / or throat using a cotton swab.

[0009] SARS-CoV-2 is an RNA virus with four structural proteins. One of these, the spike protein, is a surface protein that binds to angiotensin-converting enzyme 2 (ACE-2) present on host cells. Therefore, the spike protein is considered a relevant antigen for vaccine development.

[0010] BNT162b2 (SEQ ID NO: 20) is an mRNA vaccine for preventing COVID-19 that has demonstrated greater than 95% efficacy in preventing COVID-19. The vaccine is made with 5'-capped mRNA encoding the full-length SARS-CoV-2 spike glycoprotein (S) encapsulated in lipid nanoparticles (LNPs). The final product is presented as an injectable dispersion concentrate containing BNT162b2 as the active substance. Other ingredients are: ALC-0315 (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), ALC-0159 (2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, potassium chloride, potassium dihydrogen phosphate, sodium chloride, disodium phosphate dihydrate, sucrose, and water for injection.

[0011] The S protein sequence was selected based on the sequences of the SARS-CoV-2 isolate Wuhan-Hu-1: GenBank: MN908947.3 (complete genome) and GenBank: QHD43416.1 (spike surface glycoprotein). The active substance consists of a single-stranded, 5'-capped, codon-optimized mRNA, which is translated into the SARS-CoV-2 spike antigen. The encoded spike antigen protein sequence contains two proline mutations, ensuring antigenically optimal pre-fusion confirmation (P2S). This RNA contains no uridines; modified N1-methylpseudouridine is used instead of uridine during RNA synthesis. This mRNA is translated into the SARS-CoV-2 S protein in host cells. The S protein is then expressed on the cell surface to induce adaptive immune responses. The S protein has been identified as a target for neutralizing antibodies against the virus and is considered a relevant vaccine component. BNT162b2 will be administered intramuscularly (IM) at 30 μg of diluted vaccine solution twice, 21 days apart.

[0012] The recent emergence of new circulating variants of SARS-CoV-2 has raised serious concerns about the geographic and temporal effectiveness of vaccine interventions. One of the earliest variants to emerge and rapidly become dominant globally was D614G.

[0013] The alpha variant (also known as B.1.1.7, VOC202012 / 01, 501Y.V1, or GRY) was first detected in the United Kingdom. This alpha variant has numerous mutations, including several in the S gene. It has been found to be inherently more infectious, with growth rates estimated to be 40–70% higher than other SARS-CoV-2 lineages in multiple countries (Volz et al., 2021, Nature, https: / / doi.org / 10.1038 / s41586-021-03470-x; Washington et al., 2021, Cell https: / / doi.org / 10.1016 / j.cell.2021.03.052).

[0014] The beta variant (also known as B.1.351 or GH / 501Y.V2) was first detected in South Africa. This beta variant has several mutations in the S gene. Three of these mutations are located in the RBD at sites associated with immune evasion: N501Y (shared with alpha), E484K, and K417N.

[0015] The gamma variant (also known as P.1 or GR / 501Y.V3), first detected in Brazil, has several mutations affecting the spike protein, including two in common with the beta variant (N501Y and E484K), as well as a different mutation at position 417 (K417T).

[0016] The delta variant (also known as B.1.617.2 or G / 478K.V1) was first recorded in India. This delta variant has several point mutations affecting the spike protein, including P681R (a mutation position shared with alpha and adjacent to the furin cleavage site) and L452R, which resides within the RBD and is associated with increased binding to ACE2 and resistance to neutralizing antibodies. It also has a deletion at positions 156 / 157 in the spike protein.

[0017] These four VOCs are widespread worldwide and are the dominant variants in the geographic regions where they were first identified. Summary of the Invention [Problem to be solved by the invention]

[0018] There remains a need for effective vaccine strategies against SARS-CoV-2. [Means for solving the problem]

[0019] overview The present invention generally encompasses immunotherapeutic treatment of a subject, comprising administering RNA encoding an amino acid sequence, i.e., a vaccine antigen, comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or its immunogenic variant, i.e., an antigenic peptide or protein. Thus, the vaccine antigen comprises an epitope of the SARS-CoV-2 S protein to induce an immune response against the coronavirus S protein, particularly the SARS-CoV-2 S protein, in a subject. Upon administration, the RNA encoding the vaccine antigen provides the antigen (after expression of the polynucleotide by the appropriate target cell) for the induction, i.e., stimulation, priming, and / or proliferation, of an immune response, e.g., antibody and / or immune effector cells, targeted by the target antigen (coronavirus S protein, particularly the SARS-CoV-2 S protein) or its proliferative products. In certain embodiments, the immune response induced by the present invention is a B cell-mediated immune response, i.e., an antibody-mediated immune response. Additionally or alternatively, in certain embodiments, the immune response induced by the present invention is a T cell-mediated immune response. In certain embodiments, the immune response is an anti-coronavirus, particularly an anti-SARS-CoV-2, immune response.

[0020] The vaccines described herein contain single-stranded RNA as the active ingredient, which can be translated into the respective proteins upon entry into the recipient's cells. In addition to a wild-type or codon-optimized sequence encoding the antigen sequence, the RNA can contain one or more structural elements optimized for maximum RNA stability and translation efficiency (e.g., a 5' cap, a 5' UTR, a 3' UTR, a poly(A) tail, or a combination thereof). In some embodiments, the RNA contains all of these elements. In some embodiments, the cap1 structure can be used as a specific capping structure for the 5' end of an RNA drug substance. In some embodiments, beta-S-ARCA(D1) (m27,2'-OGppSpG) or m27,3'-OGppp(m12'-O)ApG can be used as a specific capping structure for the 5' end of an RNA drug substance. The 5' UTR sequence can be the 5' UTR sequence of human alpha-globin mRNA (e.g., SEQ ID NO: 12), optionally with an optimized "Kozak sequence" to increase translation efficiency. To ensure high maximum protein levels and long-term mRNA persistence, a combination of two sequence elements (FI elements) from the "amino terminal enhancer of split gene" (AES) mRNA (designated F) and the mitochondrial-encoded 12S ribosomal RNA (designated I) (e.g., SEQ ID NO: 13) can be used as the 3'-UTR sequence. These were identified through an ex vivo selection process for sequences that contribute to enhanced RNA stability and total protein expression (see WO 2017 / 060314, incorporated herein by reference). Alternatively, the 3'-UTR can be two repeated 3'-UTRs from human beta-globin mRNA. Furthermore, a 110-nucleotide-long poly(A)-tail (e.g., SEQ ID NO: 14) can be used, consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence (of random nucleotides), and an additional 70 adenosine residues. This poly(A)-tail sequence was designed to increase RNA stability and translation efficiency.

[0021] Additionally, a secretory signal peptide (sec) can be fused to the antigen-encoding region, preferably in such a way that the sec is translated as an N-terminal tag. In one embodiment, the sec corresponds to the secretory signal peptide of the S protein. As commonly used in fusion proteins, a sequence encoding a short linker peptide consisting mostly of the amino acids glycine (G) and serine (S) can be used as the GS / linker.

[0022] The vaccine RNAs described herein can be combined with proteins and / or lipids, preferably lipids, to produce RNA particles for administration. If different RNA combinations are used, these RNAs can be combined together or separately with proteins and / or lipids to produce RNA particles for administration.

[0023] In certain aspects, the present invention relates to a composition or pharmaceutical formulation comprising RNA encoding an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof.

[0024] In certain embodiments, the immunogenic fragment of the SARS-CoV-2 S protein comprises the S1 subunit of the SARS-CoV-2 S protein or the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 S protein.

[0025] In certain embodiments, an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or its immunogenic variant can form a multimeric complex, particularly a trimeric complex. To this end, the amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or its immunogenic variant can comprise a domain that allows the formation of a multimeric complex, particularly a trimeric complex, of the amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or its immunogenic variant. In certain embodiments, the domain that allows the formation of a multimeric complex comprises a trimerization domain, e.g., a trimerization domain described herein (e.g., a SARS-CoV-2 S protein trimerization domain). In certain embodiments, particularly when the amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof corresponds to a portion of the SARS-CoV-2 S protein that does not contain the trimerization domain, trimerization is achieved by the addition of a trimerization domain, for example, the T4-fibritin-derived "foldon" trimerization domain (e.g., SEQ ID NO: 10).

[0026] In certain embodiments, the amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof is encoded by a coding sequence that is codon-optimized and / or has an increased G / C content compared to the wild-type coding sequence, wherein the codon-optimization and / or increased G / C content preferably does not alter the sequence of the encoded amino acid sequence.

[0027] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9, or a fragment of the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9, or the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9; and / or (ii) The SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants, includes the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1.

[0028] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30, or a fragment of the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30; and / or (ii) The SARS-CoV-2 S protein, immunogenic variants thereof, or immunogenic fragments of the SARS-CoV-2 S protein or immunogenic variants thereof, comprises the amino acid sequence of amino acids 20 to 311 of SEQ ID NO:29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 311 of SEQ ID NO:29, or an immunogenic fragment of the amino acid sequence of amino acids 20 to 311 of SEQ ID NO:29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 311 of SEQ ID NO:29.

[0029] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9, or a fragment of the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9; and / or (ii) The SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants, includes the amino acid sequence of amino acids 17 to 685 of SEQ ID NO:1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO:1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 685 of SEQ ID NO:1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO:1.

[0030] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9, or a fragment of the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9, or the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9; and / or (ii) The SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants, includes the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7.

[0031] In certain embodiments, the amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a secretory signal peptide.

[0032] In one embodiment, the secretory signal peptide is fused, preferably at the N-terminus, to the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof.

[0033] In one embodiment, (i) the RNA encoding the secretory signal peptide comprises the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8, or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8, or 9, or a fragment of a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8, or 9; and / or (ii) The secretory signal peptide comprises the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1, or a functional fragment of the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1.

[0034] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of SEQ ID NO:6, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:6, or a fragment of the nucleotide sequence of SEQ ID NO:6 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:6; and / or (ii) The SARS-CoV-2 S protein, its immunogenic variant, or immunogenic fragment of the SARS-CoV-2 S protein or its immunogenic variant comprises the amino acid sequence of SEQ ID NO:5, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:5, or an immunogenic fragment of the amino acid sequence of SEQ ID NO:5 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:5.

[0035] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30, or a fragment of the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30; and / or (ii) The SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants, comprises the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29.

[0036] In some embodiments, the RNA is modified RNA, particularly stabilized mRNA. In some embodiments, the RNA comprises a modified nucleoside instead of at least one uridine. In some embodiments, the RNA comprises a modified nucleoside instead of each uridine. In some embodiments, the modified nucleoside is independently selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U).

[0037] In some embodiments, the RNA contains modified nucleosides in place of uridine.

[0038] In certain embodiments, the modified nucleoside is selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ), and 5-methyl-uridine (m5U).

[0039] In certain embodiments, the RNA comprises a 5' cap.

[0040] In certain embodiments, the RNA encoding an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a 5'UTR comprising the nucleotide sequence of SEQ ID NO:12 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:12.

[0041] In certain embodiments, the RNA encoding an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a 3'UTR comprising the nucleotide sequence of SEQ ID NO:13 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:13.

[0042] In certain embodiments, the RNA encoding an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a polyA sequence.

[0043] In some embodiments, the polyA sequence comprises at least 100 nucleotides.

[0044] In one embodiment, the polyA sequence comprises or consists of the nucleotide sequence of SEQ ID NO:14.

[0045] In certain embodiments, the RNA is or is to be formulated as a liquid, a solid, or a combination thereof.

[0046] In certain embodiments, the RNA is or is to be formulated for injection.

[0047] In certain embodiments, the RNA is or should be formulated for intramuscular administration.

[0048] In certain embodiments, the RNA is or is to be formulated as particles.

[0049] In certain embodiments, the particle is a lipid nanoparticle (LNP) or lipoplex (LPX) particle.

[0050] In some embodiments, the LNP particles comprise ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine, and cholesterol.

[0051] In some embodiments, RNA lipoplex particles can be obtained by mixing RNA with liposomes. In some embodiments, RNA lipoplex particles can be obtained by mixing RNA with lipids.

[0052] In some embodiments, the RNA is or should be formulated as a colloid. In some embodiments, the RNA is or should be formulated as particles that form the dispersed phase of the colloid. In some embodiments, 50% or more, 75% or more, or 85% or more of the RNA is present in the dispersed phase. In some embodiments, the RNA is or should be formulated as particles comprising RNA and lipids. In some embodiments, the particles are formed by exposing RNA dissolved in an aqueous phase to lipids dissolved in an organic phase. In some embodiments, the organic phase comprises ethanol. In some embodiments, the particles are formed by exposing RNA dissolved in an aqueous phase to lipids dispersed in the aqueous phase. In some embodiments, the lipids dispersed in the aqueous phase form liposomes.

[0053] In certain embodiments, the RNA is mRNA or saRNA.

[0054] In certain embodiments, the composition or pharmaceutical formulation is a pharmaceutical composition.

[0055] In certain embodiments, the composition or pharmaceutical preparation is a vaccine.

[0056] In certain embodiments, the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, diluents and / or excipients.

[0057] In certain embodiments, the composition or pharmaceutical preparation is a kit.

[0058] In some embodiments, the RNA and optionally the particle-forming components are contained in separate vials.

[0059] In certain embodiments, the kit further comprises instructions for using the composition or pharmaceutical preparation to induce an immune response against coronavirus in a subject.

[0060] In certain aspects, the present invention relates to a composition or pharmaceutical formulation described herein for pharmaceutical use.

[0061] In some embodiments, the medical use includes inducing an immune response to coronavirus in a subject.

[0062] In some embodiments, the medical uses include therapeutic or prophylactic treatment of coronavirus infections.

[0063] In certain embodiments, the compositions or pharmaceutical formulations described herein are for administration to humans.

[0064] In some embodiments, the coronavirus is a betacoronavirus.

[0065] In some embodiments, the coronavirus is a sarbecovirus.

[0066] In some embodiments, the coronavirus is SARS-CoV-2.

[0067] In one aspect, the present invention relates to a method of inducing an immune response against coronavirus in a subject, comprising administering to the subject a composition comprising RNA encoding an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof.

[0068] In certain embodiments, the immunogenic fragment of the SARS-CoV-2 S protein comprises the S1 subunit of the SARS-CoV-2 S protein or the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 S protein.

[0069] In certain embodiments, an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or its immunogenic variant can form a multimeric complex, particularly a trimeric complex. To this end, the amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or its immunogenic variant can comprise a domain that allows the formation of a multimeric complex, particularly a trimeric complex, of the amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or its immunogenic variant. In certain embodiments, the domain that allows the formation of a multimeric complex comprises a trimerization domain, e.g., a trimerization domain described herein.

[0070] In certain embodiments, the amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof is encoded by a coding sequence that is codon-optimized and / or has an increased G / C content compared to the wild-type coding sequence, wherein the codon-optimization and / or increased G / C content preferably does not alter the sequence of the encoded amino acid sequence.

[0071] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9, or a fragment of the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9, or the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9; and / or (ii) The SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants, includes the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1.

[0072] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30, or a fragment of the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30; and / or (ii) The SARS-CoV-2 S protein, immunogenic variants thereof, or immunogenic fragments of the SARS-CoV-2 S protein or immunogenic variants thereof, comprises the amino acid sequence of amino acids 20 to 311 of SEQ ID NO:29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 311 of SEQ ID NO:29, or an immunogenic fragment of the amino acid sequence of amino acids 20 to 311 of SEQ ID NO:29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 311 of SEQ ID NO:29.

[0073] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9, or a fragment of the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9; and / or (ii) The SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants, includes the amino acid sequence of amino acids 17 to 685 of SEQ ID NO:1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO:1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 685 of SEQ ID NO:1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO:1.

[0074] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9, or a fragment of the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9, or the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9; and / or (ii) The SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants, includes the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7.

[0075] In certain embodiments, the amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a secretory signal peptide.

[0076] In one embodiment, the secretory signal peptide is fused, preferably at the N-terminus, to the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof.

[0077] In one embodiment, (i) the RNA encoding the secretory signal peptide comprises the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8, or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8, or 9, or a fragment of a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8, or 9; and / or (ii) The secretory signal peptide comprises the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1, or a functional fragment of the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO: 1.

[0078] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof has the nucleotide sequence of SEQ ID NO: 6, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 6, or a fragment of the nucleotide sequence of SEQ ID NO: 6 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 6; and / or (ii) The SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants, includes the amino acid sequence of SEQ ID NO:5, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:5, or an immunogenic fragment of the amino acid sequence of SEQ ID NO:5 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:5.

[0079] In one embodiment, (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30, or a fragment of the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30; and / or (ii) The SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants, comprises the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29.

[0080] In some embodiments, the RNA is modified RNA, particularly stabilized mRNA. In some embodiments, the RNA comprises a modified nucleoside instead of at least one uridine. In some embodiments, the RNA comprises a modified nucleoside instead of each uridine. In some embodiments, the modified nucleoside is independently selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) and 5-methyl-uridine (m5U).

[0081] In some embodiments, the RNA contains modified nucleosides in place of uridine.

[0082] In certain embodiments, the modified nucleoside is selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ), and 5-methyl-uridine (m5U).

[0083] In some embodiments, the RNA includes a cap.

[0084] In certain embodiments, the RNA encoding an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a 5'UTR comprising the nucleotide sequence of SEQ ID NO:12 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:12.

[0085] In certain embodiments, the RNA encoding an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a 3'UTR comprising the nucleotide sequence of SEQ ID NO:13 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:13.

[0086] In certain embodiments, the RNA encoding an amino acid sequence comprising the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a polyA sequence.

[0087] In some embodiments, the polyA sequence comprises at least 100 nucleotides.

[0088] In one embodiment, the polyA sequence comprises or consists of the nucleotide sequence of SEQ ID NO:14.

[0089] In certain embodiments, the RNA is formulated as a liquid, a solid, or a combination thereof.

[0090] In certain embodiments, the RNA is administered by injection.

[0091] In certain embodiments, the RNA is administered by intramuscular administration.

[0092] In certain embodiments, the RNA is formulated as particles.

[0093] In certain embodiments, the particle is a lipid nanoparticle (LNP) or lipoplex (LPX) particle.

[0094] In some embodiments, the LNP particles comprise ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine, and cholesterol.

[0095] In some embodiments, RNA lipoplex particles can be obtained by mixing RNA with liposomes. In some embodiments, RNA lipoplex particles can be obtained by mixing RNA with lipids.

[0096] In some embodiments, the RNA is formulated as a colloid. In some embodiments, the RNA is formulated as particles that form the dispersed phase of the colloid. In some embodiments, 50% or more, 75% or more, or 85% or more of the RNA is present in the dispersed phase. In some embodiments, the RNA is formulated as particles comprising RNA and lipids. In some embodiments, the particles are formed by exposing RNA dissolved in an aqueous phase to lipids dissolved in an organic phase. In some embodiments, the organic phase comprises ethanol. In some embodiments, the particles are formed by exposing RNA dissolved in an aqueous phase to lipids dispersed in the aqueous phase. In some embodiments, the lipids dispersed in the aqueous phase form liposomes.

[0097] In certain embodiments, the RNA is mRNA or saRNA.

[0098] In some embodiments, the method is a method for vaccination against a coronavirus.

[0099] In certain embodiments, the method is for the therapeutic or prophylactic treatment of a coronavirus infection.

[0100] In certain embodiments, the subject is a human.

[0101] In some embodiments, the coronavirus is a betacoronavirus.

[0102] In some embodiments, the coronavirus is a sarbecovirus.

[0103] In some embodiments, the coronavirus is SARS-CoV-2.

[0104] In some embodiments of the methods described herein, the composition is a composition described herein.

[0105] In certain aspects, the invention relates to a composition or pharmaceutical formulation described herein for use in a method described herein.

[0106] Among other things, the present disclosure teaches that a composition comprising lipid nanoparticle-encapsulated mRNA encoding at least a portion (e.g., an epitope) of a polypeptide encoded by SARS-CoV-2 (e.g., the S protein encoded by SARS-CoV-2) can achieve detectable antibody titers to the epitope in serum within seven days of administration to a population of adult human subjects in a regimen comprising administering at least one dose of the vaccine composition. Furthermore, the present disclosure teaches the persistence of such antibody titers. In certain embodiments, the present disclosure teaches an increase in such antibody titers when using modified mRNA compared to that achieved with the corresponding unmodified mRNA.

[0107] In some embodiments, the provided regimen comprises at least one administration. In some embodiments, the provided regimen comprises a first administration and at least one subsequent administration. In some embodiments, the first administration is the same amount as at least one subsequent administration. In some embodiments, the first administration is the same amount as all subsequent administrations. In some embodiments, the first administration is different from the amount of at least one subsequent administration. In some embodiments, the first administration is different from the amount of all subsequent administrations. In some embodiments, the provided regimen comprises two administrations. In some embodiments, the provided regimen consists of two administrations.

[0108] In a specific embodiment, the immunogenic composition is formulated as a single dose in a container, for example, a vial. In some embodiments, the immunogenic composition is formulated as a multi-dose formulation in a vial. In some embodiments, the multi-dose formulation contains at least two doses per vial. In some embodiments, the multi-dose formulation contains a total of 2 to 20 doses per vial, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 doses per vial. In some embodiments, each dose in a vial is of equal volume. In some embodiments, the first dose has a different volume from subsequent doses.

[0109] A "stable" multi-dose formulation does not exhibit unacceptable levels of microbial growth and exhibits substantial or no degradation or degradation of the active biological molecule components. As used herein, a "stable" immunogenic composition includes a formulation that maintains the ability to elicit a desired immune response when administered to a subject.

[0110] In some embodiments, the multi-dose formulation remains stable for a specified period of time after multiple or repeated inoculations / insertion into a multi-dose container. For example, in some embodiments, the multi-dose formulation may be stable for at least 3 days and up to 10 uses when placed in a multi-dose container. In some embodiments, the multi-dose formulation remains stable for 2 to 20 inoculations / insertion.

[0111] In certain embodiments, administration of a composition comprising lipid nanoparticle-encapsulated mRNA encoding at least a portion (e.g., an epitope of or including an epitope) of a SARS-CoV-2-encoded polypeptide (e.g., a SARS-CoV-2-encoded S protein), e.g., according to a regimen described herein, may result in lymphopenia in some subjects (e.g., all subjects, a majority of subjects, about 50% or less, about 40% or less, about 40% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, etc.). Among other things, the present invention teaches that such lymphopenia may resolve over time. For example, in certain embodiments, lymphopenia resolves within about 14 days, about 10 days, about 9 days, about 8 days, about 7 days, or fewer. In certain embodiments, lymphopenia is Grade 3, Grade 2, or less.

[0112] Thus, among other things, the present invention provides compositions comprising lipid nanoparticle-encapsulated mRNA encoding at least a portion (e.g., an epitope of or including an epitope) of a SARS-CoV-2-encoded polypeptide (e.g., SARS-CoV-2-encoded S protein), characterized by exhibiting a certain characteristic (e.g., achieving a certain effect) described herein when administered to an appropriate population of adults. In certain embodiments, the provided compositions can be manufactured, stored, transported, characterized, and / or used under conditions in which the temperature does not exceed a certain threshold. Alternatively or additionally, in certain embodiments, the provided compositions can be protected from light (e.g., from certain wavelengths) during some or all of the manufacturing, storage, transport, characterization, and / or use. In certain embodiments, one or more characteristics of the provided compositions (e.g., one or more of mRNA stability; lipid nanoparticle stability or aggregation; pH; etc., which may be assessed, e.g., by size, the presence of a particular moiety or modification, etc.) can be or have been assessed at one or more time points prior to administration, manufacturing, storage, transport, and / or use.

[0113] Among other things, the present invention demonstrates that certain provided compositions and / or methods provided regarding such compositions, in which the nucleotides in the mRNA are unmodified (e.g., naturally occurring A, U, C, G), are characterized by an intrinsic adjuvant effect (e.g., when administered to a suitable population, which in some embodiments may be or include an adult population). In some embodiments, such compositions and / or methods can induce antibody and / or T cell responses. In some embodiments, such compositions and / or methods can induce enhanced T cell responses compared to conventional vaccines (e.g., non-mRNA vaccines such as protein vaccines).

[0114] Alternatively or additionally, the present invention provides that provided compositions (e.g., compositions comprising lipid nanoparticle-encapsulated mRNA encoding at least a portion (e.g., an epitope of or including an epitope) of a SARS-CoV-2-encoded polypeptide (e.g., a SARS-CoV-2-encoded S protein)) in which nucleotides within the mRNA are modified, and / or provided methods relating to such compositions, are characterized by a reduced intrinsic adjuvant effect (e.g., when administered to a suitable population, which in certain embodiments may be or include an adult population) compared to an otherwise equivalent composition (or method) having no intrinsic adjuvant effect or an unmodified result. Alternatively or additionally, in certain embodiments, such compositions (or methods) are characterized by the induction of an antibody response and / or a CD4+ T cell response (e.g., when administered to a suitable population, which in certain embodiments may be or include an adult population). Alternatively or additionally, in certain embodiments, such compositions (or methods) are characterized by inducing a higher CD4+ T cell response than observed with another vaccine format (e.g., a peptide vaccine) (e.g., when administered to a suitable population, which in certain embodiments may be or include an adult population). In certain embodiments involving modified nucleotides, such modified nucleotides may be present, for example, in the 3'UTR sequence, the antigen-encoding sequence, and / or the 5'UTR sequence. In certain embodiments, the modified nucleotides are or include one or more modified uracil residues and / or one or more modified cytosine residues.

[0115] Among other things, the present invention provides that the provided (e.g., compositions comprising lipid nanoparticle-encapsulated mRNA encoding at least a portion (e.g., that is or includes an epitope) of a SARS-CoV-2-encoded polypeptide (e.g., a SARS-CoV-2-encoded S protein)) and / or methods are characterized (e.g., when administered to a suitable population, which may be or may include, in certain embodiments, an adult population) by sustained expression of the encoded polypeptide (e.g., a SARS-CoV-2-encoded protein [e.g., S protein] or a portion thereof that may be or include, in certain embodiments, an epitope thereof). For example, in certain embodiments, such compositions and / or methods, when administered to a human, achieve detectable polypeptide expression in a biological sample (e.g., serum) from such a human, and are characterized, in certain embodiments, by such expression persisting for a period of at least at least 36 hours or more, including, e.g., at least 48 hours, at least 60 hours, at least 72 hours, at least 96 hours, at least 120 hours, at least 148 hours or more.

[0116] Those of skill in the art having access to this specification will understand that this specification describes various mRNA constructs that encode at least a portion (e.g., that is or includes an epitope) of a SARS-CoV-2-encoded polypeptide (e.g., a SARS-CoV-2-encoded S protein). Those of skill in the art having access to this specification will particularly understand that this specification describes various mRNA constructs that encode at least a portion of a SARS-CoV-2 S protein, e.g., at least the RBD portion of the SARS-CoV-2 S protein. Still further, those of skill in the art having access to this specification will understand that this specification describes particular features and / or advantages of mRNA constructs that encode at least a portion (e.g., that is or includes an epitope) of a SARS-CoV-2-encoded polypeptide (e.g., a SARS-CoV-2-encoded S protein). In certain embodiments, the mRNA construct may encode at least one domain of a SARS-CoV-2-encoded polypeptide (e.g., including one or more domains of a SARS-CoV-2-encoded polypeptide as described in WO2021 / 159040, e.g., the N-terminal domain (NTD) of the SARS-CoV-2 spike protein, the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, the heptapeptide repeat 1 (HR1) of the SARS-CoV-2 spike protein, the heptapeptide repeat 2 (HR1) of the SARS-CoV-2 spike protein, and / or combinations thereof). Among other things, this specification particularly demonstrates surprising and useful features and / or advantages of certain mRNA constructs that, in certain embodiments, encode portions of the SARS-CoV-2 RBD that do not encode the full-length SARS-CoV-2 S protein.Without wishing to be bound by any particular theory, the present specification suggests that the provided mRNA constructs encoding less than full-length SARS-CoV-2 S proteins, and in particular encoding at least the RBD portion of such SARS-CoV-2 S proteins, may be particularly useful and / or effective for use as or in immunogenic compositions (e.g., vaccines) and / or for achieving the immunological effects described herein (e.g., production of SARS-CoV-2 neutralizing antibodies and / or T cell responses (e.g., CD4+ and / or CD8+ T cell responses)).

[0117] In certain embodiments, the present invention provides RNA (e.g., mRNA) comprising an open reading frame encoding a polypeptide comprising a receptor-binding portion of the SARS-CoV-2 S protein, wherein the RNA is suitable for intracellular expression of the polypeptide. In certain embodiments, such encoded polypeptide does not comprise the entire S protein. In certain embodiments, the encoded polypeptide comprises a receptor-binding domain (RBD), e.g., as set forth in SEQ ID NO: 5. In certain embodiments, the encoded polypeptide comprises the peptide of SEQ ID NO: 29 or 31. In certain embodiments, such RNA (e.g., mRNA) can be complexed with a polycationic polymer, polyplex, protein, or peptide. In certain embodiments, such RNA can be formulated into lipid nanoparticles (e.g., those described herein). In certain embodiments, such RNA (e.g., mRNA) can be particularly useful and / or effective for use as or in an immunogenic composition (e.g., a vaccine) and / or for achieving an immunological effect described herein (e.g., production of SARS-CoV-2 neutralizing antibodies and / or T cell responses (e.g., CD4+ and / or CD8+ T cell responses)). In certain embodiments, such RNA (e.g., mRNA) may be useful for vaccination of humans (e.g., including humans known to have been exposed to and / or infected with SARS-CoV-2 and / or humans with no known exposure to SARS-CoV-2).

[0118] Those of skill in the art having access to this specification will further recognize that this specification describes various mRNA constructs comprising nucleic acid sequences encoding a full-length SARS-CoV-2 spike protein (including, e.g., embodiments in which such encoded SARS-CoV-2 spike protein can include at least one or more amino acid substitutions, e.g., a proline substitution as described herein, and / or embodiments in which the mRNA sequence has been codon-optimized, e.g., for a mammalian, e.g., human, subject). In certain embodiments, such a full-length SARS-CoV-2 spike protein can have an amino acid sequence that is set forth in or includes SEQ ID NO: 7. Still further, those of skill in the art having access to this specification will recognize that this specification describes, among other things, certain features and / or advantages of certain mRNA constructs comprising nucleic acid sequences encoding a full-length SARS-CoV-2 spike protein. Without wishing to be bound by any particular theory, the present invention suggests that the provided mRNA constructs encoding a full-length SARS-CoV-2 S protein may be particularly useful and / or effective for use as or for immunogenic compositions (e.g., vaccines), particularly in subject populations (e.g., particular age groups). For example, in certain embodiments, such mRNA compositions may be particularly useful for younger subjects (e.g., under 25, 20, 18, 15, 10, or younger); alternatively or additionally, in certain embodiments, such mRNA compositions may be particularly useful for older subjects (e.g., over 55, 60, 65, 70, 75, 80, 85, or older).In specific embodiments, immunogenic compositions comprising such mRNA constructs provided herein exhibit, at least in some subjects (e.g., in subjects of a certain age group), minimal to moderate increases (e.g., no more than a 30% increase, no more than a 20% increase, or no more than a 10% increase or less) in dose-level- and / or dose-number-dependent systemic reactogenicity (e.g., fever, fatigue, headache, chills, diarrhea, muscle and / or joint pain, etc.) and / or local tolerance (e.g., pain, redness and / or swelling, etc.); in certain embodiments, such reactogenicity and / or local tolerance is observed particularly in subjects of younger age groups (e.g., under 25 years old, 20 years old, 18 years old or younger) and / or older (e.g., elderly) age groups (e.g., 65-85 years old). In certain embodiments, the provided mRNA constructs encoding the full-length SARS-CoV-2 S protein may be particularly useful and / or effective for use as or in immunogenic compositions (e.g., vaccines) to induce SARS-CoV-2 neutralizing antibody response levels in subject populations at high risk for severe disease associated with SARS-CoV-2 infection (e.g., elderly populations, e.g., the 65-85 age group). In certain embodiments, those of skill in the art having access to this specification will recognize that the provided mRNA constructs encoding the full-length SARS-CoV-2 S protein, which exhibit, among other things, favorable reactogenicity profiles (e.g., those described herein) in younger and older age groups, may be particularly useful and / or effective for use as or in immunogenic compositions (e.g., vaccines) to achieve the immunological effects described herein (e.g., production of SARS-CoV-2 neutralizing antibodies and / or T cell responses (e.g., CD4+ and / or CD8+ T cell responses)). In certain embodiments, the present invention also provides that the provided mRNA constructs encoding the full-length SARS-CoV-2 S protein may be particularly effective in protecting against SARS-CoV-2 infection, as characterized by early clearance of SARS-CoV-2 viral RNA in non-human mammalian subjects (e.g., rhesus macaques) immunized with an immunogenic composition comprising such an mRNA construct and subsequently exposed to a SARS-CoV-2 strain.In certain embodiments, such early clearance of SARS-CoV-2 viral RNA can be observed in the nose of non-human mammalian subjects (e.g., rhesus macaques) immunized with an immunogenic composition comprising such an mRNA construct and subsequently exposed to a SARS-CoV-2 strain.

[0119] In certain embodiments, the present invention provides RNA (e.g., mRNA) comprising an open reading frame encoding a full-length SARS-CoV-2 S protein (e.g., a full-length SARS-CoV-2 S protein with one or more amino acid substitutions), wherein the RNA is suitable for intracellular expression of a polypeptide. In certain embodiments, the encoded polypeptide comprises the amino acid sequence of SEQ ID NO: 7. In certain embodiments, such RNA (e.g., mRNA) can be complexed with a polycationic polymer, polyplex, protein, or peptide. In certain embodiments, such RNA can be formulated into lipid nanoparticles (e.g., those described herein).

[0120] In certain embodiments, the immunogenic compositions provided herein may comprise multiple (e.g., at least two or more, including, e.g., at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, etc.) immunoreactive epitopes of a SARS-CoV-2 polypeptide or variants thereof. In certain such embodiments, such multiple immunoreactive epitopes may be encoded by multiple RNAs (e.g., mRNAs). In certain such embodiments, such multiple immunoreactive epitopes may be encoded by a single RNA (e.g., mRNA). In certain embodiments, nucleic acid sequences encoding multiple immunoreactive epitopes may be separated from each other in a single RNA (e.g., mRNA) by linkers (e.g., peptide linkers, in certain embodiments). Without wishing to be bound by any particular theory, in certain embodiments, provided polyepitopic immunogenic compositions (including, e.g., those encoding a full-length SARS-CoV-2 spike protein) may be particularly useful in providing protection against multiple viral variants, given the genetic diversity of SARS-CoV-2 variants, and / or may increase the chance of obtaining diverse and / or otherwise robust (e.g., durable, e.g., detectable for about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or more days after one or more administrations) neutralizing antibody and / or T cell responses, particularly robust TH1-type T cell (e.g., CD4+ and / or CD8+ T cell) responses.

[0121] In certain embodiments, the present invention demonstrates that the provided compositions and / or methods are characterized (e.g., when administered to a suitable population, which in certain embodiments may be or include an adult population) by achieving one or more particular therapeutic results (e.g., an effective immune response described herein and / or detectable expression of the encoded SARS-CoV-2 S protein or immunogenic fragment thereof) with a single dose; in certain such embodiments, the results may be evaluated, for example, as compared to those observed in the absence of an mRNA vaccine described herein. In certain embodiments, the particular results may be achieved at lower doses than would be required with one or more alternative strategies.

[0122] In some embodiments, the present invention provides immunogenic compositions comprising an isolated messenger ribonucleic acid (mRNA) polynucleotide, wherein the isolated mRNA polynucleotide comprises an open reading frame encoding a polypeptide comprising a receptor-binding portion of the SARS-CoV-2 S protein, and the isolated mRNA polynucleotide is formulated into at least one lipid nanoparticle. For example, in some embodiments, such lipid nanoparticles may comprise a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid (e.g., neutral lipid), 25-55% sterol or steroid, and 0.5-15% polymer-conjugated lipid (e.g., PEG-modified lipid). In some embodiments, the sterol or steroid contained in the lipid nanoparticles may be or may comprise cholesterol. In some embodiments, the neutral lipid may be or may comprise 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). In some embodiments, the polymer-conjugated lipid may be or may comprise PEG2000 DMG. In certain embodiments, such immunogenic compositions may contain a total lipid content of about 1 mg to 10 mg, 3 mg to 8 mg, or 4 mg to 6 mg. In certain embodiments, such immunogenic compositions may contain a total lipid content of about 5 mg / mL to 15 mg / mL, 7.5 mg / mL to 12.5 mg / mL, or 9 to 11 mg / mL. In certain embodiments, such isolated mRNA polynucleotides are provided in an amount effective for inducing an immune response in a subject administered the immunogenic composition at least once. In certain embodiments, the polypeptides encoded by the provided isolated mRNA polynucleotides do not include the complete S protein. In certain embodiments, such isolated mRNA polynucleotides provided in the immunogenic compositions are not self-replicating RNA.

[0123] In certain embodiments, the immune response can include the production of binding antibody titers against a SARS-CoV-2 protein (including, in certain embodiments, for example, a stabilized pre-fusion spike trimer) or a fragment thereof. In certain embodiments, the immune response can include the production of binding antibody titers against the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. In certain embodiments, the provided immunogenic compositions are established to achieve detectable binding antibody titers after the first administration, e.g., at least 70% (e.g., at least 80%, at least 90%, at least 95%, and up to 100%) seroconversion in a subject population receiving such provided immunogenic compositions, for example, in about two weeks.

[0124] In certain embodiments, the immune response may include the production of neutralizing antibody titers against a SARS-CoV-2 protein (including, in certain embodiments, for example, a stabilized pre-fusion spike trimer) or a fragment thereof. In certain embodiments, the immune response may include the production of neutralizing antibody titers against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. In certain embodiments, the provided immunogenic compositions have been established to achieve neutralizing antibody titers in an appropriate system (e.g., humans infected with SARS-CoV-2, humans infected with SARS-CoV-2, and / or populations thereof and / or model systems therefor). For example, in certain embodiments, such neutralizing antibody titers have been demonstrated in one or more human populations, non-human primate models (e.g., rhesus macaques), and / or mouse models.

[0125] In certain embodiments, the neutralizing antibody titer is sufficient (e.g., established to be sufficient) to reduce viral infection of B cells relative to that observed in an appropriate control (e.g., a non-vaccinated control subject or a subject vaccinated with a live-attenuated viral vaccine, an inactivated viral vaccine, or a protein subunit viral vaccine, or a combination thereof). In certain such embodiments, such reduction is at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more.

[0126] In certain embodiments, the neutralizing antibody titer is sufficient (e.g., established to be) to reduce the rate of asymptomatic viral infection relative to that observed in an appropriate control (e.g., non-vaccinated control subjects or subjects vaccinated with a live-attenuated viral vaccine, an inactivated viral vaccine, or a protein subunit viral vaccine, or a combination thereof). In certain such embodiments, such a reduction is at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more. In certain embodiments, such a reduction can be characterized by evaluation of SARS-CoV-2 N protein serology. Significant protection against asymptomatic infection was also confirmed through real-life observations (Dagan N. et al., N Engl J Med. 2021, doi: 10.1056 / NEJMoa2101765. See also Epub ahead of print. PMID: 33626250).

[0127] In certain embodiments, the neutralizing antibody titer is sufficient (e.g., established to be sufficient) to reduce or block fusion of the virus with epithelial cells and / or B cells in the vaccinated subject relative to that observed in an appropriate control (e.g., a non-vaccinated control subject or a subject vaccinated with a live-attenuated virus vaccine, an inactivated virus vaccine, or a protein subunit virus vaccine, or a combination thereof). In certain such embodiments, such reduction is at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more.

[0128] In certain embodiments, the induction of neutralizing antibody titers can be characterized by an increase in B cell numbers, which in certain embodiments can include plasma cells, class-switched IgG1- and IgG2-positive B cells, and / or germinal center B cells. In certain embodiments, provided immunogenic compositions have been shown to achieve such an increase in B cell numbers in an appropriate system (e.g., humans infected with SARS-CoV-2, humans infected with SARS-CoV-2, and / or populations thereof and / or model systems therefor). For example, in certain embodiments, such an increase in B cell numbers has been demonstrated in one or more human populations, non-human primate models (e.g., rhesus macaques), and / or mouse models. In certain embodiments, such an increase in B cell numbers can be demonstrated in the draining lymph nodes and / or spleen of mouse models after immunization of such mouse models with the provided immunogenic compositions (e.g., at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, or at least 14 days after immunization).

[0129] In certain embodiments, the induction of neutralizing antibody titers can be characterized by a reduction in the number of circulating B cells in the blood. In certain embodiments, the provided immunogenic compositions have been established to achieve such a reduction in the number of circulating B cells in an appropriate system (e.g., humans infected with SARS-CoV-2, humans infected with SARS-CoV-2, and / or populations thereof and / or model systems therefor). For example, in certain embodiments, such a reduction in the number of circulating B cells in the blood has been demonstrated in one or more human populations, non-human primate models (e.g., rhesus macaques), and / or mouse models. In certain embodiments, such a reduction in the number of circulating B cells in the blood can be demonstrated in a mouse model (e.g., at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, or at least 10 days) after immunization of such mouse model with the provided immunogenic composition. Without wishing to be bound by theory, the reduction in the number of circulating B cells in the blood may be due to B cell homing to the lymphoid compartment.

[0130] In certain embodiments, the immune response induced by the provided immunogenic compositions can include an increase in the number of T cells. In certain embodiments, such an increase in the number of T cells can include an increase in the number of T follicular helper (TFH) cells, which, in certain embodiments, can include one or more subsets with upregulated ICOS. Those skilled in the art will appreciate that TFH expansion in germinal centers is essential for adaptive B cell responses, and that in humans, TFH production in the circulation after vaccination generally correlates with a high frequency of antigen-specific antibodies. In certain embodiments, the provided immunogenic compositions have been established to achieve such an increase in the number of T cells (e.g., TFH cells) in an appropriate system (e.g., humans infected with SARS-CoV-2 and / or populations thereof and / or model systems therefor). For example, in certain embodiments, such an increase in the number of T cells (e.g., TFH cells) can be demonstrated in one or more human populations, non-human primate models (e.g., rhesus macaques), and / or mouse models. In certain embodiments, such increased numbers of T cells (e.g., T cells) can be demonstrated in the draining lymph nodes, spleen, and / or blood of a mouse model after immunization of such mouse model with a provided immunogenic composition (e.g., at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days after).

[0131] In certain embodiments, a protective response against SARS-CoV-2 induced by a provided immunogenic composition has been established in an appropriate model system for SARS-CoV-2. For example, in certain embodiments, such a protective response can be demonstrated in an animal model, such as a non-human primate model (e.g., rhesus macaque) and / or a mouse model. In certain embodiments, a non-human primate (e.g., rhesus macaque), or a population thereof, that has been immunized at least once with a provided immunogenic composition is exposed to SARS-CoV-2, for example, via the intranasal and / or intratracheal route. In certain embodiments, such exposure can be performed several weeks (e.g., 5 to 10 weeks) after at least one immunization (e.g., including at least two immunizations) with a provided immunogenic composition. In certain embodiments, such exposure may occur when a detectable level of SARS-CoV-2 neutralizing titer (e.g., an antibody response against the SARS-CoV-2 spike protein and / or fragments thereof, including, but not limited to, the stabilized prefusion spike trimer, S-2P, and / or an antibody response against the receptor-binding portion of SARS-CoV-2) is achieved in a non-human primate (e.g., rhesus macaque) that has been immunized at least once (e.g., including at least two immunizations) with a provided immunogenic composition. In certain embodiments, a protective response is characterized by the absence or reduction of detectable viral RNA in bronchoalveolar lavage fluid (BAL) and / or nasal swabs of the exposed non-human primate (e.g., rhesus macaque). In certain embodiments, the immunogenic compositions described herein may be characterized by a higher percentage of BAL and / or nasal swabs showing the absence of detectable RNA in a population of exposed animals, e.g., non-human primates (e.g., rhesus macaques), that have received at least one immunization (e.g., including at least two immunizations) with a provided immunogenic composition, compared to a population of non-immunized animals, e.g., non-human primates (e.g., rhesus macaques).In certain embodiments, the immunogenic compositions described herein can be characterized in that a population of exposed animals, e.g., non-human (e.g., rhesus macaques), that have received at least one immunization (e.g., including at least two immunizations) with a provided immunogenic composition can exhibit clearance of viral RNA in nasal swabs within 10 days, including, e.g., within 8 days, within 6 days, within 4 days, etc., compared to a population of non-immunized animals, e.g., non-human primates (e.g., rhesus macaques).

[0132] In some embodiments, the immunogenic compositions described herein do not substantially increase the risk of enhanced respiratory disease when administered to a subject in need thereof. In some embodiments, such vaccine-associated enhanced respiratory disease may be associated with antibody-dependent enhancement of replication and / or vaccine antigens that induce insufficient neutralizing activity and a Th2-biased response. In some embodiments, the immunogenic compositions described herein do not substantially increase the risk of antibody-dependent enhancement of replication when administered to a subject in need thereof.

[0133] In some embodiments, a single administration of an mRNA composition (e.g., formulated in lipid nanoparticles) can induce a therapeutic antibody response within 10 days of vaccination. In some embodiments, such a therapeutic antibody response can be characterized when such an mRNA vaccine can induce the production of approximately 10-100 μg / mL IgG in an animal model at a dose of 0.1-10 μg or 0.2-5 μg, measured 10 days after vaccination. In some embodiments, such a therapeutic antibody response can be characterized when such an mRNA vaccine can induce approximately 100-1000 μg / mL IgG in an animal model at a dose of 0.1-10 μg or 0.2-5 μg, measured 20 days after vaccination. In some embodiments, a single administration can induce a pseudovirus neutralization titer of 10-200 pVN50 titers, measured 15 days after vaccination in an animal model. In certain embodiments, a single dose can induce pseudovirus neutralization titers of 50-500 pVN50 titers 15 days after vaccination, as measured in an animal model.

[0134] In certain embodiments, a single administration of an mRNA composition can expand an antigen-specific CD8 and / or CD4 T cell response by at least 50% or more (e.g., at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more) compared to that observed in the absence of such an mRNA construct encoding a SARS-COV2 immunogenic protein or fragment thereof (e.g., spike protein and / or receptor binding domain). In certain embodiments, a single administration of an mRNA composition can expand an antigen-specific CD8 and / or CD4 T cell response by at least 1.5-fold or more (e.g., at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1000-fold or more) compared to that observed in the absence of such an mRNA construct encoding a SARS-COV2 immunogenic protein or fragment thereof (e.g., spike protein and / or receptor binding domain).

[0135] In certain embodiments, the regimen (e.g., a single administration of an mRNA composition) can expand T cells exhibiting a Th1 phenotype (e.g., as characterized by expression of IFN-gamma, IL-2, IL-4, and / or IL-5) at least 50% or more (e.g., including at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more) compared to that observed in the absence of such an mRNA construct encoding a SARS-COV2 immunogenic protein or fragment thereof (e.g., spike protein and / or receptor binding domain). In certain embodiments, the regimen (e.g., a single administration of an mRNA composition) can expand, for example, at least 1.5-fold or more (including, for example, at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1000-fold or more) T cells exhibiting a Th1 phenotype (e.g., characterized by expression of IFN-gamma, IL-2, IL-4, and / or IL-5) compared to that observed in the absence of such an mRNA construct encoding a SARS-COV2 immunogenic protein or fragment thereof (e.g., spike protein and / or receptor binding domain). In certain embodiments, the T cell phenotype can or may include a predominantly Th1 cytokine profile (e.g., characterized by IFN-gamma positivity and / or IL-2 positivity) and / or absent or biologically insignificant IL-4 secretion.

[0136] In certain embodiments, the regimens described herein (e.g., one or more administrations of an mRNA composition) induce and / or achieve the production of CD4+ T cells. Among other things, the present invention demonstrates that mRNA compositions encoding an RBD-containing portion of the SARS-CoV-2 spike protein (e.g., that do not additionally encode the full-length SARS-CoV-2 spike protein) can be particularly useful and / or effective for such induction and / or production of RBD-specific CD4+ T cells. In certain embodiments, RBD-specific CD4+ T cells induced by the mRNA compositions described herein (e.g., mRNA compositions encoding the RBD-containing portion of the SARS-CoV-2 spike protein, and in certain embodiments, that do not encode the full-length SARS-CoV-2 spike protein) exhibit a predominantly Th1 cytokine profile (e.g., characterized by INF-gamma positivity and / or IL-2 positivity) and / or exhibit absent or biologically insignificant IL-4 secretion.

[0137] In certain embodiments, characterization of CD4+ and / or CD8+ T cell responses (e.g., as described herein) in subjects who have received an mRNA composition (e.g., as described herein) can be performed using an ex vivo assay using PBMCs obtained from the subject.

[0138] In certain embodiments, the immunogenicity of the mRNA compositions described herein may be assessed by one or more serum immunogenicity assays that detect IgG, IgM, and / or IgA against the SARS-CoV-2 S protein present in a blood sample from a subject who received a provided mRNA composition and / or a neutralization assay using a SARS-CoV-2 pseudovirus and / or wild-type SARS-CoV-2 virus.

[0139] In some embodiments, mRNA compositions (e.g., those described herein) at doses of 10 μg to 100 μg or 1 μg to 50 μg result in relatively low adverse effects (e.g., grade 1 to grade 2 pain, redness, and / or swelling) within 7 days after vaccination. In some embodiments, mRNA compositions (e.g., those described herein) at doses of 10 μg to 100 μg result in relatively low observation of systemic events (e.g., grade 1 to grade 2 fever, fatigue, headache, chills, vomiting, diarrhea, muscle pain, joint pain, medication, and combinations thereof) within 7 days after vaccination.

[0140] In certain embodiments, the mRNA composition is characterized by being capable of producing IgG against a SARS-CoV2 immunogenic protein or fragment thereof (e.g., spike protein and / or receptor binding domain) at levels of 100 to 100,000 U / mL or 500 to 50,000 U / mL 21 days after vaccination when administered to a subject at a dose of 10 to 100 μg or 1 μg to 50 μg.

[0141] In some embodiments, the mRNA encodes a naturally folded trimeric receptor-binding protein of SARS-CoV-2. In some embodiments, the mRNA encodes a variant of such a receptor-binding protein such that the encoded variant binds to ACE2 with a Kd of 10 pM or less, including, for example, a Kd of 9 pM, 8 pM, 7 pM, 6 pM, 5 pM, 4 pM or less. In some embodiments, the mRNA encodes a variant of such a receptor-binding protein such that the encoded variant binds to ACE2 with a Kd of 5 pM. In some embodiments, the mRNA encodes a receptor-binding portion of trimeric SARS-CoV-2 that includes an ACE2 receptor-binding site. In some embodiments, the mRNA includes a coding sequence for a receptor-binding portion of SARS-CoV-2 and a trimerization domain (e.g., the native trimerization domain (foldon) of T4 fibritin) such that the coding sequence directs the expression of a trimeric protein that has an ACE2 receptor-binding site and binds to ACE2. In some embodiments, the mRNA encodes a receptor-binding portion of trimeric SARS-CoV-2 or a variant thereof such that the Kd is less than for the monomeric receptor binding domain (RBD) of SARS-CoV-2. For example, in some embodiments, the mRNA encodes a receptor-binding portion of trimeric SARS-CoV-2 or a variant thereof such that the Kd is at least 10-fold (including, e.g., at least 50-fold, at least 100-fold, at least 500-fold, at least 1000-fold, etc.) less than for the RBD of SARS-CoV-2.

[0142] In certain embodiments, the receptor-binding portion of trimeric SARS-CoV-2 encoded by an mRNA (e.g., as described herein) can be characterized by cryo-electron microscopy (cryoEM) and determined to have a size of approximately 3-4 angstroms when in a closed conformation and complexed with ACE2 and the B0AT1 neutral amino acid transporter. In certain embodiments, the geometric mean SARS-CoV-2 neutralization titer characterized and / or achieved by the mRNA compositions or methods described herein can reach at least 1.5-fold, including at least 2-fold, at least 2.5-fold, at least 3-fold, or more, of a COVID-19 convalescent human panel (e.g., a serum panel obtained from COVID-19 convalescent humans 20-40 days after onset of symptom onset and at least 14 days after the onset of the asymptomatic convalescent phase).

[0143] In certain embodiments, the mRNA compositions provided herein may be characterized in that subjects treated with such compositions (e.g., at least one dose, at least two doses, etc.) may exhibit reduced and / or shorter-lasting presence of viral RNA in relevant sites (e.g., nose and / or lungs, etc., and / or any other tissue susceptible to infection) compared to appropriate controls (e.g., established expected levels for comparable subjects or populations not so treated and exposed to the virus under reasonably comparable exposure conditions).

[0144] In certain embodiments, the RBD antigen expressed by an mRNA construct (e.g., one described herein) can be modified, for example, by the addition of the T4-fibritin-derived "Foldon" trimerization domain to enhance immunogenicity.

[0145] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by certain local reactions (e.g., pain, redness, and / or swelling, etc.) and / or systemic events (e.g., fever, fatigue, headache, etc.) that may appear and / or peak on day 2 after vaccination. In certain embodiments, the mRNA compositions described herein are characterized by certain local reactions (e.g., pain, redness, and / or swelling, etc.) and / or systemic events (e.g., fever, fatigue, headache, etc.) that may resolve on day 7 after vaccination.

[0146] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by the absence of Grade 1 or higher changes or laboratory abnormalities in routine laboratory tests in subjects receiving an mRNA composition (e.g., one described herein). Examples of such laboratory assays can include lymphocyte counts, hematological changes, and the like.

[0147] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by being capable of achieving a geometric mean concentration (GMC) of IgG against a SARS-CoV-2 S polypeptide or immunogenic fragment thereof (e.g., RBD) of 200-3000 Units / mL, or 500-3000 Units / mL, or 500-2000 Units / mL, compared to 602 Units / mL in a panel of COVID-19 convalescent human sera, by 21 days after the first administration (e.g., containing 10-100 μg or containing 1 μg-50 μg). In certain embodiments, the mRNA compositions described herein are characterized by the fact that by 7 days after the second administration (e.g., comprising 10-30 μg; or comprising 1 μg-50 μg), the geometric mean concentration (GMC) of IgG against the SARS-CoV-2 spike polypeptide or immunogenic fragment thereof (e.g., RBD) can be increased by at least 8-fold or more, including, for example, at least 9-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 35-fold, at least 40-fold or more. In certain embodiments, the mRNA compositions described herein are characterized by an increase in the geometric mean concentration (GMC) of IgG against a SARS-CoV-2 S polypeptide or immunogenic fragment thereof (e.g., RBD) of 1500 Units / mL to 40,000 Units / mL or 4000 Units / mL to 40,000 Units / mL by 7 days after the second administration (e.g., containing 10 to 30 μg; or containing 1 μg to 50 μg). In certain embodiments, the antibody concentrations described herein can persist for at least 20 days or more, including at least 25 days, at least 30 days, at least 35 days, at least 40 days, at least 45 days, or at least 50 days, after the first administration, or for at least 10 days or more, including at least 15 days, at least 20 days, at least 25 days, or more, after the second administration. In certain embodiments, the antibody concentrations can persist for 35 days after the first administration or for at least 14 days after the second administration.

[0148] In certain embodiments, the mRNA compositions described herein are characterized by a GMC of IgG against a SARS-CoV-2 S polypeptide or immunogenic fragment thereof (e.g., RBD) that is at least 30% higher, including, for example, at least 40% higher, at least 50% higher, at least 60% higher, at least 70% higher, at least 80% higher, at least 90% higher, or at least 95% higher, when measured 7 days after the second dose (e.g., comprising 1-50 μg), compared to antibody concentrations observed in a panel of COVID-19 convalescent human sera. In many embodiments, the geometric mean concentrations (GMCs) of IgG described herein are GMCs of RBD-binding IgG.

[0149] In certain embodiments, the mRNA compositions described herein are characterized by a GMC of IgG against a SARS-CoV-2 S polypeptide or immunogenic fragment thereof (e.g., RBD) that is at least 1.1-fold higher (including, e.g., at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold higher, at least 7-fold higher, at least 8-fold higher, at least 9-fold higher, at least 10-fold higher, at least 15-fold higher, at least 20-fold higher, at least 25-fold higher, or at least 30-fold higher) compared to antibody concentrations observed in a panel of COVID-19 convalescent human sera when measured 7 days after the second dose (e.g., containing 10-50 μg). In many embodiments, the geometric mean concentration (GMC) of IgG described herein is the GMC of RBD-binding IgG.

[0150] In certain embodiments, the mRNA compositions described herein are characterized by a GMC of IgG against a SARS-CoV-2 S polypeptide or immunogenic fragment thereof (e.g., RBD) that is at least 5-fold higher (including, e.g., at least 6-fold higher, at least 7-fold higher, at least 8-fold higher, at least 9-fold higher, at least 10-fold higher, at least 15-fold higher, at least 20-fold higher, at least 25-fold higher, or at least 30-fold higher) compared to antibody concentrations observed in a panel of COVID-19 convalescent human sera, measured 21 days after the second dose. In many embodiments, the geometric mean concentration (GMC) of IgG described herein is the GMC of RBD-binding IgG.

[0151] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by an increase in SARS-CoV-2 neutralization geometric mean titer (GMT) (e.g., at least 30%, at least 40%, at least 50% or more) observed 21 days after the first dose. In certain embodiments, the mRNA compositions described herein are characterized by a significantly greater serum neutralization GMT achieved 7 days after receiving a second dose (e.g., comprising 10 μg to 30 μg), reaching 150 to 300 compared to 94 in a COVID-19 convalescent serum panel.

[0152] In some embodiments, the mRNA compositions and / or methods described herein are characterized by a preventive efficacy of at least 60%, e.g., at least 70%, at least 80%, at least 90%, or at least 95%, 7 days after the second administration. In some embodiments, the mRNA compositions and / or methods described herein are characterized by a preventive efficacy of at least 70% 7 days after the second administration. In some embodiments, the mRNA compositions and / or methods described herein are characterized by a preventive efficacy of at least 80% 7 days after the second administration. In some embodiments, the mRNA compositions and / or methods described herein are characterized by a preventive efficacy of at least 90% 7 days after the second administration. In some embodiments, the mRNA compositions and / or methods described herein are characterized by a preventive efficacy of at least 95% 7 days after the second administration.

[0153] In some embodiments, the RNA compositions provided herein are characterized by inducing an immune response against SARS-CoV-2 at least 7 days after administration (e.g., after the second administration). In some embodiments, the RNA compositions provided herein are characterized by inducing an immune response against SARS-CoV-2 within 14 days after administration (e.g., after the second administration). In some embodiments, the RNA compositions provided herein are characterized by inducing an immune response against SARS-CoV-2 at least 7 days after a vaccination regimen. In some embodiments, the vaccination regimen includes a first administration and a second administration. In some embodiments, the first administration and the second administration are administered at least 21 days apart. In some such embodiments, the immune response against SARS-CoV-2 is induced at least 28 days after the first administration.

[0154] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by a substantially higher geometric mean concentration (GMC) of antibodies to a SARS-CoV-2 spike polypeptide or immunogenic fragment thereof (e.g., RBD) as measured in serum from a subject who received an mRNA composition of the invention (e.g., a dose of 10-30 μg, inclusive) than in a convalescent serum panel (e.g., one described herein). In certain embodiments, when a subject may have received a second dose (e.g., 21 days after the first dose), the geometric mean concentration (GMC) of antibodies to a SARS-CoV-2 spike polypeptide or immunogenic fragment thereof (e.g., RBD) as measured in the serum of the subject may be 8.0-fold to 50-fold higher than the convalescent serum panel GMC. In certain embodiments, when a subject may have received a second dose (e.g., 21 days after the first initial dose), the geometric mean concentration (GMC) of antibodies to a SARS-CoV-2 spike polypeptide or immunogenic fragment thereof (e.g., RBD), as measured in the subject's serum, may be at least 8.0-fold or more, including at least 10-fold, at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 60-fold or more, compared to the convalescent serum panel GMC.

[0155] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by the SARS-CoV-2 neutralization geometric mean titer, measured 28 days after the first dose or 7 days after the second dose, can be at least 1.5-fold or greater (including, e.g., at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold or greater) compared to the neutralization GMT of a convalescent serum panel.

[0156] In some embodiments, the regimen administered to a subject can be or include a single administration. In some embodiments, the regimen administered to a subject can include multiple administrations (e.g., at least two administrations, at least three administrations or more). In some embodiments, the regimen administered to a subject can include a first administration and a second administration, which are given at least 2 weeks apart, at least 3 weeks apart, at least 4 weeks apart or more. In some embodiments, such administrations can be at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or more apart. In certain embodiments, administrations can be separated by a number of days, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 ​​days, 49 days, 50 days, 51 days, 52 days, 53 days, 54 days, 55 days, 56 days, 57 days, 58 days, 59 days, 60 days or more. In some embodiments, administrations can be about 1 to about 3 weeks apart, or about 1 to about 4 weeks apart, or about 1 to about 5 weeks apart, or about 1 to about 6 weeks apart, or about 1 to 6 weeks or more apart. In some embodiments, administrations can be separated by a period of about 7 to about 60 days, e.g., about 14 to about 48 days. In some embodiments, the minimum number of days between administrations can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or more. In certain embodiments, the maximum number of days between doses can be about 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21 or less.In some embodiments, administrations can be about 21 to about 28 days apart. In some embodiments, administrations can be about 19 to about 42 days apart. In some embodiments, administrations can be about 7 to about 28 days apart. In some embodiments, administrations can be about 14 to about 24 days apart. In some embodiments, administrations can be about 21 to about 42 days apart.

[0157] In certain embodiments, particularly for compositions established to achieve antibody and / or T cell titer elevations for periods of greater than about three weeks—for example, in certain embodiments, provided compositions are established to achieve antibody and / or T cell titer elevations (e.g., specific to the relevant portion of the SARS-CoV-2 spike protein) for periods of greater than about three weeks—in certain such embodiments, the dosing regimen may include only a single administration or may include two administrations, which, in certain embodiments, may be separated from each other by periods of greater than about 21 days or 3 weeks. For example, in certain such embodiments, such periods may be about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 weeks or more, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more, or in certain embodiments, about 1 year or more.

[0158] In some embodiments, the first and second doses (and / or other subsequent doses) may be administered by intramuscular injection. In some embodiments, the first and second doses may be administered in the deltoid muscle. In some embodiments, the first and second doses may be administered in the same arm. In some embodiments, the mRNA compositions described herein are administered (e.g., by intramuscular injection) as a series of two doses (e.g., 0.3 mL each) spaced 21 days apart. In some embodiments, each dose is about 30 μg. In some embodiments, each dose may be greater than 30 μg, e.g., about 40 μg, about 50 μg, or about 60 μg. In some embodiments, each dose may be less than 30 μg, e.g., about 20 μg, about 10 μg, about 5 μg, etc. In some embodiments, each dose is about 3 μg or less, e.g., about 1 μg. In some such embodiments, the mRNA compositions described herein are administered to subjects aged 16 years or older (e.g., including those aged 16 to 85 years). In some such embodiments, the mRNA compositions described herein are administered to subjects between the ages of 18 and 55. In some such embodiments, the mRNA compositions described herein are administered to subjects between the ages of 56 and 85. In some embodiments, the mRNA compositions described herein are administered as a single dose (e.g., by intramuscular injection).

[0159] In certain embodiments, the mRNA compositions and / or methods described herein are characterized in that the RBD-specific IgG (e.g., polyclonal response) induced by such mRNA compositions and / or methods exhibits higher binding affinity to the RBD compared to a control human monoclonal antibody with SARS-CoV-2 RBD binding affinity (e.g., CR3022 described in J. ter Meulen et al., PLOS Med. 3, e237 (2006)).

[0160] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity across a panel of SARs-CoV-2 spike variants (e.g., at least 10, at least 15, or more). In certain embodiments, such SARs-CoV-2 spike variants include mutations in the RBD (e.g., but not limited to, Q321L, V341I, A348T, N354D, S359N, V367F, K378R, R408I, Q409E, A435S, N439K, K458R, I472V, G476S, S477N, V483A, Y508H, H519P, etc., compared to SEQ ID NO: 1) and / or mutations in the spike protein (e.g., but not limited to, D614G, etc., compared to SEQ ID NO: 1). Those skilled in the art will be aware of the various spike variants and / or resources describing them (e.g., the Table of mutating sites in Spike maintained by the COVID-19 Viral Genome Analysis Pipeline and found at https: / / cov.lanl.gov / components / sequence / COV / int_sites_tbls.com) and, having read this specification, will know that the mRNA compositions and / or methods described herein may be characterized by their ability to induce sera in vaccinated subjects that exhibit neutralizing activity with respect to any or all of such variants and / or combinations thereof.

[0161] In a specific embodiment, the mRNA composition encoding the RBD of the SARS-CoV-2 spike protein is characterized by sera from vaccinated subjects exhibiting neutralizing activity across a panel (e.g., at least 10, at least 15, or more) of SARS-CoV-2 spike variants, including RBD variants (e.g., but not limited to, Q321L, V341I, A348T, N354D, S359N, V367F, K378R, R408I, Q409E, A435S, N439K, K458R, I472V, G476S, S477N, V483A, Y508H, H519P, etc., compared to SEQ ID NO: 1) and spike protein variants (e.g., but not limited to, D614G, compared to SEQ ID NO: 1).

[0162] In a specific embodiment, an mRNA composition encoding a SARS-CoV-2 spike protein variant comprising two consecutive proline substitutions at amino acid positions 986 and 987 at the apex of the central helix in the S2 subunit is characterized in that sera from vaccinated subjects exhibit neutralizing activity across a panel (e.g., at least 10, at least 15, or more) of SARs-CoV-2 spike variants, including RBD variants (e.g., but not limited to, Q321L, V341I, A348T, N354D, S359N, V367F, K378R, R408I, Q409E, A435S, N439K, K458R, I472V, G476S, S477N, V483A, Y508H, H519P, etc., compared to SEQ ID NO: 1) and spike protein variants (e.g., but not limited to, D614G, compared to SEQ ID NO: 1). For example, in certain embodiments, an mRNA composition encoding SEQ ID NO:7 (SP2) elicits an immune response against any one of the SARs-CoV-2 spike variants, including RBD variants (e.g., but not limited to, Q321L, V341I, A348T, N354D, S359N, V367F, K378R, R408I, Q409E, A435S, N439K, K458R, I472V, G476S, S477N, V483A, Y508H, H519P, etc., compared to SEQ ID NO:1) and spike protein variants (e.g., but not limited to, D614G, compared to SEQ ID NO:1).

[0163] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising a mutation at position 501 of the spike protein compared to SEQ ID NO: 1. In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising a N501Y mutation in the spike protein compared to SEQ ID NO: 1.

[0164] The one or more SARs-CoV-2 spike variants comprising a mutation at position 501 of the spike protein compared to SEQ ID NO: 1 or the one or more SARs-CoV-2 spike variants comprising a N501Y mutation in the spike protein compared to SEQ ID NO: 1 may comprise one or more additional mutations compared to SEQ ID NO: 1 (such as, but not limited to, an H69 / V70 deletion, a Y144 deletion, A570D, D614G, P681H, T716I, S982A, D1118H, D80A, D215G, E484K, A701V, L18F, R246I, K417N, or an L242 / A243 / L244 deletion compared to SEQ ID NO: 1).

[0165] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARS-CoV-2 spike variant "Variant of Concern 202012 / 01" (VOC-202012 / 01; also known as lineage B.1.1.7). The variant was previously designated by Public Health England as Variant Under Investigation in December 2020 (VUI - 202012 / 01) but has since been reclassified as Variant of Concern (VOC-202012 / 01). VOC-202012 / 01 is a variant of SARS-CoV-2 that was first detected in the UK in October 2020 during the COVID-19 pandemic in samples collected the previous month and began spreading rapidly by mid-December. This correlates with a significant increase in COVID-19 infection rates in the UK; this increase is thought to be due, at least in part, to the N501Y mutation within the receptor-binding domain of the spike glycoprotein, which is required for binding to ACE2 in human cells. The VOC-202012 / 01 variant is defined by 23 mutations: 13 nonsynonymous, 4 deletions, and 6 synonymous mutations (i.e., 17 protein-altering mutations and 6 non-altering mutations). Spike protein changes in VOC-202012 / 01 include deletions 69-70, 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. One of the most significant changes in VOC-202012 / 01 involves an asparagine (N) to tyrosine (Y) change at amino acid position 501, N501Y. This mutation, alone or together with the deletion at positions 69 / 70 in the N-terminal domain (NTD), can enhance viral infectivity.

[0166] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against SARs-CoV-2 spike variants comprising the following mutations compared to SEQ ID NO:1: deletion 69-70, deletion 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H.

[0167] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARs-CoV-2 spike variant "501.V2." This variant was first observed in samples in October 2020; since then, over 300 cases of the 501.V2 variant have been confirmed by whole genome sequencing (WGS) in South Africa, where it became the dominant form of virus by December 2020. Preliminary results indicate that this variant may have increased transmissibility. The 501.V2 variant is defined by multiple spike protein changes, including D80A, D215G, E484K, N501Y, and A701V; more recently collected viruses harbor additional changes: L18F, R246I, K417N, and deletion 242-244.

[0168] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising mutations D80A, D215G, E484K, N501Y, and A701V compared to SEQ ID NO: 1, and optionally L18F, R246I, K417N, and deletion 242-244 compared to SEQ ID NO: 1. The SARs-CoV-2 spike variant may also comprise a D614G mutation compared to SEQ ID NO: 1.

[0169] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising an H69 / V70 deletion in the spike protein compared to SEQ ID NO:1.

[0170] In certain embodiments, one or more SARs-CoV-2 spike variants comprising an H69 / V70 deletion in the spike protein compared to SEQ ID NO: 1 may comprise one or more additional mutations compared to SEQ ID NO: 1 (e.g., but not limited to, a Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, D80A, D215G, E484K, A701V, L18F, R246I, K417N, an L242 / A243 / L244 deletion, Y453F, I692V, S1147L, M1229I, etc. compared to SEQ ID NO: 1).

[0171] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARs-CoV-2 spike variant "Variant of Concern 202012 / 01" (VOC-202012 / 01; also known as lineage B.1.1.7).

[0172] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against SARs-CoV-2 spike variants comprising the following mutations compared to SEQ ID NO:1: deletion 69-70, deletion 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H.

[0173] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARs-CoV-2 spike variant "Cluster 5," also designated ΔFVI-spike by the Danish Serum Institute (SSI). It was discovered in North Denmark and is believed to have spread from mink to humans on mink farms. Several different mutations in the viral spike protein have been identified in Cluster 5. Specific mutations include 69-70 deltaHV (deletion of histidine and valine residues at positions 69 and 79 of the protein), Y453F (a tyrosine to phenylalanine change at position tyrosine), I692V (isoleucine to valine at position isoleucine), M1229I (methionine to isoleucine at position methionine), and, optionally, S1147L (serine to leucine at position serine).

[0174] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising deletions 69-70, Y453F, I692V, M1229I, and optionally the mutation S1147L compared to SEQ ID NO:1.

[0175] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising a mutation at position 614 in the spike protein compared to SEQ ID NO: 1. In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising a D614G mutation in the spike protein compared to SEQ ID NO: 1.

[0176] In certain embodiments, one or more SARs-CoV-2 spike variants comprising a mutation at position 614 in the spike protein compared to SEQ ID NO: 1 or one or more SARs-CoV-2 spike variants comprising a D614G mutation in the spike protein compared to SEQ ID NO: 1 may comprise one or more additional mutations compared to SEQ ID NO: 1 (e.g., but not limited to, H69 / V70 deletion, Y144 deletion, N501Y, A570D, P681H, T716I, S982A, D1118H, D80A, D215G, E484K, A701V, L18F, R246I, K417N, L242 / A243 / L244 deletion, Y453F, I692V, S1147L, M1229I, etc., compared to SEQ ID NO: 1).

[0177] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARs-CoV-2 spike variant "Variant of Concern 202012 / 01" (VOC-202012 / 01; also known as lineage B.1.1.7).

[0178] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against SARs-CoV-2 spike variants comprising the following mutations compared to SEQ ID NO:1: deletion 69-70, deletion 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H.

[0179] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising the following mutations relative to SEQ ID NO:1: D80A, D215G, E484K, N501Y, A701V, and D614G, and optionally L18F, R246I, K417N, and deletion 242-244, relative to SEQ ID NO:1.

[0180] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising mutations at positions 501 and 614 in the spike protein compared to SEQ ID NO: 1. In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising mutations at positions N501Y and D614G in the spike protein compared to SEQ ID NO: 1.

[0181] In certain embodiments, one or more SARs-CoV-2 spike variants comprising mutations at positions 501 and 614 in the spike protein compared to SEQ ID NO: 1 or one or more SARs-CoV-2 spike variants comprising N501Y and D614G mutations in the spike protein compared to SEQ ID NO: 1 may comprise one or more additional mutations compared to SEQ ID NO: 1 (e.g., but not limited to, H69 / V70 deletion, Y144 deletion, A570D, P681H, T716I, S982A, D1118H, D80A, D215G, E484K, A701V, L18F, R246I, K417N, L242 / A243 / L244 deletion, Y453F, I692V, S1147L, M1229I, etc., compared to SEQ ID NO: 1).

[0182] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARs-CoV-2 spike variant "Variant of Concern 202012 / 01" (VOC-202012 / 01; also known as lineage B.1.1.7).

[0183] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against SARs-CoV-2 spike variants comprising the following mutations compared to SEQ ID NO:1: deletion 69-70, deletion 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H.

[0184] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising the following mutations relative to SEQ ID NO:1: D80A, D215G, E484K, N501Y, A701V, and D614G, and optionally L18F, R246I, K417N, and deletion 242-244, relative to SEQ ID NO:1.

[0185] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising a mutation at position 484 in the spike protein compared to SEQ ID NO: 1. In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising an E484K mutation in the spike protein compared to SEQ ID NO: 1.

[0186] In certain embodiments, one or more SARs-CoV-2 spike variants comprising a mutation at position 484 in the spike protein compared to SEQ ID NO: 1 or one or more SARs-CoV-2 spike variants comprising an E484K mutation in the spike protein compared to SEQ ID NO: 1 may comprise one or more additional mutations compared to SEQ ID NO: 1 (e.g., a H69 / V70 deletion, a Y144 deletion, a Examples of such deletions include, but are not limited to, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, D80A, D215G, A701V, L18F, R246I, K417N, L242 / A243 / L244 deletion, Y453F, I692V, S1147L, M1229I, T20N, P26S, D138Y, R190S, K417T, H655Y, T1027I, and V1176F.

[0187] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against SARs-CoV-2 spike variant "501.V2."

[0188] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising the following mutations relative to SEQ ID NO: 1: D80A, D215G, E484K, N501Y, and A701V, and optionally L18F, R246I, K417N, and deletion 242-244, relative to SEQ ID NO: 1. The SARs-CoV-2 spike variant may also comprise the D614G mutation relative to SEQ ID NO: 1.

[0189] The lineage B.1.1.248, also known as the Brazilian variant, is one of the SARS-CoV-2 variants designated the P.1 lineage. It contains 17 unique amino acid changes, 10 of which are in its spike protein, including N501Y and E484K. B.1.1.248 originated from B.1.1.28. E484K is present in both B.1.1.28 and B.1.1.248. B.1.1.248 contains multiple S-protein polymorphisms [L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, and V1176F] and is similar to the variant reported from South Africa at certain critical RBD positions (K417, E484, and N501).

[0190] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARs-CoV-2 spike variant "B.1.1.28."

[0191] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARs-CoV-2 spike variant "B.1.1.248."

[0192] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising the following mutations compared to SEQ ID NO:1: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, and V1176F.

[0193] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising mutations at positions 501 and 484 in the spike protein compared to SEQ ID NO: 1. In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising mutations at positions N501Y and E484K in the spike protein compared to SEQ ID NO: 1.

[0194] In certain embodiments, one or more SARs-CoV-2 spike variants comprising mutations at positions 501 and 484 in the spike protein compared to SEQ ID NO: 1 or one or more SARs-CoV-2 spike variants comprising N501Y and E484K mutations in the spike protein compared to SEQ ID NO: 1 may comprise one or more additional mutations compared to SEQ ID NO: 1 (e.g., H69 / V compared to SEQ ID NO: 1). 70 deletion, Y144 deletion, A570D, D614G, P681H, T716I, S982A, D1118H, D80A, D215G, A701V, L18F, R246I, K417N, L242 / A243 / L244 deletion, Y453F, I692V, S1147L, M1229I, T20N, P26S, D138Y, R190S, K417T, H655Y, T1027I, V1176F, etc.).

[0195] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against SARs-CoV-2 spike variant "501.V2."

[0196] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising mutations D80A, D215G, E484K, N501Y, and A701V compared to SEQ ID NO: 1, and optionally L18F, R246I, K417N, and deletion 242-244 compared to SEQ ID NO: 1. The SARs-CoV-2 spike variant may also comprise a D614G mutation compared to SEQ ID NO: 1.

[0197] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARs-CoV-2 spike variant "B.1.1.248."

[0198] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising the following mutations compared to SEQ ID NO:1: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, and V1176F.

[0199] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising mutations at positions 501, 484, and 614 in the spike protein compared to SEQ ID NO: 1. In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising mutations at positions N501Y, E484K, and D614G in the spike protein compared to SEQ ID NO: 1.

[0200] In certain embodiments, one or more SARs-CoV-2 spike variants comprising mutations at positions 501, 484, and 614 in the spike protein compared to SEQ ID NO: 1 or one or more SARs-CoV-2 spike variants comprising N501Y, E484K, and D614G mutations in the spike protein compared to SEQ ID NO: 1 may comprise one or more additional mutations compared to SEQ ID NO: 1 (e.g., In comparison, mutations such as, but not limited to, H69 / V70 deletion, Y144 deletion, A570D, P681H, T716I, S982A, D1118H, D80A, D215G, A701V, L18F, R246I, K417N, L242 / A243 / L244 deletion, Y453F, I692V, S1147L, M1229I, T20N, P26S, D138Y, R190S, K417T, H655Y, T1027I, and V1176F.

[0201] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising the following mutations relative to SEQ ID NO:1: D80A, D215G, E484K, N501Y, A701V, and D614G, and optionally L18F, R246I, K417N, and deletion 242-244, relative to SEQ ID NO:1.

[0202] In certain embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against one or more SARs-CoV-2 spike variants comprising an L242 / A243 / L244 deletion in the spike protein compared to SEQ ID NO:1.

[0203] In certain embodiments, one or more SARs-CoV-2 spike variants comprising an L242 / A243 / L244 deletion in the spike protein compared to SEQ ID NO: 1 may comprise one or more additional mutations compared to SEQ ID NO: 1 (e.g., but not limited to, an H69 / V70 deletion, a Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, D80A, D215G, E484K, A701V, L18F, R246I, K417N, Y453F, I692V, S1147L, M1229I, T20N, P26S, D138Y, R190S, K417T, H655Y, T1027I, V1176F, etc., compared to SEQ ID NO: 1).

[0204] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against SARs-CoV-2 spike variant "501.V2."

[0205] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising mutations at D80A, D215G, E484K, N501Y, A701V, and deletions 242-244 relative to SEQ ID NO: 1, and optionally L18F, R246I, and K417N relative to SEQ ID NO: 1. The SARs-CoV-2 spike variant may also comprise a D614G mutation relative to SEQ ID NO: 1.

[0206] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising a mutation at position 417 in the spike protein compared to SEQ ID NO: 1. In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising a K417N or K417T mutation in the spike protein compared to SEQ ID NO: 1.

[0207] In certain embodiments, one or more SARs-CoV-2 spike variants comprising a mutation at position 417 in the spike protein compared to SEQ ID NO: 1 or one or more SARs-CoV-2 spike variants comprising a K417N or K417T mutation in the spike protein compared to SEQ ID NO: 1 may comprise one or more additional mutations compared to SEQ ID NO: 1 (e.g., a H69 / V70 deletion, Examples include, but are not limited to, Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, D80A, D215G, E484K, A701V, L18F, R246I, L242 / A243 / L244 deletion, Y453F, I692V, S1147L, M1229I, T20N, P26S, D138Y, R190S, H655Y, T1027I, and V1176F.

[0208] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against SARs-CoV-2 spike variant "501.V2."

[0209] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising D80A, D215G, E484K, N501Y, A701V, and K417N compared to SEQ ID NO: 1, and optionally L18F, R246I, and deletions 242-244 compared to SEQ ID NO: 1. The SARs-CoV-2 spike variant may also comprise a D614G mutation compared to SEQ ID NO: 1.

[0210] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARs-CoV-2 spike variant "B.1.1.248."

[0211] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising the following mutations compared to SEQ ID NO:1: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, and V1176F.

[0212] In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising mutations at positions 417 and 484 and / or 501 in the spike protein compared to SEQ ID NO: 1. In certain embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against one or more SARs-CoV-2 spike variants comprising mutations at positions 417 and 484 and / or 501 in the spike protein compared to SEQ ID NO: 1.

[0213] In some embodiments, one or more SARs-CoV-2 spike variants comprising mutations at positions 417 and 484 and / or 501 in the spike protein compared to SEQ ID NO: 1 or comprising a K417N or K417T mutation and an E484K and / or N501Y mutation in the spike protein compared to SEQ ID NO: 1 may comprise one or more further mutations compared to SEQ ID NO: 1. (For example, compared to SEQ ID NO: 1, H69 / V70 deletion, Y144 deletion, A570D, D614G, P681H, T716I, S982A, D1118H, D80A, D215G, A701V, L18F, R246I, L242 / A243 / L244 deletion, Y453F, I692V, S1147L, M1229I, T20N, P26S, D138Y, R190S, H655Y, T1027I, V1176F, etc., but are not limited to these.)

[0214] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against SARs-CoV-2 spike variant "501.V2."

[0215] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising the following mutations relative to SEQ ID NO: 1: D80A, D215G, E484K, N501Y, A701V, and K417N, and optionally L18F, R246I, and deletion 242-244, relative to SEQ ID NO: 1. The SARs-CoV-2 spike variant may also comprise the D614G mutation relative to SEQ ID NO: 1.

[0216] In specific embodiments, the mRNA compositions and / or methods described herein are characterized by sera from vaccinated subjects exhibiting neutralizing activity against the SARs-CoV-2 spike variant "B.1.1.248."

[0217] In specific embodiments, the mRNA compositions and / or methods described herein are characterized in that sera from vaccinated subjects exhibit neutralizing activity against a SARs-CoV-2 spike variant comprising the following mutations compared to SEQ ID NO:1: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, and V1176F.

[0218] The SARs-CoV-2 spike variants described herein may or may not contain the D614G mutation compared to SEQ ID NO:1.

[0219] In certain embodiments, the mRNA compositions and / or methods described herein can provide protection against SARS-CoV-2 and / or reduce the severity of SARS-CoV-2 infection in at least 50% of subjects receiving such mRNA compositions and / or methods.

[0220] In some embodiments, the population treated with the mRNA compositions described herein includes subjects aged 18-55. In some embodiments, the population treated with the mRNA compositions described herein includes subjects aged 56-85. In some embodiments, the population treated with the mRNA compositions described herein includes older subjects (e.g., subjects over 60, 65, 70, 75, 80, 85, etc., e.g., subjects aged 65-85). In some embodiments, the population treated with the mRNA compositions described herein includes subjects aged 18-85. In some embodiments, the population treated with the mRNA compositions described herein includes subjects under 18. In some embodiments, the population treated with the mRNA compositions described herein includes subjects under 12. In some embodiments, the population treated with the mRNA compositions described herein includes subjects under 10. In some embodiments, the population treated with the mRNA compositions described herein can include an adolescent population (e.g., individuals between about 12 and about 17 years of age). In certain embodiments, the population treated with the mRNA compositions described herein can include a pediatric population (e.g., as described herein). In certain embodiments, the population treated with the mRNA compositions described herein includes infants (e.g., under 1 year old). In certain embodiments, the population treated with the mRNA compositions described herein does not include infants (e.g., under 1 year old) whose mothers received such mRNA compositions described herein during pregnancy. Without wishing to be bound by any particular theory, rat studies suggest that SARS-CoV-2 neutralizing antibody responses induced in female rats fed such mRNA compositions during pregnancy can be inherited by the fetus. In certain embodiments, the population treated with the mRNA compositions described herein includes infants (e.g., under 1 year old) whose mothers did not receive such mRNA compositions described herein during pregnancy.In certain embodiments, populations treated with the mRNA compositions described herein can include pregnant women; in certain embodiments, infants whose mothers were vaccinated during pregnancy (e.g., only those who received at least one dose or both doses) are not vaccinated for several weeks, months, or years after birth (e.g., 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks or more, or 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months or more, or 1 year, 2 years, 3 years, 4 years, 5 years or more). Alternatively or additionally, in certain embodiments, infants whose mothers were vaccinated during pregnancy (e.g., only those who received at least one dose or both doses) may require reduced vaccinations (e.g., lower doses and / or fewer administrations - e.g., booster - times and / or lower total exposure over a period of time) or reduced vaccinations (e.g., lower doses and / or fewer administrations - e.g., booster - times) after birth, e.g., within weeks, months, or years of age (e.g., 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, or more, or 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, or more, or 1 year, 2 years, 3 years, 4 years, 5 years, or more). In some embodiments, the compositions provided herein are administered to a population that does not include pregnant women.

[0221] In certain embodiments, the compositions provided herein are administered to a pregnant woman using a regimen that includes a first administration after about 24 weeks of gestation (e.g., after about 22, 23, 24, 25, 26, 27, 28, or later weeks of gestation); in certain embodiments, the compositions provided herein are administered to a pregnant woman using a regimen that includes a first administration before about 34 weeks of gestation (e.g., before about 30, 31, 32, 33, 34, 35, 36, 37, 38 weeks of gestation). In certain embodiments, the compositions provided herein are administered to a pregnant woman using a regimen that includes a first administration after about 24 weeks of gestation (e.g., after about 27 weeks of gestation, e.g., between about 24 and 34 weeks or between about 27 and 34 weeks of gestation) and a second administration about 21 days later; in certain embodiments, both administrations are administered before birth. Without wishing to be bound by any particular theory, such a regimen (e.g., comprising a first administration after about 24 or 27 weeks of gestation and optionally before about 34 weeks of gestation), ideally before birth, and optionally a second administration within about 21 days, may have certain advantages in terms of safety (e.g., reduced risk of premature birth or fetal morbidity or mortality) and / or efficacy (e.g., carrying over vaccinations to the infant) compared to alternative administration regimens (e.g., administration at any time during pregnancy, withholding administration during pregnancy, and / or administration later in pregnancy, e.g., allowing for only one administration during pregnancy). In certain embodiments, for example, with certain regimens described herein, infants born to mothers vaccinated during pregnancy may not require further vaccinations or may require reduced vaccinations (e.g., lower doses and / or fewer administrations - e.g., boosters - and / or reduced overall exposure over a period of time) for a period of time after birth (e.g., as described herein).

[0222] In some embodiments, the compositions provided herein are administered to a population in which women are instructed not to become pregnant for a period of time after receiving the vaccine (e.g., after receiving the first dose of the vaccine, after receiving the last dose of the vaccine, etc.); in some such embodiments, the period of time can be at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks or more, or at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months or more.

[0223] In some embodiments, the population treated with the mRNA compositions described herein includes one or more populations with a history of one or more particularly high-risk conditions or behaviors, e.g., as described herein. For example, in some embodiments, the population treated with the mRNA compositions described herein can include subjects whose job expertise and / or environmental exposures may dramatically increase their risk of SARS-CoV-2 infection (e.g., public transportation workers, prisoners, grocery store clerks, long-term care facility residents, meat processors or other meat processing workers, medical workers and / or first responders, e.g., emergency responders). In specific embodiments, the population treated with the mRNA compositions described herein can include medical workers and / or first responders, e.g., emergency responders. In some embodiments, the population treated with the mRNA compositions described herein can include those with a history of smoking or vaping (e.g., including chronic smoking or vaping, for 6 months, 12 months, or more). In certain embodiments, the populations treated with the mRNA compositions described herein may include certain ethnic groups that have been identified as being more susceptible to SARS-CoV-2 infection.

[0224] In certain embodiments, populations treated with the mRNA compositions described herein may include populations with blood types that may be identified as being more susceptible to SARS-CoV-2 infection. In certain embodiments, populations treated with the mRNA compositions described herein may include immunocompromised subjects (e.g., those with HIV / AIDS; cancer patients (e.g., undergoing anti-tumor treatment); patients taking certain immunosuppressive agents (e.g., transplant patients, cancer patients, etc.); autoimmune diseases or other physiological conditions predicted to warrant immunosuppressive treatment (e.g., within three months, six months, or more); and those with genetic diseases affecting the immune system (e.g., congenital agammaglobulinemia, congenital IgA deficiency)). In certain embodiments, populations treated with the mRNA compositions described herein may include those with infectious diseases. For example, in certain embodiments, populations treated with the mRNA compositions described herein may include those infected with human immunodeficiency virus (HIV) and / or hepatitis viruses (e.g., HBV, HCV). In some embodiments, the population treated with the mRNA compositions described herein may include individuals with underlying diseases. Examples of such underlying diseases include, but are not limited to, hypertension, cardiovascular disease, diabetes, chronic respiratory diseases, such as chronic lung disease and asthma, cancer, and other chronic diseases, such as lupus, rheumatoid arthritis, chronic liver disease, and chronic kidney disease (e.g., in some embodiments, stage 3 or worse, as characterized by a glomerular filtration rate (GFR) of less than 60 mL / min / 1.73 m2). In some embodiments, the population treated with the mRNA compositions described herein may include overweight or obese subjects, including, for example, those with a body mass index (BMI) greater than about 30 kg / m2. In some embodiments, the population treated with the mRNA compositions described herein may include subjects who have been previously diagnosed with COVID-19 or who have evidence of current or prior SARS-CoV-2 infection, for example, based on serology or nasal swabs. In some embodiments, the population treated includes white and / or non-Hispanic / non-Latino individuals.

[0225] In certain embodiments, certain mRNA compositions described herein can be selected for administration to Asian populations (e.g., Chinese populations), or in specific embodiments, to elderly Asian populations (e.g., 60 years of age or older, e.g., 60-85 or 65-85 years of age).

[0226] In certain embodiments, the mRNA compositions provided herein are administered to and / or evaluated in subjects who are found to have no evidence of prior and / or current infection prior to administration; in certain embodiments, evidence of prior and / or current infection can be or may include evidence of intact virus or any viral nucleic acid, protein, lipid, etc. present in the subject (e.g., in a biological sample thereof, such as blood, cells, mucus, and / or tissue) and / or evidence of the subject's immune response thereto. In certain embodiments, the mRNA compositions provided herein are administered to and / or evaluated in subjects who are found to have evidence of prior and / or current infection prior to administration; in certain embodiments, evidence of prior and / or current infection can be or may include evidence of intact virus or any viral nucleic acid, protein, lipid, etc. present in the subject (e.g., in a biological sample thereof, such as blood, cells, mucus, and / or tissue) and / or evidence of the subject's immune response thereto. In certain embodiments, a subject is considered to have had a prior infection based on a positive N-linked antibody test result or a positive nucleic acid amplification test (NAAT) result on day 1 of administration.

[0227] In some embodiments, the RNA (e.g., mRNA) compositions provided herein are administered to subjects who have been informed of the risk of side effects, which may include, for example, one or more of chills, fever, headache, injection site pain, muscle pain, and fatigue; in some embodiments, the RNA (e.g., mRNA) compositions are administered to subjects who have been requested to notify a medical professional if one or more such side effects occur, are more than mild or moderate, and persist for a period of one or more days, or if the subject experiences any severe or unpredictable event that the subject reasonably believes may be associated with inoculation with the composition. In some embodiments, the RNA (e.g., mRNA) compositions provided herein are administered to subjects who have been requested to notify a medical professional of a particular health condition, which may include, for example, one or more of: allergies, bleeding disorders or anticoagulant medication, breastfeeding, fever, immunocompromised state or medication that affects the immune system, pregnancy or planning a pregnancy, etc. In some embodiments, the RNA (e.g., mRNA) compositions provided herein are administered to subjects who have been administered another COVID-19 vaccine and have been requested to notify a medical professional. In some embodiments, the RNA (e.g., mRNA) compositions provided herein are administered to subjects who are not experiencing a febrile illness, receiving immunosuppressant therapy, receiving anticoagulant therapy, suffering from a bleeding disorder (e.g., one that contraindicates intramuscular injection), or who are pregnant and / or breastfeeding / lactation-related. In some embodiments, the RNA (e.g., mRNA) compositions provided herein are administered to subjects who have not received other COVID-19 vaccines. In some embodiments, the RNA (e.g., mRNA) compositions provided herein are administered to subjects who do not have an allergic reaction to any component of the RNA (e.g., mRNA) composition. Examples of such allergic reactions include, but are not limited to, shortness of breath, facial and / or pharyngeal swelling, palpitations, rash, dizziness, and / or weakness. In some embodiments, the RNA (e.g., mRNA) compositions provided herein are administered to subjects who have received an initial dose and have not had an allergic reaction (e.g., one described herein) to the initial dose.In certain embodiments, if a subject experiences an allergic reaction after receiving an RNA (e.g., mRNA) composition provided herein, such subject may be administered one or more interventions, such as treatments to manage and / or reduce such allergic reaction, e.g., antipyretic and / or anti-inflammatory agents.

[0228] In certain embodiments, a subject who has received at least one administration of an RNA (e.g., mRNA) composition provided herein is instructed to avoid exposure to coronavirus (e.g., SARS-CoV-2) unless and until several days (e.g., at least 7 days, at least 8 days, 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, etc.) have passed since the second administration. For example, a subject who has received at least one administration of an RNA (e.g., mRNA) composition provided herein is instructed to take preventative measures against SARS-CoV-2 infection (e.g., maintaining social distancing, wearing a mask, washing hands frequently, etc.) unless and until several days (e.g., at least 7 days, at least 8 days, 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, etc.) have passed since the second administration. Thus, in some embodiments, the methods of administering an RNA (e.g., mRNA) composition provided herein include administering a second dose of such an RNA (e.g., mRNA) composition provided herein to a subject who has received an initial dose and has taken precautions to avoid exposure to a coronavirus (e.g., SARS-CoV-2).

[0229] In some embodiments, the mRNA compositions described herein can be delivered to the draining lymph nodes of a subject in need thereof, for example, for vaccine priming. In some embodiments, such delivery can be performed by intramuscular administration of the provided mRNA compositions.

[0230] In some embodiments, different specific mRNA compositions can be administered to different subject populations; alternatively or additionally, in some embodiments, different dosing regimens can be administered to different subject populations.For example, in some embodiments, the mRNA compositions administered to specific subject populations can be characterized by one or more specific effects (for example, the incidence and / or degree of effect) in these subject populations.In some embodiments, such effects can be or include, for example, the titer and / or duration of neutralizing antibodies and / or T cells (for example, TH1-type T cells, such as CD4+ and / or CD8+ T cells), protection against exposure (for example, injection and / or intranasal exposure), the incidence, severity and / or duration of side effects (for example, reactogenicity), etc.

[0231] In certain embodiments, one or more mRNA compositions described herein may be administered according to a regimen established to reduce the incidence of COVID-19 per 1000 person-years, based on a clinical test, such as a nucleic acid amplification test (NAAT). In certain embodiments, one or more mRNA compositions described herein may be administered according to a regimen established to reduce the incidence of COVID-19 per 1000 person-years, based on a clinical test, such as a nucleic acid amplification test (NAAT), in subjects who have received at least one dose of a provided mRNA composition and who have no serological or virological evidence of prior SARS-CoV-2 infection (e.g., up to 7 days after receiving their last dose). In certain embodiments, one or more mRNA compositions described herein may be administered according to a regimen established to reduce the incidence of confirmed severe COVID-19 per 1000 person-years. In certain embodiments, one or more of the mRNA compositions described herein may be administered according to a regimen established to reduce the incidence of confirmed severe COVID-19 per 1000 person-years in subjects who receive at least one dose of a provided mRNA composition and who have no serological or virological evidence of previous SARS-CoV-2 infection.

[0232] In certain embodiments, one or more mRNA compositions described herein can be administered using a regimen established to produce neutralizing antibodies to a SARS-CoV-2 spike polypeptide and / or immunogenic fragment thereof (e.g., RBD) that meets or exceeds a control level (e.g., a control level determined based on human SARS-CoV-2 infected / COVID-19 convalescent sera) for a period of time as measured in serum from the subject, and / or to induce a cell-mediated immune response (e.g., a T cell response to SARS-CoV-2) for a period of time, e.g., in certain embodiments, including the induction of T cells that recognize at least one or more MHC-restricted (e.g., MHC class I-restricted) epitopes within the SARS-CoV-2 spike polypeptide and / or immunogenic fragment thereof (e.g., RBD). In certain such embodiments, the period of time can be at least 2 months, 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, or longer. In certain embodiments, one or more epitopes recognized by vaccine-induced T cells (e.g., CD8+ T cells) can be presented on an MHC class I allele present in at least 50%, including, e.g., at least 60%, at least 70%, at least 80%, at least 90% or more, of subjects in a population; in certain such embodiments, the MHC class I allele can be HLA-B*0702, HLA-A*2402, HLA-B*3501, HLA-B*4401, or HLA-A*0201. In certain embodiments, the epitope may include HLA-A*0201 YLQPRTFLL; HLA-A*0201 RLQSLQTYV; HLA-A*2402 QYIKWPWYI; HLA-A*2402 NYNYLYRLF; HLA-A*2402 KWPWYIWLGF; HLA-B*3501 QPTESIVRF; HLA-B*3501 IPFAMQMAY; or HLA-B*3501 LPFNDGVYF.

[0233] In certain embodiments, efficacy is assessed as the incidence of COVID-19 per 1000 person-years in individuals without serological or virological evidence of previous SARS-CoV-2 infection before and during the vaccination regimen; alternatively or additionally, in certain embodiments, efficacy is assessed as the incidence of COVID-19 per 1000 person-years in subjects with and without serological or virological evidence of previous SARS-CoV-2 infection before and during the vaccination regimen. In certain such embodiments, such incidence is confirmed COVID-19 cases within a certain period of time after the final vaccination (e.g., the first dose in a single-dose regimen; the second dose in a two-dose regimen, etc.); in certain embodiments, such period can be within a certain number of days (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more days) (i.e., up to and including 7 days). In certain embodiments, such period can be within 7 days, or within 14 days, or within 21 days, or within 28 days. In certain embodiments, such period can be within 7 days. In certain embodiments, such period can be within 14 days.

[0234] In some embodiments (e.g., in some embodiments evaluating efficacy), a subject is determined to have experienced COVID-19 infection if one or more of the following is established in a sample from the subject: detection of SARS-CoV-2 nucleic acid; detection of an antibody that specifically recognizes SARS-CoV-2 (e.g., SARS-CoV-2 spike protein); one or more symptoms of COVID-19 infection; and combinations thereof. In some such embodiments, detection of SARS-CoV-2 nucleic acid may include, for example, NAAT testing of a middle turbinate swab sample. In some such embodiments, detection of relevant antibodies may include serology testing of a blood sample or portion thereof. In some such embodiments, symptoms of COVID-19 infection may include fever, a new or increased cough, a new or increased shortness of breath, chills, a new or increased muscle pain, a new loss of taste or smell, sore throat, diarrhea, vomiting, and combinations thereof. In some such embodiments, symptoms of COVID-19 infection may include or include fever, a new or increased cough, a new or increased shortness of breath, chills, a new or increased muscle pain, a new or increased loss of taste or smell, sore throat, diarrhea, vomiting, fatigue, headache, nasal congestion or runny nose, nausea, and combinations thereof. In some such embodiments, a subject is determined to have experienced a COVID-19 infection if such subject experiences one of these symptoms and tests positive for SARS-CoV-2 nucleic acid or antibody, or both. In some such embodiments, a subject is determined to have experienced a COVID-19 infection if such subject experiences one of these symptoms and tests positive for SARS-CoV-2 nucleic acid. In some such embodiments, a subject is determined to have experienced a COVID-19 infection if such subject experiences one of these symptoms and tests positive for SARS-CoV-2 antibody.

[0235] In certain embodiments (e.g., in certain embodiments evaluating efficacy), a subject is determined to have experienced a severe COVID-19 infection if such subject experiences one or more of the following clinical signs of severe systemic illness at rest (e.g., one or more of a respiratory rate of 30 or more per minute, a heart rate of 125 or more beats per minute, an SpO2 of 93% or less at sea level on room air, or a PaO2 / FiO2 of less than 300 mHg), respiratory failure (e.g., one or more of high oxygen flow, noninvasive ventilation, mechanical ventilation, need for ECMO), evidence of shock (systolic blood pressure less than 90 mmHg, diastolic blood pressure less than 60 mmHg, need for vasopressors), significant acute renal, hepatic, or neurological dysfunction, intensive care unit admission, death, and combinations thereof.

[0236] In certain embodiments, one or more mRNA compositions described herein may be administered using a regimen established to reduce the percentage of subjects reporting at least one of: (i) one or more local reactions (e.g., those described herein) up to 7 days after each dose; (ii) one or more systemic events up to 7 days after each dose; (iii) an adverse event (e.g., those described herein) from the first dose up to 1 month after the last dose; and / or (iv) a severe adverse event (e.g., those described herein) from the first dose up to 6 months after the last dose.

[0237] In certain embodiments, one or more subjects who receive an RNA (e.g., mRNA) composition described herein can be monitored (e.g., at 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 years, 8 years, 9 years, 10 years, or more), e.g., to assess the presence of an immune response to components of the administered composition, evidence of exposure to and / or an immune response to SARS-CoV-2 or other coronaviruses, any adverse events, etc. (For example, for a period of at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, or more, including 1 month, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months or more). In some embodiments, monitoring can be by remote visit. Alternatively or additionally, in some embodiments, monitoring can be in person.

[0238] In certain embodiments, the therapeutic effect provided by one or more mRNA compositions described herein may be characterized by (i) a SARS-CoV-2 anti-S1-binding antibody level above a predetermined threshold; (ii) a SARS-CoV-2 anti-RBD-binding antibody level above a predetermined threshold; and / or (iii) a SARS-CoV-2 serum neutralizing titer above a threshold level, e.g., baseline, at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, and / or 24 months post-vaccination. In certain embodiments, the anti-S1-binding antibody and / or anti-RBD-binding antibody level and / or serum neutralizing titer may be characterized by the geometric mean concentration (GMC), geometric mean titer (GMT), or geometric mean fold increase (GMFR).

[0239] In certain embodiments, the therapeutic effect provided by one or more mRNA compositions described herein can be characterized, for example, by a higher percentage of treated subjects exhibiting SARS-CoV-2 serum neutralizing titers above a predetermined threshold at baseline, 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, and / or 24 months post-vaccination than the percentage of untreated subjects exhibiting SARS-CoV-2 serum neutralizing titers above such predetermined threshold (e.g., those described herein). In certain embodiments, serum neutralizing titers can be characterized by geometric mean concentration (GMC), geometric mean titer (GMT), or geometric mean fold increase (GMFR).

[0240] In certain embodiments, the therapeutic effect provided by one or more of the mRNA compositions described herein can be characterized by the detection of SARS-CoV-2 NVA-specific binding antibodies.

[0241] In certain embodiments, the therapeutic effect provided by one or more of the mRNA compositions described herein can be characterized by detection of SARS-CoV-2 by nucleic acid amplification testing.

[0242] In certain embodiments, the therapeutic effect provided by one or more mRNA compositions described herein can be characterized by the induction of a cell-mediated immune response (e.g., a T cell response to SARS-CoV-2), including, for example, in certain embodiments, the induction of T cells that recognize at least one or more MHC-restricted (e.g., MHC class I-restricted) epitopes within a SARS-CoV-2 spike polypeptide and / or an immunogenic fragment thereof (e.g., RBD). In certain embodiments, the one or more epitopes recognized by vaccine-induced T cells (e.g., CD8+ T cells) can be presented on an MHC class I allele present in at least 50%, including, for example, at least 60%, at least 70%, at least 80%, at least 90% or more of the subjects in a population; in some such embodiments, the MHC class I allele can be HLA-B*0702, HLA-A*2402, HLA-B*3501, HLA-B*4401, or HLA-A*0201. In certain embodiments, the epitope may include HLA-A*0201 YLQPRTFLL; HLA-A*0201 RLQSLQTYV; HLA-A*2402 QYIKWPWYI; HLA-A*2402 NYNYLYRLF; HLA-A*2402 KWPWYIWLGF; HLA-B*3501 QPTESIVRF; HLA-B*3501 IPFAMQMAY; or HLA-B*3501 LPFNDGVYF.

[0243] In certain embodiments, the primary vaccine efficacy (VE) of one or more mRNA compositions described herein can be established when there is sufficient evidence (posterior probability) that primary VE1 or both primary VE1 and primary VE2 are >30% or higher (including, for example, greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, or higher), where primary VE is defined as primary VE = 100 × (1 - IRR); IRR is calculated as the ratio of COVID-19 disease rate in the vaccine group to the corresponding disease rate in the placebo group. Primary VE1 represents the VE of a prophylactic mRNA composition described herein against confirmed COVID-19 in participants who had no evidence of pre-vaccination infection, and primary VE2 represents the VE of a prophylactic mRNA composition described herein against confirmed COVID-19 in all participants after vaccination. In some embodiments, the primary VE1 and VE2 can be evaluated sequentially to control a 2.5% overall type I error (tiered testing). In some embodiments, when one or more RNA (e.g., mRNA) compositions described herein are shown to achieve the primary VE endpoint, secondary VE endpoints (e.g., confirmed severe COVID-19 in participants without evidence of pre-vaccination infection and confirmed severe COVID-19 in all participants) can be evaluated sequentially, for example, using the same method as used for the primary VE endpoint evaluation (tiered testing). In some embodiments, the evaluation of the primary and / or secondary VE endpoints can be based on at least 20,000 or more subjects (e.g., at least 25,000 or more subjects) randomized in a 1:1 ratio to the vaccine or placebo group, based on the following hypotheses: (i) a 1.0% incidence rate per year in the placebo group; and (ii) 20% of participants will be unevaluable or have serologic evidence of prior SARS-CoV-2 infection and may be immune to further infection.

[0244] In certain embodiments, one or more mRNA compositions described herein may be administered according to a regimen established to maintain and / or enhance the immune response. For example, in certain embodiments, the administration regimen may include an initial administration, followed by one or more subsequent administrations, if desired; in certain embodiments, the necessity, timing, and / or intensity of any such subsequent administrations may be selected to maintain, enhance, and / or modify one or more immune responses or characteristics thereof. In certain embodiments, the number, timing, and / or amount of administrations may be established to be effective when administered to an appropriate population. In certain embodiments, the number, timing, and / or amount of administrations may be adjusted for individual subjects; for example, in certain embodiments, one or more characteristics of the immune response in an individual subject may be assessed at least once (and optionally more than once, e.g., often at preselected intervals, generally multiple times apart) after receiving the initial administration. For example, the presence and / or extent of antibodies, B cells, and / or T cells (e.g., CD4+ and / or CD8+ T cells) and / or cytokines secreted thereby and / or the characteristics and / or extent of the response to a particular antigen and / or epitope may be assessed. In certain embodiments, the need, timing and / or amount of subsequent administrations may be determined in light of such evaluation.

[0245] As noted above, in certain embodiments, one or more subjects who receive an RNA (e.g., mRNA) composition described herein may be monitored (e.g., for 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, or more) after receiving any particular administration to assess, for example, the presence of an immune response to components of the administered composition, evidence of exposure to and / or an immune response to SARS-CoV-2 or other coronaviruses, any adverse events, etc., including conducting an assessment of the presence of antibodies, B cells and / or T cells (e.g., CD4+ and / or CD8+ T cells) and / or cytokines secreted thereby and / or the nature and / or extent of the response to a particular antigen and / or epitope. (For example, for a period of at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or more, including 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months or more.) Administration of the compositions described herein can be administered in a regimen that includes one or more such monitoring steps.

[0246] For example, in certain embodiments, the necessity, timing, and / or amount of a second administration relative to a first administration (and / or a subsequent administration relative to a prior administration) is evaluated, determined, and / or selected such that such second (or subsequent) administration achieves an amplification or modification of the immune response (e.g., one described herein) observed with the first (or other prior) administration. In certain embodiments, such amplification of the immune response (e.g., one described herein) can be at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more compared to the level of the immune response observed after the first administration. In certain embodiments, such amplification of the immune response can be at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 20-fold, at least 30-fold or more compared to the level of the immune response observed after the first administration.

[0247] In certain embodiments, the necessity, timing, and / or amount of a second administration relative to a first administration (and / or subsequent administration relative to a prior administration) is assessed, determined, and / or selected such that the subsequent administration extends the durability of an immune response (e.g., one described herein) observed after the prior administration; in certain such embodiments, the durability may be extended for at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, or more. In certain embodiments, the immune response observed after the first administration may be characterized by the production of neutralizing antibodies to the SARS-CoV-2 spike polypeptide and / or an immunogenic fragment thereof (e.g., RBD) and / or a cell-mediated immune response (e.g., induction of a T cell response to SARS-CoV-2, including, in certain embodiments, induction of T cells that recognize at least one or more MHC-restricted (e.g., MHC class I-restricted) epitopes within the SARS-CoV-2 spike polypeptide and / or an immunogenic fragment thereof (e.g., RBD)) as measured in serum from the subject. In certain embodiments, one or more epitopes recognized by vaccine-induced T cells (e.g., CD8+ T cells) can be presented on an MHC class I allele present in at least 50%, including, e.g., at least 60%, at least 70%, at least 80%, at least 90% or more, of subjects in a population; in certain such embodiments, the MHC class I allele can be HLA-B*0702, HLA-A*2402, HLA-B*3501, HLA-B*4401, or HLA-A*0201. In certain embodiments, the epitope may include HLA-A*0201 YLQPRTFLL; HLA-A*0201 RLQSLQTYV; HLA-A*2402 QYIKWPWYI; HLA-A*2402 NYNYLYRLF; HLA-A*2402 KWPWYIWLGF; HLA-B*3501 QPTESIVRF; HLA-B*3501 IPFAMQMAY; or HLA-B*3501 LPFNDGVYF.

[0248] In certain embodiments, the necessity, timing, and / or amount of a second administration relative to a first administration (or other subsequent administration relative to a prior administration) is assessed, determined, and / or selected such that such second (or subsequent) administration maintains or exceeds a control level of immune response; in certain such embodiments, the control level is determined based on human SARS-CoV-2 infected / COVID-19 convalescent serum and / or PBMC samples taken from the subject (e.g., at least a period of time, such as at least 14 days or more, including, e.g., 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60 or more days after PCR-confirmed diagnosis if the subject was asymptomatic). In certain embodiments, the immune response may be characterized by the production of neutralizing antibodies to the SARS-CoV-2 spike polypeptide and / or an immunogenic fragment thereof (e.g., RBD) and / or a cell-mediated immune response (e.g., induction of a T cell response to SARS-CoV-2, including, in certain embodiments, induction of T cells that recognize at least one or more MHC-restricted (e.g., MHC class I-restricted) epitopes within the SARS-CoV-2 spike polypeptide and / or an immunogenic fragment thereof (e.g., RBD)) as measured in serum from the subject. In certain embodiments, one or more epitopes recognized by vaccine-induced T cells (e.g., CD8+ T cells) can be presented on an MHC class I allele present in at least 50%, including, e.g., at least 60%, at least 70%, at least 80%, at least 90% or more, of subjects in a population; in certain such embodiments, the MHC class I allele can be HLA-B*0702, HLA-A*2402, HLA-B*3501, HLA-B*4401, or HLA-A*0201.In certain embodiments, the epitope may include HLA-A*0201 YLQPRTFLL; HLA-A*0201 RLQSLQTYV; HLA-A*2402 QYIKWPWYI; HLA-A*2402 NYNYLYRLF; HLA-A*2402 KWPWYIWLGF; HLA-B*3501 QPTESIVRF; HLA-B*3501 IPFAMQMAY; or HLA-B*3501 LPFNDGVYF.

[0249] In certain embodiments, determining the need, timing, and / or amount of a second (or subsequent) administration may include one or more steps of evaluating the presence and / or expression levels of neutralizing antibodies to the SARS-CoV-2 spike polypeptide and / or immunogenic fragment thereof (e.g., RBD) and / or a cell-mediated immune response (e.g., induction of a T cell response to SARS-CoV-2, including, in certain embodiments, induction of T cells that recognize at least one or more MHC-restricted (e.g., MHC class I-restricted) epitopes within the SARS-CoV-2 spike polypeptide and / or immunogenic fragment thereof (e.g., RBD)) measured in serum from the subject after the first (or other prior) administration (e.g., 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or more days later). In certain embodiments, one or more epitopes recognized by vaccine-induced T cells (e.g., CD8+ T cells) can be presented on an MHC class I allele present in at least 50%, including, e.g., at least 60%, at least 70%, at least 80%, at least 90% or more, of subjects in a population; in certain such embodiments, the MHC class I allele can be HLA-B*0702, HLA-A*2402, HLA-B*3501, HLA-B*4401, or HLA-A*0201. In certain embodiments, the epitope may include HLA-A*0201 YLQPRTFLL; HLA-A*0201 RLQSLQTYV; HLA-A*2402 QYIKWPWYI; HLA-A*2402 NYNYLYRLF; HLA-A*2402 KWPWYIWLGF; HLA-B*3501 QPTESIVRF; HLA-B*3501 IPFAMQMAY; or HLA-B*3501 LPFNDGVYF.

[0250] In certain embodiments, the kits provided herein can include a device for real-time transport monitoring logging, which can provide, for example, in certain embodiments, shipping temperature, shipping time and / or location.

[0251] In certain embodiments, the RNA (e.g., mRNA) compositions described herein can be transported, stored, and / or utilized in a container (e.g., a vial or syringe), e.g., a glass container (e.g., a glass vial or syringe), which, in certain embodiments, can be a single-dose container or a multi-dose container (e.g., arranged and constructed to hold, and / or in certain embodiments, can hold, a single dose or multiple doses for administration). In certain embodiments, a multi-dose container (e.g., a multi-dose vial or syringe) can hold and / or can hold 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses; in certain embodiments, it can be designed to hold and / or can hold 5 doses. In certain embodiments, a single-dose or multi-dose container (e.g., a single-dose or multi-dose vial or syringe) can be arranged and constructed to hold and / or hold a volume or amount greater than the indicated dose, e.g., to allow for some loss during transfer and / or administration. In certain embodiments, the RNA (e.g., mRNA) compositions described herein may be shipped, stored, and / or utilized in a preservative-free glass container (e.g., a preservative-free glass vial or syringe, e.g., a single-dose or multi-dose preservative-free glass vial or syringe). In certain embodiments, the RNA (e.g., mRNA) compositions described herein may be shipped, stored, and / or utilized in a preservative-free glass container (e.g., a preservative-free glass vial or syringe, e.g., a single-dose or multi-dose preservative-free glass vial or syringe) containing frozen liquid (e.g., in certain embodiments, 0.45 ml of frozen liquid (e.g., containing 5 doses)). In certain embodiments, the RNA (e.g., mRNA) compositions described herein and / or the containers (e.g., vials or syringes) in which they are contained, transported, stored, and / or utilized may be maintained below room temperature, at or below 4°C, at or below 0°C, at or below -20°C, at or below -60°C, at or below -70°C, at or below -80°C, at or below -90°C, etc.In certain embodiments, the RNA (e.g., mRNA) compositions described herein and / or the containers (e.g., vials or syringes) in which they are contained, transported, stored, and / or used can be maintained at a temperature of -80°C to -60°C, and in certain embodiments, are protected from light. In certain embodiments, the RNA (e.g., mRNA) compositions described herein and / or the containers (e.g., vials or syringes) in which they are contained, transported, stored, and / or used can be maintained at a temperature below about 25°C, and in certain embodiments, are protected from light. In certain embodiments, the RNA (e.g., mRNA) compositions described herein and / or the containers (e.g., vials or syringes) in which they are contained, transported, stored, and / or used can be maintained at a temperature below about 5°C (e.g., below about 4°C), and in certain embodiments, are protected from light. In certain embodiments, the RNA (e.g., mRNA) compositions described herein and / or the containers (e.g., vials or syringes) in which they are contained, transported, stored, and / or utilized can be maintained at a temperature of about −20° C. and, in certain embodiments, protected from light. In certain embodiments, the RNA (e.g., mRNA) compositions described herein and / or the containers (e.g., vials or syringes) in which they are contained, transported, stored, and / or utilized can be maintained at a temperature of about −60° C. or higher (e.g., in certain embodiments, about −20° C. or higher, and in certain embodiments, about 4-5° C. or higher, in either case optionally below about 25° C.) and, in certain embodiments, protected from light, or conversely, no active steps (e.g., cooling measures) are taken to achieve a storage temperature substantially below about −20° C.

[0252] In some embodiments, the RNA (e.g., mRNA) compositions described herein and / or the containers (e.g., vials or syringes) in which they are contained are transported, stored, and / or used with and / or under conditions of heat-resistant materials or containers and / or temperature-regulating materials. For example, in some embodiments, the RNA (e.g., mRNA) compositions described herein and / or the containers (e.g., vials or syringes) in which they are contained are transported, stored, and / or used with ice and / or dry ice and / or cold packs. In certain embodiments, the containers (e.g., vials or syringes) in which the RNA (e.g., mRNA) compositions are contained are placed in trays or other maintenance devices, and are further in contact with (or are otherwise in the presence of) temperature-regulating (e.g., ice and / or dry ice) materials and / or cold packs. In certain embodiments, multiple containers (e.g., multiple vials or syringes, e.g., single-use or multi-use vials or syringes described herein) containing the provided RNA (e.g., mRNA) compositions are co-present (e.g., on a common tray, rack, box, etc.) and packaged together (or otherwise in the presence of) temperature-regulating (e.g., ice and / or dry ice) and / or cold packs. By way of example only, in certain embodiments, multiple containers (e.g., multiple vials or syringes, e.g., single-use or multi-use vials or syringes described herein) containing the RNA (e.g., mRNA) compositions are placed in a common tray or rack, and multiple such trays or racks are arranged in a bin surrounded by temperature-regulating (e.g., dry ice) in an insulated (e.g., thermally insulated) shipper. In some embodiments, the temperature-modulating material is replenished periodically (e.g., within 24 hours of arrival at the site and / or every 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, etc.). Preferably, reintroduction to the insulated shipper is infrequent, desirably no more than twice a day.In some embodiments, the insulated shipper must be reclosed within 5, 4, 3, 2, or 1 minute or less after being opened. In some embodiments, a provided RNA (e.g., mRNA) composition stored in an insulated shipper for a period of time, optionally within a particular temperature range, remains useful. For example, in some embodiments, if an insulated shipper described herein containing a provided RNA (e.g., mRNA) composition is at or maintained (e.g., stored) at a temperature within a range of about 15°C to about 25°C, the RNA (e.g., mRNA) composition can be used for up to 10 days; i.e., in some embodiments, a provided RNA (e.g., mRNA) composition maintained in an insulated shipper at a temperature within a range of about 15°C to about 25°C for a period of not more than 10 days is administered to a subject. Alternatively or additionally, in certain embodiments, the provided RNA (e.g., mRNA) compositions can be used for up to 10 days if they are in or maintained (e.g., stored) in an insulated shipper maintained at a temperature within the range of about 15°C to about 25°C; i.e., in certain embodiments, the provided RNA (e.g., mRNA) compositions maintained in an insulated shipper maintained at a temperature within the range of about 15°C to about 25°C for a period not exceeding 10 days are administered to a subject.

[0253] In certain embodiments, the provided RNA (e.g., mRNA) compositions are shipped and / or stored in a frozen state. In certain embodiments, the provided RNA (e.g., mRNA) compositions are shipped and / or stored as a frozen suspension, which, in certain embodiments, does not contain a preservative. In certain embodiments, the frozen RNA (e.g., mRNA) composition is thawed. In certain embodiments, the thawed RNA (e.g., mRNA) composition (e.g., suspension) may comprise white to off-white opaque amorphous particles. In certain embodiments, the thawed RNA (e.g., mRNA) composition can be used up to several days (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, or 6 days) after thawing, provided that it is maintained (e.g., stored) at a temperature below room temperature (e.g., about 30°C, 25°C, 20°C, 15°C, 10°C, 8°C, less than 4°C, etc.). In certain embodiments, the thawed RNA (e.g., mRNA) composition can be used after storage (e.g., several days) at a temperature of about 2°C to about 8°C; alternatively or additionally, the thawed RNA (e.g., mRNA) composition can be used after several hours (e.g., 1 hour, The composition may be used within 2, 3, 4, 5, or 6 hours (e.g., 2, 3, 4, 5, or 6 hours). Thus, in certain embodiments, a provided RNA (e.g., mRNA) composition is administered to a subject after thawing and maintaining a temperature below room temperature, and in certain embodiments, at about 2°C to about 8°C, for a period not exceeding 6, 5, 4, 3, 2, or 1 day. Alternatively or additionally, in certain embodiments, a provided RNA (e.g., mRNA) composition is administered to a subject after thawing and maintaining a temperature at room temperature for not exceeding 6, 5, 4, 3, 2, or 1 hour. In certain embodiments, a provided RNA (e.g., mRNA) composition is transported and / or stored in a concentrated state. In certain embodiments, such concentrated compositions are diluted prior to administration. In certain embodiments, a diluted composition is administered within about 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 hour after dilution; in certain embodiments, such administration is within 6 hours after dilution.Thus, in certain embodiments, diluted preparations of provided RNA (e.g., mRNA) compositions are administered to a subject within 6 hours after dilution (e.g., after being maintained at an appropriate temperature, as described herein, e.g., below room temperature, 4°C or below, 0°C or below, -20°C or below, -60°C or below, -70°C or below, -80°C or below, etc., and generally at about 2°C or above, e.g., about 2°C to about 8°C or about 2°C to about 25°C). In certain embodiments, unused composition is discarded within several hours (e.g., about 10 hours, about 9 hours, about 8 hours, about 7 hours, about 6 hours, about 5 hours, or less) after dilution; in certain embodiments, unused composition is discarded within 6 hours of dilution.

[0254] In certain embodiments, an RNA (e.g., mRNA) composition (e.g., frozen composition, liquid concentrated composition, diluted liquid composition, etc.) to be stored, transported, or utilized is maintained at a temperature substantially above −60° C. for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or more, or for at least 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, or more, or for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more; in certain such embodiments, such compositions may be maintained at a temperature above about −20° C. for such periods and / or at a temperature up to about 4-5° C. for such periods and / or may be maintained at a temperature above about 4-5° C., and optionally about 25° C., for a period of less than two (2) months and / or optionally up to about one (1) month. In certain embodiments, such compositions cannot be stored, transported, or used (or otherwise exposed to) temperatures substantially above about 4-5° C., particularly at or about 25° C., for a period of about 2 weeks, or in some embodiments, 1 week. In certain embodiments, such compositions cannot be stored, transported, or used (or otherwise exposed to) temperatures substantially above about −20° C., particularly at or about 4-5° C., for a period of about 12 months, 11 months, 10 months, 9 months, 8 months, 7 months, 6 months, 5 months, 4 months, 3 months, 2 months, or in some embodiments, for a period of about 8 weeks or 6 weeks, or substantially more than about 2 months, or in some embodiments, 3 months, or in some embodiments, more than 4 months.

[0255] In certain embodiments, RNA (e.g., mRNA) compositions (e.g., frozen compositions, liquid concentrated compositions, diluted liquid compositions, etc.) stored, transported, or used can be protected from light. In certain embodiments, one or more steps can be taken to reduce or minimize exposure of such compositions to light (e.g., they can be placed in a container such as a vial or syringe). In certain embodiments, exposure to direct sunlight and / or ultraviolet light is avoided. In certain embodiments, diluted solutions can be handled and / or used under normal room lighting conditions (e.g., without taking specific steps to minimize or reduce exposure to room lighting). It should be understood that strict adherence to aseptic technique is desirable during handling (e.g., dilution and / or administration) of the RNA (e.g., mRNA) compositions described herein. In certain embodiments, the RNA (e.g., mRNA) compositions described herein are not administered intravenously (e.g., injected). In certain embodiments, the RNA (e.g., mRNA) compositions described herein are not administered intradermally (e.g., injected). In certain embodiments, the RNA (e.g., mRNA) compositions described herein are not administered subcutaneously (e.g., injected). In certain embodiments, the RNA (e.g., mRNA) compositions described herein are not administered (e.g., injected) intravenously, intradermally, or subcutaneously. In certain embodiments, the RNA (e.g., mRNA) compositions described herein are not administered to subjects known to be hypersensitive to any of their components. In certain embodiments, the subject to whom the RNA (e.g., mRNA) composition is administered is monitored for one or more signs of anaphylaxis. In certain embodiments, the subject to whom the RNA (e.g., mRNA) composition is administered has previously received at least one dose of a different vaccine against SARS-CoV-2; in certain embodiments, the subject to whom the RNA (e.g., mRNA) composition is administered has not previously received a different vaccine against SARS-CoV-2. In certain embodiments, the subject's temperature is taken immediately prior to administration of the RNA (e.g., mRNA) composition (e.g., immediately before or after thawing, diluting, and / or administering such a composition); in certain embodiments, administration is delayed or canceled if such a subject develops a fever.In some embodiments, the RNA (e.g., mRNA) compositions described herein are not administered to subjects receiving anticoagulant therapy or who are suffering from or suspected of having a bleeding disorder or a condition for which intramuscular injection is contraindicated. In some embodiments, the RNA (e.g., mRNA) compositions described herein are administered by a medical professional who the subject contacts to obtain composition information regarding side effects and risks. In some embodiments, the RNA (e.g., mRNA) compositions described herein are administered by a medical professional who has agreed to provide adverse event reporting for any serious adverse events, which may include, for example, one or more of the following: death, disability, or birth defects / congenital anomalies (e.g., in the subject's child), inpatient hospitalization (including an extension of a current hospitalization), a life-threatening event, medical or surgical intervention to prevent death, a persistent or significant or substantial disruption in the ability to perform normal life functions; or other significant medical events that may endanger the individual and require medical or surgical intervention (treatment) to prevent one of the other consequences.

[0256] In certain embodiments, provided RNA compositions are administered to a population of individuals under the age of 18, or under the age of 17, or under the age of 16, or under the age of 15, or under the age of 14, or under the age of 13, e.g., by a regimen that has been established to result in an incidence of one or more local reaction events that does not exceed the incidence set forth below: · Pain at the injection site (75% after the first and / or second dose and / or low incidence after the second dose, e.g., 65% after the second dose); injection site redness (less than 5% after the first and / or second dose); and / or · Swelling at the injection site (less than 5% after the first and / or second dose).

[0257] In certain embodiments, provided RNA compositions are administered to a population of individuals under the age of 18, or under the age of 17, or under the age of 16, or under the age of 15, or under the age of 14, or under the age of 13, e.g., by a regimen that has been established to result in an incidence of one or more systemic reaction events that does not exceed the incidence set forth below: fatigue (55% after the first and / or second dose); Headache (50% after the first and / or second dose); · Myalgia (40% after the first and / or second dose); · Chills (40% after the first and / or second dose); · arthralgia (20% after the first and / or second dose); · Fever (25% after the first and / or second dose); Vomiting (10% after the first and / or second dose); and / or Diarrhea (10% after the first and / or second dose).

[0258] In certain embodiments, a medication that alleviates one or more symptoms (e.g., as described herein) of one or more local and / or systemic reaction events is administered to an individual under the age of 18, or under 17, or under 16, or under 15, or under 14, or under 13 who has been administered a provided RNA composition and experienced one or more local and / or systemic reaction events (e.g., as described herein). In certain embodiments, antipyretic and / or pain medication may be administered to such individuals. [Brief explanation of the drawings]

[0259] [Figure 1] Schematic representation of the SARS-CoV-2 S protein. The S1 subunit sequence consists of a signal sequence (SS) and a receptor-binding domain (RBD), which is an important subunit within the S protein involved in binding to the human cell receptor ACE2. The S2 subunit contains the S2 protease cleavage site (S2'), a fusion peptide (FP) for subsequent membrane fusion, heptad repeat regions (HR1 and HR2) with a central helix (CH) domain, a transmembrane domain (TM), and a cytoplasmic tail (CT). [Figure 2]Exemplary SARS-CoV-2 vaccine constructs. Based on the complete and wild-type S protein, different constructs were designed encoding (1) the complete protein with mutations in the first seventh repeat (HRP1) containing stabilizing mutations that preserve the neutralization-sensitive site, (2) the S1 domain, or (3) only the RB domain (RBD). Additionally, a fibritin domain (F) was fused to the C-terminus to stabilize the protein fragment. All constructs began with a signal peptide (SP) to ensure Golgi transport to the plasma membrane. [Figure 3] General structure of RNA. Schematic representation of the general structure of an RNA vaccine with 5' cap, 5' and 3' untranslated regions, coding sequence with endogenous secretory signal peptide and GS linker, and poly(A) tail. Note that individual elements are not listed with exact lengths for each sequence length. UTR = untranslated region; sec = secretory signal peptide; RBD = receptor binding domain; GS = glycine-serine linker. [Figure 4] General structure of RNA. Schematic representation of the general structure of drug substance RNA with 5' cap, 5' and 3' untranslated regions, coding sequence with endogenous secretory signal peptide and GS linker, and poly(A) tail. Note that individual elements are not listed with exact lengths for each sequence length. GS = glycine-serine linker; UTR = untranslated region; Sec = secretory signal peptide; RBD = receptor binding domain. [Figure 5] General structure of RNA. Schematic representation of the general structure of an RNA vaccine: 5' cap, 5' and 3' untranslated regions, Venezuelan equine encephalitis virus (VEEV) RNA-dependent RNA polymerase replicase, and coding sequence for SARS-CoV-2 antigens with endogenous secretory signal peptide and GS linker, and poly(A) tail. Note that individual elements are not listed with exact lengths for each sequence length. UTR = untranslated region; Sec = secretory signal peptide; RBD = receptor-binding domain; GS = glycine-serine linker. [Figure 6]Schematic overview of the S protein organization of the SARS-CoV-2 S protein and constructs for SARS-CoV-2 vaccine development. Based on the wild-type S protein, two different transmembrane-anchored RBD-based vaccine constructs were designed, encoding RBD fragments fused to the T4 fibritin trimerization domain (F) and the spontaneous transmembrane domain (TM). Construct (1) starts with the SARS-CoV-2-S signal peptide (SP; AA1-19 of the S protein), while construct (2) starts with the human Ig heavy chain signal peptide (huSec) to ensure Golgi transport to the plasma membrane. [Figure 7] Anti-S protein IgG responses 6, 14, and 21 days after immunization with LNP-C12-formulated modRNA encoding a transmembrane-anchored RBD-based vaccine construct. BALB / c mice were immunized IM once with 4 μg of LNP-C12-formulated transmembrane-anchored RBD-based vaccine construct (surrogate for BNT162b3c / BNT162b3d). At 6, 14, and 21 days post-immunization, animals were bled, and serum samples were analyzed for total anti-S1 (left) and anti-RBD (right) antigen-specific immunoglobulin G (IgG) as measured by ELISA. Different serum dilutions were included on the graph for days 6 (1:50), 14 (1:300), and 21 (1:900). Each point on the graph represents one mouse, and all mouse samples were measured in duplicate (group size n = 8; mean + SEM for group is included). [Figure 8]Neutralization of SARS-CoV-2 pseudovirus 6, 14, and 21 days after immunization with LNP-C12-formulated modRNA encoding a transmembrane-anchored RBD-based vaccine construct. BALB / c mice were immunized IM once with 4 μg of LNP-C12-formulated transmembrane-anchored RBD-based vaccine construct (surrogate for BNT162b3c / BNT162b3d). At 6, 14, and 21 days post-immunization, animals were bled and serum was tested for SARS-CoV-2 pseudovirus neutralization. Graph shows pVN50 serum dilution (50% reduction in infection events compared to the no-serum positive control). Each point on the graph represents one mouse. All mouse samples were measured in duplicate. Group size n=8. Mean + SEM is shown by the horizontal bar with whiskers for each group. LLOQ, lower limit of quantitation. ULOQ, upper limit of quantitation. [Figure 9A] BNT162b3 - Exemplary functional 50% SARS-CoV-2 neutralizing antibody titers (VN50). (A) Young participants (18-55 years old) and (B) older participants (56-85 years old) were immunized with 3, 10, 20, and 30 μg of BNT162b3 on days 1 (all dose levels) and 22 (all dose levels except the 30 μg young participant cohort) (n=12 per group). Serum was collected on days 1 (baseline), 8, 22 (pre-boost), 29, 36, 43, 50, 85, and 184. SARS-CoV-2 50% neutralizing titers (VN50 titers) and 95% confidence intervals are shown. Values ​​below the limit of detection (LOD) are plotted as 0.5*LOD. Arrowheads indicate baseline (pre-dose 1, day 1) and dose 2 (day 22). Horizontal dotted lines represent LOD. VN50 = 50% SARS-CoV-2 neutralizing antibody titer. [Figure 9B]BNT162b3 - Exemplary functional 50% SARS-CoV-2 neutralizing antibody titers (VN50). (A) Young participants (18-55 years old) and (B) older participants (56-85 years old) were immunized with 3, 10, 20, and 30 μg of BNT162b3 on days 1 (all dose levels) and 22 (all dose levels except the 30 μg young participant cohort) (n=12 per group). Serum was collected on days 1 (baseline), 8, 22 (pre-boost), 29, 36, 43, 50, 85, and 184. SARS-CoV-2 50% neutralizing titers (VN50 titers) and 95% confidence intervals are shown. Values ​​below the limit of detection (LOD) are plotted as 0.5*LOD. Arrowheads indicate baseline (pre-dose 1, day 1) and dose 2 (day 22). Horizontal dotted lines represent LOD. VN50 = 50% SARS-CoV-2 neutralizing antibody titer. [Figure 10] Exemplary frequency of participants with SARS-CoV-2 GMT seroconversion after immunization with BNT162b3. Vaccination schedule and serum sampling are the same as in Figure 9. Seroconversion in terms of 50% SARS-CoV-2 neutralizing antibody titers (VN50) is shown for (A) young participants (18-55 years old) and (B) older participants (56-85 years old) administered 3, 10, 20, and 30 μg BNT162b3. Young participants immunized with 30 μg BNT162b3 did not receive a booster dose. Seroconversion is defined as a minimum 4-fold increase in functional antibody response compared to baseline. Arrowheads indicate baseline (pre-dose 1, day 1) and dose 2 (day 22). GMT = geometric mean titer. [Figure 11A]Exemplary S1-binding antibody titers after immunization with BNT162b3. Vaccination schedule and serum sampling are the same as in Figure 9. Geometric mean S1-binding antibody titers and 95% confidence intervals are shown for (A) young participants (18-55 years old) and (B) elderly participants (56-85 years old) immunized with 3, 10, 20, and 30 μg BNT162b3. Values ​​less than the lower limit of quantitation (LLOQ) are plotted as 0.5*LLOQ. Values ​​greater than the upper limit of quantitation (ULOQ) are plotted as 2*ULOQ. Dashed horizontal lines represent LLOQ and ULOQ. Arrowheads indicate baseline (pre-dose 1, day 1) and dose 2 (day 22). Young participants immunized with 30 μg BNT162b3 did not receive a booster dose. S1 = subunit of the SARS-CoV-2 spike protein. [Figure 11B] Exemplary S1-binding antibody titers after immunization with BNT162b3. Vaccination schedule and serum sampling are the same as in Figure 9. Geometric mean S1-binding antibody titers and 95% confidence intervals are shown for (A) young participants (18-55 years old) and (B) elderly participants (56-85 years old) immunized with 3, 10, 20, and 30 μg BNT162b3. Values ​​less than the lower limit of quantitation (LLOQ) are plotted as 0.5*LLOQ. Values ​​greater than the upper limit of quantitation (ULOQ) are plotted as 2*ULOQ. Dashed horizontal lines represent LLOQ and ULOQ. Arrowheads indicate baseline (pre-dose 1, day 1) and dose 2 (day 22). Young participants immunized with 30 μg BNT162b3 did not receive a booster dose. S1 = subunit of the SARS-CoV-2 spike protein. [Figure 12A]Exemplary RBD-binding antibody titers after immunization with BNT162b3. Vaccination schedule and serum sampling are the same as in Figure 9. Geometric mean RBD-binding antibody titers and 95% confidence intervals are shown for (A) young participants (18-55 years old) and (B) elderly participants (56-85 years old) immunized with 3, 10, 20, and 30 μg BNT162b3. Values ​​less than the lower limit of quantitation (LLOQ) are plotted as 0.5*LLOQ. Values ​​greater than the upper limit of quantitation (ULOQ) are plotted as 2*ULOQ. Dashed horizontal lines represent LLOQ and ULOQ. Arrowheads indicate baseline (pre-dose 1, day 1) and dose 2 (day 22). Young participants immunized with 30 μg BNT162b3 did not receive a booster dose. RBD = receptor-binding domain. [Figure 12B] Exemplary RBD-binding antibody titers after immunization with BNT162b3. Vaccination schedule and serum sampling are the same as in Figure 9. Geometric mean RBD-binding antibody titers and 95% confidence intervals are shown for (A) young participants (18-55 years old) and (B) elderly participants (56-85 years old) immunized with 3, 10, 20, and 30 μg BNT162b3. Values ​​less than the lower limit of quantitation (LLOQ) are plotted as 0.5*LLOQ. Values ​​greater than the upper limit of quantitation (ULOQ) are plotted as 2*ULOQ. Dashed horizontal lines represent LLOQ and ULOQ. Arrowheads indicate baseline (pre-dose 1, day 1) and dose 2 (day 22). Young participants immunized with 30 μg BNT162b3 did not receive a booster dose. RBD = receptor-binding domain. [Figure 13]Cytokine polarization of BNT162b3-induced T cells in young participants (18-55 years old). PBMCs obtained on day 1 (before dose 1) and day 29 (7 days after dose 2) (young participants: 3 μg, n=9; 10 μg, n=10; 20 μg and 30 μg (no boost), n=11 each) were stimulated overnight with overlapping peptide pools representing the RBD [aa 1-19 fused to aa 327-528 of S] and analyzed by flow cytometry. (A) shows RBD-specific CD8+ and (B) shows CD4+ T cells producing the indicated cytokines as fractions of total circulating T cells from the same subsets. Values ​​above the data points represent the average fraction per dose cohort. Participant PBMCs were tested as a single instance (a-b). [Figure 14] Cytokine polarization of BNT162b3-induced T cells in elderly participants (56-85 years old). PBMCs obtained on day 1 (before dose 1) and day 29 (7 days after dose 2) (elderly participants: 3 μg, n = 9; 10 μg and 30 μg, n = 12 each; 20 μg, n = 11) were stimulated overnight with overlapping peptide pools representing the RBD [aa 1-19 fused to aa 327-528 of S] and analyzed by flow cytometry. (A) shows S-specific CD8+ and (B) shows CD4+ T cells producing the indicated cytokines as fractions of total circulating T cells from the same subsets. Values ​​above the data points represent the average fraction per dose cohort. Participant PBMCs were tested as a single instance (a-b). Due to high background responses in unstimulated control PBMCs, the following numbers of elderly participants were excluded from the CD8 dataset: 3 μg: n=2, 20 μg: n=1; and 30 μg: n=1. [Figure 15]Incidence and magnitude of BNT162b3-induced T cell responses. PBMCs obtained on day 1 (preprime) and day 29 (7 days postboost, excluding adults who received 30 μg and did not receive any boost) were enriched for CD4+ or CD8+ T cell effectors and stimulated overnight with a pool of overlapping peptides representing the RBD and TBD sequences encoded by BNT162b3 (RBDb3 and TMDb3) for direct ex vivo IFNγ ELISpot assessment. Cell culture medium served as a negative control. Each dot represents the normalized mean spot count from duplicate wells for one study participant after subtraction from the medium-only control. The number of participants with detectable T cell responses at day 29 relative to the total number of participants per dose cohort with evaluable ELISPOT data is provided. Data for adult subjects (3 μg, n = 9; 10 and 20 μg, n = 10 each; 30 μg, n = 8) and elderly subjects (3 μg, n = 8; 10 and 30 μg, n = 9 each; 20 μg, n = 11). [Figure 16A] Frequency of local non-spontaneous reactions (subject-assessed) by worst grade. Prime up to 7 days post-prime. Young dose-ranging cohort. Frequency of local non-spontaneous reactions (worst grade) reported by young participants (18-55 years old) after prime (first vaccine dose) up to 7 days post-prime. The denominator for percentage calculations is the number of subjects with local reaction information available by dose group and interval. [Figure 16B] Frequency of local spontaneous reactions (subject-assessed) by worst grade. Boost up to 7 days post-boost. Young dose-ranging cohort. Frequency of local spontaneous reactions (worst grade) reported by young participants (18-55 years old) after boost (second vaccine dose) up to 7 days post-boost. The denominator for calculating percentages is the number of subjects with local reaction information available per dose group and interval. The boost was withheld for the 30 μg young cohort. [Figure 17A]Frequency of local non-spontaneous reactions (subject-assessed) by worst grade. Prime up to 7 days post-prime. Elderly dose-ranging cohort. Frequency of local non-spontaneous reactions (worst grade) reported by elderly participants (56-85 years old) after prime (first vaccine dose) up to 7 days post-prime. The denominator for percentage calculations is the number of subjects with local reaction information available by dose group and interval. [Figure 17B] Frequency of local unspontaneous reactions (subject-assessed) by worst grade. Boost up to day 7 post-boost. Elderly dose-ranging cohort. Frequency of local unspontaneous reactions (worst grade) reported by elderly participants (56-85 years old) after boost (second vaccine dose) up to day 7 post-boost. The denominator for percentage calculations is the number of subjects with information on local reactions available by dose group and interval. [Figure 18A] Frequency of unspontaneous systemic reactions (subject-assessed) by worst grade. Prime up to 7 days post-prime. Young dose-ranging cohort. Frequency of unspontaneous systemic reactions (worst grade) reported by young participants (18-55 years old) after prime (first vaccine dose) up to 7 days post-prime. The denominator for percentage calculations is the number of subjects with information on local reactions available by dose group and interval. [Figure 18B] Frequency of unspontaneous systemic reactions (subject-assessed) by worst grade. Boost up to 7 days post-boost. Young dose-ranging cohort. Frequency of unspontaneous systemic reactions (worst grade) reported by young participants (18-55 years old) after boost (second vaccine dose) up to 7 days post-boost. The denominator for calculating percentages is the number of subjects with available local reaction information per dose group and interval. The boost was withheld for the 30 μg young cohort. [Figure 19A]Frequency of unspontaneous systemic reactions (subject-assessed) by worst grade. Prime up to 7 days post-prime. Elderly dose-ranging cohort. Frequency of unspontaneous systemic reactions (worst grade) reported by elderly participants (56-85 years old) after prime (first vaccine dose) up to 7 days post-prime. The denominator for percentage calculations is the number of subjects with information on local reactions available by dose group and interval. [Figure 19B] Frequency of unspontaneous systemic reactions (subject-assessed) by worst grade. Boost up to day 7 post-boost. Elderly dose-ranging cohort. Frequency of unspontaneous systemic reactions (worst grade) reported by elderly participants (56-85 years old) after boost (second vaccine dose) up to day 7 post-boost. The denominator for percentage calculations is the number of subjects with information on local reactions available by dose group and interval. DETAILED DESCRIPTION OF THE INVENTION

[0260] Detailed Description Although the present invention is described in detail below, it is understood that this invention is not limited to particular methodologies, protocols, and reagents, as these may vary. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0261] Preferably, the terms used herein are as defined in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", H.G.W. Leuenberger, B. Nagel, and H. Koelbl, Eds., Helvetica Chimica Acta, CH-4010 Basel, Switzerland, (1995).

[0262] The practice of the present invention employs, unless otherwise indicated, conventional methods of chemistry, biochemistry, cell biology, immunology, and recombinant DNA technology as described in the literature in the art (see, e.g., Molecular Cloning: A Laboratory Manual, 2nd Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989).

[0263] Below, elements of the present invention are described. Although these elements are listed with specific embodiments, it should be understood that they can be combined in any manner and in any number to create additional embodiments. The various described examples and embodiments should not be construed as limiting the invention to only the specifically described embodiments. The description should be understood to disclose and encompass embodiments combining any number of the disclosed elements with the specifically described embodiments. Furthermore, all permutations and combinations of all described elements should be considered disclosed by this description, unless the context dictates otherwise.

[0264] Several documents are cited throughout this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, is hereby incorporated by reference in its entirety. Nothing herein should be construed as an admission that the present disclosure is not entitled to antedate such disclosure.

[0265] definition The following definitions are provided which apply to all aspects of the present invention. The following terms have the following meanings unless otherwise specified: Any undefined terms have their art-recognized meanings.

[0266] The term "about" means approximately or approximation, and in the context of a numerical value or range herein, means, in certain embodiments, ±20%, ±10%, ±5%, or ±3% of the stated or claimed numerical value or range.

[0267] In the context of describing the present invention (particularly in the context of the claims), the singular "a," "an," "the ...

[0268] Unless otherwise indicated, the term "comprising" is used herein to indicate that additional members may optionally be present in addition to the listed members introduced by "comprising." However, it is contemplated that the term "comprising" may be a specific embodiment of the present invention that does not exclude the possibility of additional members being present, i.e., for the purposes of this embodiment, "comprising" is understood to have the meaning of "consisting of" or "consisting essentially of."

[0269] As used herein, terms such as "reduce," "reduce," "inhibit," or "impair" refer to an overall decrease or the ability to cause an overall decrease in a level, preferably at least 5%, at least 10%, at least 20%, at least 50%, at least 75% or more. These terms include complete or essentially complete inhibition, i.e., a decrease to or essentially to zero.

[0270] Terms such as "increase," "enhancement," or "exceed" preferably relate to an increase or enhancement of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 80%, at least 100%, at least 200%, at least 500% or more.

[0271] According to this disclosure, the term "peptide" includes oligo- and polypeptides and refers to a substance comprising about 2 or more, about 3 or more, about 4 or more, about 6 or more, about 8 or more, about 10 or more, about 13 or more, about 16 or more, about 20 or more, and up to about 50, about 100, or about 150 consecutive amino acids joined together by peptide bonds. The term "protein" or "polypeptide" refers to large peptides, particularly peptides having at least about 150 amino acids, although the terms "peptide," "protein," and "polypeptide" are generally used interchangeably herein.

[0272] A "therapeutic protein" when provided to a subject in a therapeutically effective amount has a positive or beneficial effect on the subject's condition or disease state. In certain embodiments, a therapeutic protein has therapeutic or palliative properties and can be administered to improve, alleviate, relieve, reverse, delay the onset, or reduce the severity of one or more symptoms of a disease or disorder. A therapeutic protein can have prophylactic properties and can be used to delay the onset of such a disease or reduce the severity of such a disease or condition. The term "therapeutic protein" includes whole proteins or peptides and can also refer to therapeutically active fragments thereof. It can also include therapeutically active variants of proteins. Examples of therapeutically active proteins include, but are not limited to, vaccination antigens and immunostimulants such as cytokines.

[0273] A "fragment" in relation to an amino acid sequence (peptide or protein) refers to a portion of the amino acid sequence, i.e., a sequence representing an amino acid sequence truncated at the N-terminus and / or C-terminus. A C-terminally truncated fragment (N-terminal fragment) can be obtained, for example, by translating a truncated open reading frame lacking the 3' end of the open reading frame. A N-terminally truncated fragment (C-terminal fragment) can be obtained, for example, by translating a truncated open reading frame lacking the 5' end of the open reading frame, as long as the truncated open reading frame contains a start codon that serves for translation initiation. A fragment of an amino acid sequence contains, for example, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the amino acid residues of the amino acid sequence. A fragment of an amino acid sequence preferably contains at least 6, particularly at least 8, at least 12, at least 15, at least 20, at least 30, at least 50, or at least 100 consecutive amino acids of the amino acid sequence.

[0274] As used herein, "variant" refers to an amino acid sequence that differs from a parent amino acid sequence by at least one amino acid modification. The parent amino acid sequence may be a naturally occurring or wild-type (WT) amino acid sequence or may be a modified version of the wild-type amino acid sequence. Preferably, the variant amino acid sequence has at least one amino acid modification compared to the parent amino acid sequence, e.g., 1 to about 20 amino acid modifications compared to the parent, and preferably 1 to about 10 or 1 to about 5 amino acid modifications.

[0275] As used herein, "wild-type" or "WT" or "native" refers to an amino acid sequence found in nature, including allelic versions. A wild-type amino acid sequence, peptide, or protein has an amino acid sequence that has not been intentionally modified.

[0276] For the purposes of the present invention, a "variant" of an amino acid sequence (peptide, protein, or polypeptide) includes amino acid insertion variants, amino acid addition variants, amino acid deletion variants, and / or amino acid substitution variants. The term "variant" includes total mutants, splice variants, post-translationally modified variants, conformations, isoforms, allelic variants, species variants, and species homologs, particularly those occurring naturally. The term "variant" particularly includes fragments of an amino acid sequence.

[0277] Amino acid insertion variants include the insertion of one, two, or more amino acids into a specific amino acid sequence. In amino acid sequence variants with insertions, one or more amino acid residues are inserted at specific sites in the amino acid sequence, although random insertion and appropriate screening of the resulting products are also possible. Amino acid addition variants include amino- and / or carboxy-terminal fusions of one or more amino acids, e.g., 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids. Amino acid deletion variants are characterized by the removal of one or more amino acids from the sequence, e.g., 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids. The deletion may occur at any position in the protein. Amino acid deletion variants that include deletions at the N-terminus and / or C-terminus of the protein are also referred to as N- and / or C-terminal truncated variants. Amino acid substitution variants are characterized by the removal of at least one residue in the sequence and the insertion of another residue in its place. Modifications that substitute amino acid positions and / or amino acids that are not conserved in homologous proteins or peptides with others having similar properties are preferred. Preferably, the amino acid changes in peptide and protein variants are conservative amino acid changes, i.e., substitutions of similarly charged or uncharged amino acids. Conservative amino acid changes include substitutions of one member of a family of amino acids related in their side chains. Naturally occurring amino acids are generally classified into four families: acidic (aspartic acid, glutamic acid), basic (lysine, arginine, histidine), nonpolar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes collectively classified as aromatic amino acids. In some embodiments, conservative amino acid substitutions include substitutions within the following groups: Glycine, Alanine; valine, isoleucine, leucine; Aspartic acid, glutamic acid; Asparagine, glutamine; Serine, threonine; lysine, arginine; and Phenylalanine, tyrosine.

[0278] Preferably, the degree of similarity, preferably identity, between an amino acid sequence and an amino acid sequence that is a variant of the given amino acid sequence is at least about 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. The degree of similarity or identity is preferably displayed over an amino acid region that is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of the entire length of the reference amino acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids, the degree of similarity or identity is preferably expressed for at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 amino acids, in some embodiments, consecutive amino acids. In some embodiments, the degree of similarity or identity is expressed for the entire length of the reference amino acid sequence. Alignment for determining sequence similarity, preferably sequence identity, can be performed using tools known in the art, preferably using best sequence alignment, for example, Align, using standard settings, preferably EMBOSS::needle, Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.

[0279] "Sequence similarity" refers to the percentage of amino acids that are identical or represent conservative amino acid substitutions. "Sequence identity" between two amino acid sequences refers to the percentage of amino acids that are identical between the sequences. "Sequence identity" between two nucleic acid sequences refers to the percentage of nucleotides that are identical between the sequences.

[0280] The terms "% identical", "% identity" or similar terms refer specifically to the percentage of nucleotides or amino acids that are identical in optimal alignment of the compared sequences. The percentage is purely statistical, and the differences between the two sequences are not necessarily randomly distributed throughout the compared sequences. Comparison of two sequences is usually performed by comparing the sequences over a segment or "comparison window" after optimal alignment to identify local regions of corresponding sequences. Optimal alignment for comparison can be performed manually or with the aid of the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, with the aid of the local homology algorithm of Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443, with the aid of the similarity search algorithm of Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 88, 2444, or with the aid of computer programs that use such algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N, and TFASTA from the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.). In one embodiment, the percent identity of two sequences is determined using the BLASTN or BLASTP algorithm available at the United States National Center for Biotechnology Information (NCBI) website (e.g., blast.ncbi.nlm.nih.gov / Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&LINK_LOC=align2seq).In one embodiment, the algorithm parameters used in the BLASTN algorithm on the NCBI website include (i) a prediction threshold setting of 10; (ii) a word size setting of 28; (iii) a maximum match within the query range setting of 0; (iv) a match / mismatch score setting of 1 or -2; (v) a gap cost setting of linear; and (vi) use of a filter for low complexity regions. In one embodiment, the algorithm parameters used in the BLASTP algorithm on the NCBI website include (i) a prediction threshold setting of 10; (ii) a word size setting of 3; (iii) a maximum match within the query range setting of 0; (iv) a matrix setting of BLOSUM62; (v) gap costs set to presence: 11 and extension: 1; and (vi) a conditional compositional score matrix adjustment.

[0281] Percentage identity is obtained by determining the number of corresponding identical positions in the compared sequences, dividing this number by the number of positions being compared (eg, the number of positions in the reference sequence) and multiplying the result by 100.

[0282] In some embodiments, the degree of similarity or identity is expressed over a region that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the entire length of the reference sequence. For example, if the reference nucleic acid sequence consists of 200 nucleotides, the degree of identity is expressed over at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 nucleotides, in some embodiments, consecutive nucleotides. In some embodiments, the degree of similarity or identity is expressed over the entire length of the reference sequence.

[0283] Homologous amino acid sequences according to the present disclosure exhibit at least 40%, in particular at least 50%, at least 60%, at least 70%, at least 80%, at least 90% and preferably at least 95%, at least 98% or at least 99% identity of the amino acid residues.

[0284] The amino acid sequence variants described herein can be readily prepared by one of skill in the art, for example, by recombinant DNA manipulation. The manipulation of DNA sequences to prepare peptides or proteins with substitutions, additions, insertions, or deletions is described in detail, for example, in Sambrook et al. (1989). Furthermore, the peptides and amino acid variants described herein can be readily produced with the aid of known peptide synthesis techniques, such as, for example, by solid-phase synthesis and similar methods.

[0285] In some embodiments, a fragment or variant of an amino acid sequence (peptide or protein) is preferably a "functional fragment" or "functional variant." The term "functional fragment" or "functional variant" of an amino acid sequence refers to any fragment or variant that exhibits one or more functional properties identical or similar to those of the amino acid sequence from which it is derived, i.e., is functionally equivalent. With respect to an antigen or antigenic sequence, a particular function is one or more immunogenic activities exhibited by the amino acid sequence from which the fragment or variant is derived. As used herein, the term "functional fragment" or "functional variant" particularly refers to a variant molecule or sequence that contains an amino acid sequence in which one or more amino acids have been changed compared to the amino acid sequence of the parent molecule or sequence, yet still fulfills one or more functions of the parent molecule or sequence, such as inducing an immune response. In some embodiments, modifications to the amino acid sequence of the parent molecule or sequence do not significantly affect or alter the characteristics of the molecule or sequence. In different embodiments, the function of the functional fragment or functional variant may be reduced, but still significantly present, for example, the immunogenicity of the functional variant may be at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of that of the parent molecule or sequence. However, in other embodiments, the immunogenicity of the functional fragment or functional variant may be enhanced compared to the parent molecule or sequence.

[0286] An amino acid sequence (peptide, protein, or polypeptide) "derived from" a specified amino acid sequence (peptide, protein, or polypeptide) refers to the origin of the initial amino acid sequence. Preferably, an amino acid sequence derived from a particular amino acid sequence has an amino acid sequence that is identical, essentially identical, or homologous to the particular sequence or a fragment thereof. An amino acid sequence derived from a particular amino acid sequence may be a variant of the particular sequence or a fragment thereof. For example, it will be understood by those skilled in the art that antigens suitable for use herein may be altered in sequence to differ from the naturally occurring or native sequence from which they are derived while maintaining the desired activity of the native sequence.

[0287] As used herein, "instruction material" or "instructions" includes publications, records, diagrams, or any other medium of representation that can be used to communicate the utility of the compositions and methods of the invention. The instruction material of the kits of the invention can be, for example, attached to or shipped with a container containing a composition of the invention. Alternatively, the instruction material can be shipped separately from the container, with the intention that the instruction material and the composition be used cooperatively by the recipient.

[0288] "Isolated" means altered or removed from the natural state. For example, a nucleic acid or peptide naturally occurring in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from the coexisting materials in its natural state is "isolated." An isolated nucleic acid or protein can exist in substantially purified form, or it can exist in a non-native environment, such as, for example, a host cell.

[0289] The term "recombinant" in the context of the present invention means "produced through genetic engineering." Preferably, a "recombinant entity," such as a recombinant nucleic acid, in the context of the present invention does not occur in nature.

[0290] As used herein, the term "naturally occurring" refers to the fact that an object can be found in nature. For example, a peptide or nucleic acid that is present in an organism (including a virus), can be isolated from a natural source, and has not been artificially modified in a laboratory is naturally occurring.

[0291] As used herein, "physiological pH" refers to a pH of about 7.5.

[0292] The term "genetic modification" or simply "modification" includes the transfection of cells with nucleic acids. The term "transfection" refers to the introduction of nucleic acids, particularly RNA, into cells. For purposes of the present invention, the term "transfection" also includes the introduction of nucleic acids into cells or the uptake of nucleic acids by such cells, where the cells may be present in a subject, e.g., a patient. Thus, according to the present invention, cells for transfection of nucleic acids described herein can be present in vitro or in vivo; for example, the cells may form part of a patient's organ, tissue, and / or organism. According to the present invention, transfection can be transient or stable. For some applications of transfection, it is sufficient if the transfected genetic material is only transiently expressed. RNA can be transfected into cells to transiently express its encoded protein. Because nucleic acids introduced during transfection are usually not integrated into the nuclear genome, the foreign nucleic acid is diluted or degraded through mitosis. Cells capable of episomal amplification of nucleic acids have a greatly reduced dilution rate. If transfected nucleic acid is desired to remain in the genome of the cell and its daughter cells, stable transfection should be performed.Such stable transfection can be achieved by using a virus-based system or a transposon-based system for transfection.Generally, the nucleic acid encoding antigen is transiently transfected into cells.RNA can be transfected so that cells transiently express the protein it encodes.

[0293] The term "seroconversion" includes a 4-fold or greater increase from pre-vaccination to 1 month after dose 2.

[0294] coronavirus Coronaviruses are enveloped, positive-sense, single-stranded RNA ((+)ssRNA) viruses. They possess the largest genomes (26–32 kb) among known RNA viruses and are phylogenetically classified into four genera (α, β, γ, and Δ), with betacoronaviruses further subdivided into four lineages (A, B, C, and D). Coronaviruses infect a wide range of avian and mammalian species, including humans. Some human coronaviruses generally cause mild respiratory illness, although the severity of the illness can be greater in infants, the elderly, and immunocompromised individuals. Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), which belong to betacoronavirus lineages C and B, respectively, are highly pathogenic. Both viruses have emerged from animal reservoirs into human populations within the last 15 years and caused highly lethal pandemics. A severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak, which causes atypical pneumonia (coronavirus disease 2019; COVID-19), emerged in China in mid-December 2019 and has developed into a public health emergency of international concern. SARS-CoV-2 (MN908947.3) belongs to the betacoronavirus lineage B and shares at least 70% sequence similarity with SARS-CoV.

[0295] Generally, coronaviruses have four structural proteins: envelope (E), membrane (M), nucleocapsid (N), and spike (S). The E and M proteins have important functions in virus assembly, while the N protein is required for viral RNA synthesis. A key glycoprotein is responsible for virus binding and entry into target cells. The S protein is synthesized as a single-chain inactive precursor and is cleaved into two noncovalently linked subunits, S1 and S2, by a furin-like host protease in the producing cell. The S1 subunit contains a receptor-binding domain (RBD) that recognizes host cell receptors. The S2 subunit contains a fusion peptide, two heptad repeat regions, and a transmembrane domain, all of which undergo large conformational rearrangements to mediate fusion between the virus and host cell membranes. The S1 and S2 subunits trimerize to form the large prefusion spike.

[0296] The SARS-CoV-2 S precursor protein is proteolytically cleaved into S1 (685 aa) and S2 (588 aa) subunits. The S1 subunit contains the receptor-binding domain (RBD) that mediates viral entry into susceptible cells via the host angiotensin-converting enzyme 2 (ACE2) receptor.

[0297] antigen The present invention includes the use of RNA encoding an amino acid sequence comprising the SARS-CoV-2 S protein, its immunogenic variants, or an immunogenic fragment of the SARS-CoV-2 S protein or its immunogenic variants. Thus, the RNA encodes a peptide or protein comprising at least an epitope of the SARS-CoV-2 S protein or its immunogenic variants to induce an immune response in a subject against the coronavirus S protein, particularly the SARS-CoV-2 S protein. Amino acid sequences comprising the SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants (i.e., antigenic peptides or proteins) are also referred to herein as "vaccine antigens," "peptide and protein antigens," "antigenic molecules," or simply "antigens." The SARS-CoV-2 S protein, its immunogenic variants, or immunogenic fragments of the SARS-CoV-2 S protein or its immunogenic variants are also referred to herein as "antigenic peptides or proteins" or "antigenic sequences." The SARS-CoV-2 coronavirus full-length spike (S) protein consists of 1273 amino acids and is set forth in SEQ ID NO: 1: (SEQ ID NO: 1) It has the amino acid sequence:

[0298] For purposes of this disclosure, the above sequences are considered to be the amino acid sequences of wild-type SARS-CoV-2 proteins. The position numbering of the SARS-CoV-2 S protein shown herein is relative to the amino acid sequence of SEQ ID NO: 1 and the corresponding positions in SARS-CoV-2 S protein variants.

[0299] In certain embodiments, the full-length spike (S) protein of SEQ ID NO: 1 is modified in such a way that the prototype pre-fusion conformation is stabilized. Stabilization of the pre-fusion conformation can be obtained by introducing two consecutive proline substitutions at AS residues 986 and 987 of the full-length spike protein. In particular, a spike (S) protein stabilized protein variant is obtained in such a way that amino acid residue 986 is replaced with proline and amino acid residue 987 is also replaced with proline.

[0300] In one embodiment, the SARS-CoV-2 S protein variant in which the prototype pre-fusion conformation is stabilized is SEQ ID NO: 7: (SEQ ID NO: 7) The amino acid sequence of

[0301] Those skilled in the art are aware of various spike variants and / or resources describing same. For example, the following strains, their SARS-CoV-2 S protein amino acid sequences, and particularly variants thereof compared to the wild-type SARS-CoV-2 S protein amino acid sequence, e.g., variants compared to SEQ ID NO: 1, are useful herein:

[0302] B.1.1.7(“Variant of Concern 202012 / 01”(VOC-202012 / 01) B.1.1.7 is a SARS-CoV-2 variant first detected in the UK in October 2020 during the COVID-19 pandemic in samples collected the previous month and began to spread rapidly by mid-December. This correlated with a significant increase in COVID-19 infection rates in the UK; this increase is thought to be due, at least in part, to an N501Y mutation within the receptor-binding domain of the spike glycoprotein, which is required for binding to ACE2 in human cells. The B.1.1.7 variant is defined by 23 mutations: 13 nonsynonymous mutations, 4 deletions, and 6 synonymous mutations (i.e., 17 protein-altering mutations and 6 non-altering mutations). Spike protein alterations in B.1.1.7 include deletions 69-70, 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H.

[0303] B.1.351(501.V2) The lineage B.1.351, commonly known as the South African COVID-19 variant, is a variant of SARS-CoV-2. Preliminary results indicate that this variant may have increased transmissibility. The B.1.351 variant is defined by multiple spike protein alterations, including L18F, D80A, D215G, deletions 242-244, R246I, K417N, E484K, N501Y, D614G, and A701V. The spike region of the B.1.351 genome contains three mutations of particular interest: K417N, E484K, and N501Y.

[0304] B.1.1.298(Cluster 5) B.1.1.298 was discovered in North Jutland, Denmark, and is believed to have spread from minks to humans via mink farms. Several different mutations in the viral spike protein have been identified. Specific mutations include deletions 69-70, Y453F, D614G, I692V, M1229I, and possibly S1147L.

[0305] P.1(B.1.1.248) The B.1.1.248 lineage, also known as the Brazilian variant, is one of several SARS-CoV-2 variants designated the P.1 lineage. P.1 has many S protein modifications [L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F] and is similar to the B.1.351 variant from South Africa at certain key RBD positions (K417, E484, and N501).

[0306] B.1.427 / B.1.429(CAL.20C) The B.1.427 / B.1.429 lineage, also known as CAL.20C, is defined by the following modifications in the S protein: S13I, W152C, L452R, and D614G, of which the L452R modification is of particular concern. The CDC lists B.1.427 / B.1.429 as a "variant of concern."

[0307] B.1.525 B.1.525 has the same E484K modification found in the P.1 and B.1.351 variants, and the same ΔH69 / ΔV70 deletion found in B.1.1.7 and B.1.1.298. It also has the modifications D614G, Q677H, and F888L.

[0308] B.1.526 B.1.526 has been detected as a new lineage of the virus isolated in the New York area and shares mutations with previously reported variants. The most common spike mutations in this lineage are L5F, T95I, D253G, E484K, D614G, and A701V.

[0309] The table below provides an overview of SARS-CoV-2 circulating strains that are VOI / VOC.

[0310] [Table 1]

[0311] In certain embodiments, the vaccine antigens described herein comprise, consist essentially of, or consist of the spike protein of SARS-CoV-2, a variant thereof, or a fragment thereof.

[0312] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7.

[0313] In some embodiments, the RNA encoding the vaccine antigen is (i) a fragment of the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9, a fragment of the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9, or ... and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 3819 of SEQ ID NO: 2, 8, or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 1273 of SEQ ID NO: 1 or 7.

[0314] In certain embodiments, the vaccine antigen comprises, consists essentially of, or consists of the SARS-CoV-2 spike S1 fragment (S1) (the S1 subunit of the spike protein of SARS-CoV-2), a variant thereof, or a fragment thereof.

[0315] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1.

[0316] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8, or 9, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8, or 9 or the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8, or 9 and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 2049 of SEQ ID NO: 2, 8, or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 683 of SEQ ID NO: 1.

[0317] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1.

[0318] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9 or the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9 and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 49 to 2055 of SEQ ID NO: 2, 8, or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 17 to 685 of SEQ ID NO: 1.

[0319] In some embodiments, the vaccine antigen comprises, consists essentially of, or consists of the receptor binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2, a variant thereof, or a fragment thereof. The amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, a variant thereof, or a fragment thereof is also referred to herein as "RBD" or "RBD domain."

[0320] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1.

[0321] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9 or the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9 and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 979 to 1584 of SEQ ID NO: 2, 8, or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 327 to 528 of SEQ ID NO: 1.

[0322] In some embodiments, the signal peptide is fused directly or via a linker to the SARS-CoV-2 S protein, its variants, or fragments thereof, i.e., antigenic peptide or protein. Thus, in some embodiments, the signal peptide is fused to the amino acid sequence derived from the SARS-CoV-2 S protein or its immunogenic fragment (antigenic peptide or protein) contained in the vaccine antigen.

[0323] Such signal peptides generally have a length of about 15-30 amino acids and are preferably, but not limited to, sequences located at the N-terminus of an antigenic peptide or protein. A signal peptide as defined herein preferably enables transport of an antigenic peptide or protein encoded by an RNA to a predetermined intracellular compartment, preferably the cell surface, the endoplasmic reticulum (ER), or an endosomal-lysosomal compartment. In certain embodiments, a signal peptide sequence as defined herein includes, but is not limited to, the signal peptide sequence of the SARS-CoV-2 S protein, particularly a sequence comprising amino acids 1-16 or 1-19 of SEQ ID NO: 1, or a functional variant thereof.

[0324] In certain embodiments, the signal sequence comprises the amino acid sequence of amino acids 1-16 of SEQ ID NO:1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-16 of SEQ ID NO:1, or a functional fragment of the amino acid sequence of amino acids 1-16 of SEQ ID NO:1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-16 of SEQ ID NO:1. In certain embodiments, the signal sequence comprises the amino acid sequence of amino acids 1-16 of SEQ ID NO:1.

[0325] In certain embodiments, the RNA encoding the signal sequence comprises (i) a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8, or 9, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8, or 9, or the nucleotide sequence of nucleotides 1 to 48 of SEQ ID NO: 2, 8, or 9. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1-16 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-16 of SEQ ID NO: 1, or a functional fragment of the amino acid sequence of amino acids 1-16 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-16 of SEQ ID NO: 1. In certain embodiments, the RNA encoding the signal sequence (i) comprises the nucleotide sequence of nucleotides 1-48 of SEQ ID NO: 2, 8, or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1-16 of SEQ ID NO: 1.

[0326] In certain embodiments, the signal sequence comprises the amino acid sequence of amino acids 1-19 of SEQ ID NO:1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-19 of SEQ ID NO:1, or a functional fragment of the amino acid sequence of amino acids 1-19 of SEQ ID NO:1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-19 of SEQ ID NO:1. In certain embodiments, the signal sequence comprises the amino acid sequence of amino acids 1-19 of SEQ ID NO:1.

[0327] In certain embodiments, the RNA encoding the signal sequence comprises (i) a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 57 of SEQ ID NO: 2, 8, or 9, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 57 of SEQ ID NO: 2, 8, or 9, or the nucleotide sequence of nucleotides 1 to 57 of SEQ ID NO: 2, 8, or 9. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1-19 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-19 of SEQ ID NO: 1, or a functional fragment of the amino acid sequence of amino acids 1-19 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-19 of SEQ ID NO: 1. In certain embodiments, the RNA encoding the signal sequence (i) comprises the nucleotide sequence of nucleotides 1-57 of SEQ ID NO: 2, 8, or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1-19 of SEQ ID NO: 1.

[0328] The signal peptide sequence defined herein further includes, but is not limited to, an immunoglobulin signal peptide sequence, for example, the signal peptide sequence of an immunoglobulin heavy chain variable region, where the immunoglobulin may be a human immunoglobulin. In particular, the signal peptide sequence defined herein includes a sequence comprising the amino acid sequence of amino acids 1 to 22 of SEQ ID NO: 31, or a functional variant thereof.

[0329] In certain embodiments, the signal sequence comprises the amino acid sequence of amino acids 1-22 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-22 of SEQ ID NO: 31, or a functional fragment of the amino acid sequence of amino acids 1-22 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-22 of SEQ ID NO: 31. In certain embodiments, the signal sequence comprises the amino acid sequence of amino acids 1-22 of SEQ ID NO: 31.

[0330] In certain embodiments, the RNA encoding the signal sequence is (i) nucleotides 54 to 119 of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 119 of SEQ ID NO: 32, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 119 of SEQ ID NO: 32 or the nucleotide sequence of nucleotides 54 to 119 of SEQ ID NO: 32. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1-22 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-22 of SEQ ID NO: 31, or a functional fragment of the amino acid sequence of amino acids 1-22 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1-22 of SEQ ID NO: 31. In certain embodiments, the RNA encoding the signal sequence (i) comprises the nucleotide sequence of nucleotides 54-119 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1-22 of SEQ ID NO: 31.

[0331] Such signal peptides are preferably used to facilitate secretion of the encoded antigenic peptide or protein. More preferably, a signal peptide as defined herein is fused to the encoded antigenic peptide or protein as defined herein.

[0332] Thus, in particularly preferred embodiments, the RNA described herein comprises at least one coding region encoding an antigenic peptide or protein and a signal peptide, the signal peptide preferably being fused to the N-terminus of the antigenic peptide or protein, more preferably an antigenic peptide or protein described herein.

[0333] In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 1 or 7 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 1 or 7. In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO: 1 or 7.

[0334] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of SEQ ID NO: 2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 2, 8 or 9, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 2, 8 or 9 or the nucleotide sequence of SEQ ID NO: 2, 8 or 9. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 1 or 7, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 1 or 7 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 1 or 7. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 2, 8, or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1 or 7.

[0335] In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO:7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:7, or a fragment of the amino acid sequence of SEQ ID NO:7 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:7. In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO:7.

[0336] In certain embodiments, the RNA encoding the vaccine antigen is (i) a nucleotide sequence of SEQ ID NO: 15, 16, 19, 20, 24 or 25, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of SEQ ID NO: 15, 16, 19, 20, 24 or 25 or ... and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 7, or a fragment of the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 7. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 15, 16, 19, 20, 24, or 25; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 7.

[0337] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1.

[0338] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 2049 of SEQ ID NO: 2, 8, or 9, or to the nucleotide sequence of nucleotides 1 to 2049 of SEQ ID NO: 2, 8, or 9, or to the nucleotide sequence of nucleotides 1 to 2049 of SEQ ID NO: 2, 8, or 9. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 1 to 2049 of SEQ ID NO: 2, 8, or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 683 of SEQ ID NO: 1.

[0339] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1.

[0340] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 1 to 2055 of SEQ ID NO: 2, 8, or 9, or to the nucleotide sequence of nucleotides 1 to 2055 of SEQ ID NO: 2, 8, or 9, or to the nucleotide sequence of nucleotides 1 to 2055 of SEQ ID NO: 2, 8, or 9. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 1 to 2055 of SEQ ID NO: 2, 8, or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 685 of SEQ ID NO: 1.

[0341] In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO:3, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:3, or an immunogenic fragment of the amino acid sequence of SEQ ID NO:3 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:3. In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO:3.

[0342] In certain embodiments, the RNA encoding the vaccine antigen encodes (i) an amino acid sequence comprising the nucleotide sequence of SEQ ID NO:4, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:4, or a fragment of the nucleotide sequence of SEQ ID NO:4 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:4; and / or (ii) an amino acid sequence comprising the amino acid sequence of SEQ ID NO:3, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:3, or an immunogenic fragment of the amino acid sequence of SEQ ID NO:3 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:3. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO:4; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO:3.

[0343] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29.

[0344] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of nucleotides 54 to 716 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 716 of SEQ ID NO: 30, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 716 of SEQ ID NO: 30 or the nucleotide sequence of nucleotides 54 to 716 of SEQ ID NO: 30. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 716 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 221 of SEQ ID NO: 29.

[0345] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31.

[0346] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of nucleotides 54 to 725 of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 725 of SEQ ID NO: 32, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 725 of SEQ ID NO: 32 or the nucleotide sequence of nucleotides 54 to 725 of SEQ ID NO: 32. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 725 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 224 of SEQ ID NO: 31.

[0347] According to one embodiment, the trimerization domain is fused directly or via a linker to the SARS-CoV-2 S protein, its variants or fragments thereof, i.e., antigenic peptide or protein. Thus, in one embodiment, the trimerization domain is fused to the amino acid sequence from the SARS-CoV-2 S protein or immunogenic fragment thereof (antigenic peptide or protein) contained in the vaccine antigen (which may be fused to a signal peptide, as described above, if desired).

[0348] Such trimerization domains are preferably located at the C-terminus of the antigenic peptide or protein, but are not limited thereto. The trimerization domains defined herein preferably enable trimerization of antigenic peptides or proteins encoded by RNA. Examples of trimerization domains defined herein include, but are not limited to, Foldon, the natural trimerization domain of T4 fibritin. The C-terminal domain of T4 fibritin (Foldon) is essential for the formation of the fibritin trimer structure and can be used as an artificial trimerization domain. In certain embodiments, trimerization domains defined herein include, but are not limited to, a sequence comprising the amino acid sequence of amino acids 3-29 of SEQ ID NO: 10, or a functional variant thereof. In certain embodiments, trimerization domains defined herein include, but are not limited to, a sequence comprising the amino acid sequence of SEQ ID NO: 10, or a functional variant thereof.

[0349] In certain embodiments, the trimerization domain comprises the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10, or a functional fragment of the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10. In certain embodiments, the trimerization domain comprises the amino acid sequence of amino acids 3 to 29 of SEQ ID NO: 10.

[0350] In certain embodiments, the RNA encoding the trimerization domain is selected from the group consisting of: i) the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11 or the nucleotide sequence of nucleotides 7 to 87 of SEQ ID NO: 11. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 3-29 of SEQ ID NO: 10, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 3-29 of SEQ ID NO: 10, or a functional fragment of the amino acid sequence of amino acids 3-29 of SEQ ID NO: 10 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 3-29 of SEQ ID NO: 10. In certain embodiments, the RNA encoding the trimerization domain i) comprises the nucleotide sequence of nucleotides 7-87 of SEQ ID NO: 11; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 3-29 of SEQ ID NO: 10.

[0351] In certain embodiments, the trimerization domain comprises the amino acid sequence of SEQ ID NO: 10, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 10, or a functional fragment of the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 10. In certain embodiments, the trimerization domain comprises the amino acid sequence of SEQ ID NO: 10.

[0352] In certain embodiments, the RNA encoding the trimerization domain i) comprises the nucleotide sequence of SEQ ID NO: 11, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 11, or a fragment of the nucleotide sequence of SEQ ID NO: 11 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 11; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 10, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 10, or a functional fragment of the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 10. In certain embodiments, the RNA encoding the trimerization domain (i) comprises the nucleotide sequence of SEQ ID NO:11; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO:10.

[0353] Such trimerization domains are preferably used to promote trimerization of the encoded antigenic peptide or protein, and more preferably, a trimerization domain as defined herein is fused to an antigenic peptide or protein as defined herein.

[0354] Thus, in a particularly preferred embodiment, the RNA described herein comprises at least one coding region encoding an antigenic peptide or protein and a trimerization domain as defined herein, wherein the trimerization domain is fused to the antigenic peptide or protein, more preferably to the C-terminus of the antigenic peptide or protein.

[0355] In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO:5, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:5, or an immunogenic fragment of the amino acid sequence of SEQ ID NO:5 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:5. In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO:5.

[0356] In certain embodiments, the RNA encoding the vaccine antigen encodes (i) an amino acid sequence comprising the nucleotide sequence of SEQ ID NO: 6, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 6, or a fragment of the nucleotide sequence of SEQ ID NO: 6 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 6; and / or (ii) an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 5, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 5 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO:6; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO:5.

[0357] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) a nucleotide sequence of SEQ ID NO: 17, 21 or 26, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of SEQ ID NO: 17, 21 or 26, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of SEQ ID NO: 17, 21 or 26 or the nucleotide sequence of SEQ ID NO: 17, 21 or 26. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 5, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 5 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 17, 21, or 26; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 5.

[0358] In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO: 18, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 18, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 18. In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO: 18.

[0359] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29.

[0360] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of nucleotides 54 to 824 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 824 of SEQ ID NO: 30, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 824 of SEQ ID NO: 30 or the nucleotide sequence of nucleotides 54 to 824 of SEQ ID NO: 30. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 824 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 257 of SEQ ID NO: 29.

[0361] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31.

[0362] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of nucleotides 54 to 833 of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 833 of SEQ ID NO: 32, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 833 of SEQ ID NO: 32 or the nucleotide sequence of nucleotides 54 to 833 of SEQ ID NO: 32. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 833 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 260 of SEQ ID NO: 31.

[0363] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29.

[0364] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of nucleotides 111 to 824 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 111 to 824 of SEQ ID NO: 30, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 111 to 824 of SEQ ID NO: 30 or the nucleotide sequence of nucleotides 111 to 824 of SEQ ID NO: 30. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 111 to 824 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 20 to 257 of SEQ ID NO: 29.

[0365] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31.

[0366] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of nucleotides 120 to 833 of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 120 to 833 of SEQ ID NO: 32, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 120 to 833 of SEQ ID NO: 32 or the nucleotide sequence of nucleotides 120 to 833 of SEQ ID NO: 32. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 120 to 833 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 23 to 260 of SEQ ID NO: 31.

[0367] In some embodiments, the transmembrane domain is fused to the SARS-CoV-2 S protein, its variants, or fragments thereof, i.e., antigenic peptide or protein, either directly or via a linker (e.g., a glycine / serine linker). Thus, in some embodiments, the transmembrane domain is fused to the amino acid sequence from the SARS-CoV-2 S protein or immunogenic fragment thereof (antigenic peptide or protein) contained in the vaccine antigen (which may optionally be fused to a signal peptide and / or trimerization domain, as described above).

[0368] Such a transmembrane domain is preferably located at the C-terminus of the antigenic peptide or protein, but is not limited thereto. Preferably, such a transmembrane domain, if present, is located at the C-terminus of the trimerization domain, but is not limited thereto. In some embodiments, the trimerization domain is present in the SARS-CoV-2 S protein, its variant or fragment thereof, i.e., between the antigenic peptide or protein and the transmembrane domain.

[0369] A transmembrane domain as defined herein allows for the anchoring of an antigenic peptide or protein, preferably encoded by an RNA, to a cell membrane.

[0370] In certain embodiments, the transmembrane domain sequence defined herein includes, but is not limited to, the transmembrane domain sequence of the SARS-CoV-2 S protein, particularly a sequence comprising the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1, or a functional variant thereof.

[0371] In certain embodiments, the transmembrane domain sequence comprises the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1, or a functional fragment of the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1. In certain embodiments, the transmembrane domain sequence comprises the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1.

[0372] In certain embodiments, the RNA encoding the transmembrane domain sequence is (i) a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 3619 to 3762 of SEQ ID NO: 2, 8, or 9, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 3619 to 3762 of SEQ ID NO: 2, 8, or 9 or the nucleotide sequence of nucleotides 3619 to 3762 of SEQ ID NO: 2, 8, or 9 and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1, or a functional fragment of the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1. In certain embodiments, the RNA encoding the transmembrane domain sequence (i) comprises the nucleotide sequence of nucleotides 3619 to 3762 of SEQ ID NO: 2, 8, or 9; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1207 to 1254 of SEQ ID NO: 1.

[0373] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 311 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 311 of SEQ ID NO: 29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO: 29. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 311 of SEQ ID NO: 29.

[0374] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30 or the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 311 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 311 of SEQ ID NO: 29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO: 29. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 986 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 311 of SEQ ID NO: 29.

[0375] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 314 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 314 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 314 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 314 of SEQ ID NO: 31. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 1 to 314 of SEQ ID NO: 31.

[0376] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of nucleotides 54 to 995 of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 995 of SEQ ID NO: 32, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 54 to 995 of SEQ ID NO: 32 or the nucleotide sequence of nucleotides 54 to 995 of SEQ ID NO: 32. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 314 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 314 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 314 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 1 to 314 of SEQ ID NO: 31. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 54 to 995 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 1 to 314 of SEQ ID NO: 31.

[0377] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 20 to 311 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 311 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 20 to 311 of SEQ ID NO: 29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 311 of SEQ ID NO: 29. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 20 to 311 of SEQ ID NO: 29.

[0378] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30 or the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 20 to 311 of SEQ ID NO: 29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 311 of SEQ ID NO: 29, or an immunogenic fragment of the amino acid sequence of amino acids 20 to 311 of SEQ ID NO: 29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 20 to 311 of SEQ ID NO: 29. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 111 to 986 of SEQ ID NO: 30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 20 to 311 of SEQ ID NO: 29.

[0379] In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 23 to 314 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 314 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 23 to 314 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 314 of SEQ ID NO: 31. In certain embodiments, the vaccine antigen comprises the amino acid sequence of amino acids 23 to 314 of SEQ ID NO: 31.

[0380] In certain embodiments, the RNA encoding the vaccine antigen comprises (i) the nucleotide sequence of nucleotides 120 to 995 of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 120 to 995 of SEQ ID NO: 32, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of nucleotides 120 to 995 of SEQ ID NO: 32 or the nucleotide sequence of nucleotides 120 to 995 of SEQ ID NO: 32. and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 23 to 314 of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 314 of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of amino acids 23 to 314 of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of amino acids 23 to 314 of SEQ ID NO: 31. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of nucleotides 120 to 995 of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of amino acids 23 to 314 of SEQ ID NO: 31.

[0381] In certain embodiments, the RNA encoding the vaccine antigen encodes (i) an amino acid sequence comprising the nucleotide sequence of SEQ ID NO:30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:30, or a fragment of the nucleotide sequence of SEQ ID NO:30 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:30; and / or (ii) an amino acid sequence comprising the amino acid sequence of SEQ ID NO:29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:29, or an immunogenic fragment of the amino acid sequence of SEQ ID NO:29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:29. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO:30; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO:29.

[0382] In certain embodiments, the RNA encoding the vaccine antigen encodes (i) an amino acid sequence comprising the nucleotide sequence of SEQ ID NO: 32, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 32, or a fragment of the nucleotide sequence of SEQ ID NO: 32 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 32; and / or (ii) an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 31, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 31, or an immunogenic fragment of the amino acid sequence of SEQ ID NO: 31 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 31. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO: 32; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 31.

[0383] In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO:28, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:28, or an immunogenic fragment of the amino acid sequence of SEQ ID NO:28 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:28. In certain embodiments, the vaccine antigen comprises the amino acid sequence of SEQ ID NO:28.

[0384] In certain embodiments, the RNA encoding the vaccine antigen encodes (i) an amino acid sequence comprising the nucleotide sequence of SEQ ID NO:27, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:27, or a fragment of the nucleotide sequence of SEQ ID NO:27 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:27; and / or (ii) an amino acid sequence comprising the amino acid sequence of SEQ ID NO:28, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:28, or an immunogenic fragment of the amino acid sequence of SEQ ID NO:28 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO:28. In certain embodiments, the RNA encoding the vaccine antigen (i) comprises the nucleotide sequence of SEQ ID NO:27; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO:28.

[0385] In certain embodiments, the vaccine antigen comprises a continuous sequence of the SARS-CoV-2 coronavirus spike (S) protein consisting of or consisting essentially of the above amino acid sequence from the SARS-CoV-2 S protein or immunogenic fragment (antigenic peptide or protein) contained in the vaccine antigen. In certain embodiments, the vaccine antigen comprises a continuous sequence of the SARS-CoV-2 coronavirus spike (S) protein of no more than 220 amino acids, 215 amino acids, 210 amino acids, or 205 amino acids.

[0386] In some embodiments, the RNA encoding the vaccine antigen is a nucleoside-modified messenger RNA (modRNA) described herein as BNT162b1 (RBP020.3), BNT162b2 (RBP020.1 or RBP020.2), or BNT162b3 (e.g., BNT162b3c). In some embodiments, the RNA encoding the vaccine antigen is a nucleoside-modified messenger RNA (modRNA) described herein as RBP020.2. In some embodiments, the RNA encoding the vaccine antigen is a nucleoside-modified messenger RNA (modRNA) described herein as BNT162b3 (e.g., BNT162b3c).

[0387] In certain embodiments, the RNA encoding the vaccine antigen is nucleoside-modified messenger RNA (modRNA) and (i) comprises the nucleotide sequence of SEQ ID NO: 21, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 21; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 5. In certain embodiments, the RNA encoding the vaccine antigen is nucleoside-modified messenger RNA (modRNA) and (i) comprises the nucleotide sequence of SEQ ID NO: 21; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 5.

[0388] In certain embodiments, the RNA encoding the vaccine antigen is nucleoside-modified messenger RNA (modRNA) and (i) comprises the nucleotide sequence of SEQ ID NO: 19 or 20, or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 19 or 20; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the amino acid sequence of SEQ ID NO: 7. In certain embodiments, the RNA encoding the vaccine antigen is nucleoside-modified messenger RNA (modRNA) and (i) comprises the nucleotide sequence of SEQ ID NO: 19 or 20; and / or (ii) encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 7.

[0389] In certain embodiment...

Claims

1. A composition or pharmaceutical formulation comprising an RNA encoding an amino acid sequence constituting the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of said SARS-CoV-2 S protein or an immunogenic variant thereof.

2. 2. The composition or pharmaceutical formulation of claim 1, wherein the immunogenic fragment of the SARS-CoV-2 S protein comprises the S1 subunit of the SARS-CoV-2 S protein or the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 S protein.

3. 3. The composition or pharmaceutical formulation of claim 1 or 2, wherein the amino acid sequence constituting the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of said SARS-CoV-2 S protein or an immunogenic variant thereof is encoded by a coding sequence that has been codon-optimized and / or has an increased G / C content compared to a wild-type coding sequence, and wherein said codon-optimization and / or increased G / C content preferably does not alter the sequence of the encoded amino acid sequence.

4. (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises nucleotides 979-1584 of SEQ ID NO:2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 979-1584 of SEQ ID NO:2, 8 or 9, or a nucleotide sequence of a fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 979-1584 of SEQ ID NO:2, 8 or 9; and / or (ii) the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the amino acid sequence of amino acids 327-528 of SEQ ID NO:1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 327-528 of SEQ ID NO:1, or the amino acid sequence of amino acids 327-528 of SEQ ID NO:1, or an immunogenic fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 327-528 of SEQ ID NO:1; A composition or pharmaceutical formulation according to any one of claims 1 to 3.

5. (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 111-986 of SEQ ID NO:30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of nucleotides 111-986 of SEQ ID NO:30, or a fragment of the nucleotide sequence of nucleotides 111-986 of SEQ ID NO:30 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of nucleotides 111-986 of SEQ ID NO:30; and / or (ii) the SARS-CoV-2 S protein, immunogenic variant thereof, or immunogenic fragment of the SARS-CoV-2 S protein or immunogenic variant thereof comprises the amino acid sequence of amino acids 20-311 of SEQ ID NO:29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 20-311 of SEQ ID NO:29, or an immunogenic fragment of the amino acid sequence of amino acids 20-311 of SEQ ID NO:29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 20-311 of SEQ ID NO:29; A composition or pharmaceutical formulation according to any one of claims 1 to 4.

6. (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises nucleotides 49-3819 of SEQ ID NO:2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 49-3819 of SEQ ID NO:2, 8 or 9, or a nucleotide sequence of a fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 49-3819 of SEQ ID NO:2, 8 or 9; and / or (ii) the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the amino acid sequence of amino acids 17-1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 17-1273 of SEQ ID NO: 1 or 7, or the amino acid sequence of amino acids 17-1273 of SEQ ID NO: 1 or 7, or an immunogenic fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 17-1273 of SEQ ID NO: 1 or 7; A composition or pharmaceutical formulation according to any one of claims 1 to 5.

7. 7. The composition or pharmaceutical formulation of any one of claims 1 to 6, wherein the amino acid sequence constituting the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a secretory signal peptide.

8. 8. The composition or pharmaceutical formulation of claim 7, wherein the secretory signal peptide is fused, preferably at the N-terminus, to the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof.

9. (i) the RNA encoding the secretory signal peptide comprises nucleotides 1-48 of SEQ ID NO:2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 1-48 of SEQ ID NO:2, 8 or 9, or a nucleotide sequence of a fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 1-48 of SEQ ID NO:2, 8 or 9, or nucleotides 1-48 of SEQ ID NO:2, 8 or 9; and / or (ii) the secretory signal peptide comprises the amino acid sequence of amino acids 1 to 16 of SEQ ID NO:1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO:1, or a functional fragment of the amino acid sequence of amino acids 1 to 16 of SEQ ID NO:1, or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO:1, 9. A composition or pharmaceutical formulation according to claim 7 or 8.

10. (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of SEQ ID NO:6, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of SEQ ID NO:6, the nucleotide sequence of SEQ ID NO:6 or a fragment thereof having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of SEQ ID NO:6; and / or (ii) the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the amino acid sequence of SEQ ID NO:5, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of SEQ ID NO:5, or the amino acid sequence of SEQ ID NO:5 or an immunogenic fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of SEQ ID NO:5; A composition or pharmaceutical formulation according to any one of claims 1 to 9.

11. (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 54-986 of SEQ ID NO:30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of nucleotides 54-986 of SEQ ID NO:30, or a fragment of the nucleotide sequence of nucleotides 54-986 of SEQ ID NO:30 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of nucleotides 54-986 of SEQ ID NO:30; and / or (ii) the SARS-CoV-2 S protein, immunogenic variant thereof, or immunogenic fragment of the SARS-CoV-2 S protein or immunogenic variant thereof comprises the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29; A composition or pharmaceutical formulation according to any one of claims 1 to 10.

12. 11. The composition or pharmaceutical formulation of any one of claims 1 to 10, wherein the RNA comprises a modified nucleoside instead of uridine, in particular the modified nucleoside is selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ), and 5-methyl-uridine (m5U), in particular the modified nucleoside is N1-methyl-pseudouridine (m1ψ).

13. The composition or pharmaceutical formulation of any one of claims 1 to 12, wherein the RNA comprises a 5' cap.

14. 14. The composition or pharmaceutical formulation of any one of claims 1 to 13, wherein the RNA encoding an amino acid sequence constituting a SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of said SARS-CoV-2 S protein or an immunogenic variant thereof comprises a 5'UTR comprising a nucleotide sequence of SEQ ID NO: 12 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:

12.

15. 15. The composition or pharmaceutical formulation of any one of claims 1 to 14, wherein the RNA encoding an amino acid sequence constituting a SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of said SARS-CoV-2 S protein or an immunogenic variant thereof comprises a 3'UTR comprising a nucleotide sequence of SEQ ID NO: 13 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:

13.

16. 16. The composition or pharmaceutical formulation of any one of claims 1 to 15, wherein the RNA encoding an amino acid sequence constituting the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a polyA sequence.

17. 17. The composition or pharmaceutical preparation of claim 16, wherein the polyA sequence comprises at least 100 nucleotides.

18. 18. A composition or pharmaceutical formulation according to claim 16 or 17, wherein the polyA sequence comprises or consists of the nucleotide sequence of SEQ ID NO:

14.

19. 19. The composition or pharmaceutical formulation of any one of claims 1 to 18, wherein the RNA is or is formulated as a liquid, a solid, or a combination thereof.

20. The composition or pharmaceutical preparation of any one of claims 1 to 19, wherein said RNA is or is formulated for injection.

21. 21. The composition or pharmaceutical preparation of any one of claims 1 to 20, wherein the RNA is or is formulated for intramuscular administration.

22. A composition or pharmaceutical formulation according to any one of claims 1 to 21, wherein said RNA is or is formulated as a particle.

23. 23. The composition or pharmaceutical formulation of claim 22, wherein the particle is a lipid nanoparticle (LNP) or a lipoplex (LPX) particle.

24. 24. The composition or pharmaceutical formulation of claim 23, wherein said LNP particles comprise ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine, and cholesterol.

25. 24. The composition or pharmaceutical formulation of claim 23, wherein said RNA lipoplex particles are obtainable by mixing said RNA with liposomes.

26. The composition or pharmaceutical formulation of any one of claims 1 to 25, wherein the RNA is mRNA or saRNA.

27. The composition or pharmaceutical formulation according to any one of claims 1 to 26, which is a pharmaceutical composition.

28. A composition or pharmaceutical preparation according to any one of claims 1 to 27 which is a vaccine.

29. 29. The composition or pharmaceutical formulation of claim 27 or 28, wherein the pharmaceutical composition further comprises one or more pharma- ceutically acceptable carriers, diluents, and / or excipients.

30. The composition or pharmaceutical preparation according to any one of claims 1 to 26, which is a kit.

31. 31. A composition or pharmaceutical formulation according to claim 30, wherein the RNA and optionally the particle-forming components are in separate vials.

32. 32. The composition or pharmaceutical preparation of claim 30 or 31, further comprising instructions for using the composition or pharmaceutical preparation for inducing an immune response against coronavirus in a subject.

33. A composition or pharmaceutical formulation according to any one of claims 1 to 32 for pharmaceutical use.

34. 34. The composition or pharmaceutical preparation of claim 33, wherein the medical use comprises inducing an immune response against coronavirus in a subject.

35. 35. A composition or pharmaceutical formulation according to claim 33 or 34, wherein said medical use comprises therapeutic or prophylactic treatment of a coronavirus infection.

36. A composition or pharmaceutical formulation according to any one of claims 1 to 35, for administration to a human.

37. A composition or pharmaceutical formulation according to any one of claims 32 to 36, wherein the coronavirus is a betacoronavirus.

38. A composition or pharmaceutical formulation according to any one of claims 32 to 37, wherein the coronavirus is a sarbecovirus.

39. The composition or pharmaceutical preparation of any one of claims 32 to 38, wherein the coronavirus is SARS-CoV-2.

40. 1. A method of inducing an immune response to a coronavirus in a subject, comprising administering to the subject a composition comprising RNA encoding an amino acid sequence comprising a SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof.

41. 41. The method of claim 40, wherein the immunogenic fragment of the SARS-CoV-2 S protein comprises the S1 subunit of the SARS-CoV-2 S protein or the receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 S protein.

42. 42. The method of claim 40 or 41, wherein the amino acid sequence constituting the SARS-CoV-2 S protein, an immunogenic variant thereof or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof is encoded by a coding sequence that has been codon-optimized and / or has an increased G / C content compared to a wild-type coding sequence, and wherein the codon-optimization and / or the increased G / C content preferably does not alter the sequence of the encoded amino acid sequence.

43. (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises nucleotides 979-1584 of SEQ ID NO:2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 979-1584 of SEQ ID NO:2, 8 or 9, or a nucleotide sequence of a fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 979-1584 of SEQ ID NO:2, 8 or 9; and / or (ii) the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the amino acid sequence of amino acids 327-528 of SEQ ID NO:1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 327-528 of SEQ ID NO:1, or the amino acid sequence of amino acids 327-528 of SEQ ID NO:1, or an immunogenic fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 327-528 of SEQ ID NO:1; 43. The method according to any one of claims 40 to 42.

44. (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 111-986 of SEQ ID NO:30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of nucleotides 111-986 of SEQ ID NO:30, or a fragment of the nucleotide sequence of nucleotides 111-986 of SEQ ID NO:30 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of nucleotides 111-986 of SEQ ID NO:30; and / or (ii) the SARS-CoV-2 S protein, immunogenic variant thereof, or immunogenic fragment of the SARS-CoV-2 S protein or immunogenic variant thereof comprises the amino acid sequence of amino acids 20-311 of SEQ ID NO:29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 20-311 of SEQ ID NO:29, or an immunogenic fragment of the amino acid sequence of amino acids 20-311 of SEQ ID NO:29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 20-311 of SEQ ID NO:29; 44. The method according to any one of claims 40 to 43.

45. (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises nucleotides 49-3819 of SEQ ID NO:2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 49-3819 of SEQ ID NO:2, 8 or 9, or a nucleotide sequence of a fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 49-3819 of SEQ ID NO:2, 8 or 9; and / or (ii) the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the amino acid sequence of amino acids 17-1273 of SEQ ID NO: 1 or 7, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 17-1273 of SEQ ID NO: 1 or 7, or the amino acid sequence of amino acids 17-1273 of SEQ ID NO: 1 or 7, or an immunogenic fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 17-1273 of SEQ ID NO: 1 or 7; 45. The method according to any one of claims 40 to 44.

46. 46. ​​The method of any one of claims 40 to 45, wherein the amino acid sequence constituting the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a secretory signal peptide.

47. 47. The method of claim 46, wherein the secretory signal peptide is fused, preferably N-terminally, to the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof.

48. (i) the RNA encoding the secretory signal peptide comprises nucleotides 1-48 of SEQ ID NO:2, 8 or 9, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 1-48 of SEQ ID NO:2, 8 or 9, or a nucleotide sequence of a fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to nucleotides 1-48 of SEQ ID NO:2, 8 or 9, or nucleotides 1-48 of SEQ ID NO:2, 8 or 9; and / or (ii) the secretory signal peptide comprises the amino acid sequence of amino acids 1 to 16 of SEQ ID NO:1, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO:1, or a functional fragment of the amino acid sequence of amino acids 1 to 16 of SEQ ID NO:1, or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 1 to 16 of SEQ ID NO:1, 48. The method of claim 46 or 47.

49. (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of SEQ ID NO:6, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of SEQ ID NO:6, the nucleotide sequence of SEQ ID NO:6 or a fragment thereof having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of SEQ ID NO:6; and / or (ii) the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the amino acid sequence of SEQ ID NO:5, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of SEQ ID NO:5, or the amino acid sequence of SEQ ID NO:5 or an immunogenic fragment having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of SEQ ID NO:5; 49. The method according to any one of claims 40 to 48.

50. (i) the RNA encoding the SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises the nucleotide sequence of nucleotides 54-986 of SEQ ID NO:30, a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of nucleotides 54-986 of SEQ ID NO:30, or a fragment of the nucleotide sequence of nucleotides 54-986 of SEQ ID NO:30 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the nucleotide sequence of nucleotides 54-986 of SEQ ID NO:30; and / or (ii) the SARS-CoV-2 S protein, immunogenic variant thereof, or immunogenic fragment of the SARS-CoV-2 S protein or immunogenic variant thereof comprises the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29, or an immunogenic fragment of the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29 or an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85% or 80% identity to the amino acid sequence of amino acids 1 to 311 of SEQ ID NO:29; 50. The method according to any one of claims 40 to 49.

51. 50. The method of any one of claims 40 to 49, wherein the RNA comprises a modified nucleoside instead of uridine, in particular the modified nucleoside is selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ), and 5-methyl-uridine (m5U), in particular the modified nucleoside is N1-methyl-pseudouridine (m1ψ).

52. 52. The method of any one of claims 40 to 51, wherein the RNA comprises a cap.

53. 53. The method of any one of claims 40-52, wherein the RNA encoding an amino acid sequence constituting a SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a 5'UTR comprising the nucleotide sequence of SEQ ID NO:12 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:

12.

54. 54. The method of any one of claims 40-53, wherein the RNA encoding an amino acid sequence constituting a SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof comprises a 3'UTR comprising the nucleotide sequence of SEQ ID NO: 13 or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO:

13.

55. 55. The method of any one of claims 40 to 54, wherein the RNA encoding an amino acid sequence constituting a SARS-CoV-2 S protein, an immunogenic variant thereof, or an immunogenic fragment of the SARS-CoV-2 S protein or an immunogenic variant thereof, comprises a polyA sequence.

56. 56. The method of claim 55, wherein the polyA sequence comprises at least 100 nucleotides.

57. 57. The method of claim 55 or 56, wherein the polyA sequence comprises or consists of the nucleotide sequence of SEQ ID NO:

14.

58. 58. The method of any one of claims 40-57, wherein the RNA is formulated as a liquid, a solid, or a combination thereof.

59. The method of any one of claims 40 to 58, wherein the RNA is administered by injection.

60. 60. The method of any one of claims 40 to 59, wherein the RNA is administered by intramuscular administration.

61. 61. The method of any one of claims 40 to 60, wherein the RNA is formulated as a particle.

62. 62. The method of claim 61 , wherein the particle is a lipid nanoparticle (LNP) or a lipoplex (LPX) particle.

63. 63. The method of claim 62, wherein the LNP particles comprise ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine and cholesterol.

64. 63. The method of claim 62, wherein the RNA lipoplex particles are obtainable by mixing the RNA with liposomes.

65. The composition or pharmaceutical formulation of any one of claims 40 to 64, wherein the RNA is mRNA or saRNA.

66. 66. The method according to any one of claims 40 to 65, which is a method for vaccination against coronavirus.

67. 67. The method according to any one of claims 40 to 66, which is a method for the therapeutic or prophylactic treatment of a coronavirus infection.

68. The method of any one of claims 40 to 67, wherein the subject is a human.

69. The method of any one of claims 40 to 68, wherein the coronavirus is a betacoronavirus.

70. 70. The method of any one of claims 40 to 69, wherein the coronavirus is a sarbecovirus.

71. The method of any one of claims 40 to 70, wherein the coronavirus is SARS-CoV-2.

72. The method according to any one of claims 40 to 71, wherein the composition is a composition according to any one of claims 1 to 39.

73. A composition or pharmaceutical formulation according to any one of claims 1 to 39 for use in a method according to any one of claims 40 to 72.